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The Role of Mitochondrial Folate Enzymes in Cancer 
By Aoife MacCooey 
Abstract 
Folic acid is an essential B vitamin, the metabolism of folic acid via one carbon 
metabolism results in the production of important components for the cell, such as 
DNA bases and methyl donor groups. The importance of mitochondrial one carbon 
metabolism has recently been highlighted with the discovery of the novel enzyme 
Dihydrofolate Reductase like 1 (DHFRL1) and the association of other mitochondrial 
enzymes, in particular Methylenetetrahydrofolate dehydrogenase (NADP+ 
dependent) 1-like (MTHFD1L) with rapid proliferation and mortality in cancer. The 
novel DHFRL1 enzyme has been shown to be a much less active enzyme with a 
reduced affinity for dihydrofolate relative to DHFR. The MTHFD1L enzyme is 
responsible for the last step in the production of formate for cytoplasmic one 
carbon metabolism. Due to MTHFD1L’s associations with rapid proliferation rate in 
cancer and mortality, a biomarker for its expression is desirable. Formate analysis 
by Gas chromatography–mass spectrometry (GC-MS) in Human Embryonic Kidney 
(HEK) 293 cells with modulated MTHFD1L expression demonstrated that knocking 
down the gene resulted in reduced formate levels and reduced cell growth. 
Similarly overexpressing the MTHFD1L gene in HEK 293 cells resulted in an 
increased formate level and growth rate relative to the controls. Investigation was 
undertaken into the amino acid differences between DHFR and DHFRL1 to begin to 
understand their functional relevance. It was identified that the arginine at amino 
acid position 24 may result in DHFRL1 having an altered structure, which may 
account in part for DHFRL1’s reduced affinity for dihydrofolate. In addition, DHFRL1 
and other mitochondrial folate enzymes, MTHFD1L, Methylenetetrahydrofolate 
dehydrogenase (NADP+ dependent) 2 (MTHFD2), Serine Hydroxymethyltransferase 
(mitochondrial isoform) 2 (SHMT2) were found to be up-regulated in a metastatic 
cancer cell line but their cytosolic paralogues showed no such up-regulation. The 
results presented provide further evidence of the mitochondrial driven role in 
cancer progression and are supportive for the use of formate as a biomarker for 
mitochondrial gene up-regulation.   
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1.0 Overview 
Cancer may be defined as the uncontrolled growth of cells and is a leading cause of 
death in Ireland and worldwide (WHO 2015a). The molecular mechanisms which 
underpin cancer are constantly being uncovered through cancer research. One such 
area of research which has recently garnered interest within the scientific 
community is cancer cell metabolism, specifically the expression and functionality 
of mitochondrial folate metabolic enzymes in relation to cancer (Jain et al. 2012, 
McEntee et al. 2011, Selcuklu et al. 2012, Nilsson et al. 2014) 
 
One carbon metabolism is an essential biochemical pathway required for folate 
metabolism. One carbon metabolism is compartmentalised within the cell between 
the cytoplasm, the mitochondria and the nucleus and is responsible for the 
production of DNA bases, thymidine, adenine and guanine and the re-methylation 
of homocysteine to methionine for cellular methylation reactions (Fox and Stover 
2008). Folate is an essential nutrient as it cannot be synthesised de novo and so it 
must be consumed through the diet from foods naturally rich in folate, folic acid 
fortified foods and supplements. The enzyme Dihydrofolate Reductase (DHFR) is 
responsible for converting folic acid and dihydrofolate to its biologicaly active form 
Tetrahydrofolate (THF) within the cell (Stover 2009). The conversion of folate to its 
biologically active form THF sets off a cascade of biochemical reactions resulting in 
the production of purines, thymidylate and methionine (Fox and Stover 2008). The 
essentiality of the DHFR enzyme in initiating this enzyme cascade has led to it being 
targeted with anti-folate chemotherapeutics in the treatment of cancer (Visentin et 
al. 2012). Up until recently it was thought there was only one active and expressed 
DHFR enzyme and a number of pseudogenes; however, it has come to light that 
there is a second expressed DHFR enzyme, DHFRL1 (McEntee et al. 2011, Anderson 
et al. 2011). DHFRL1 has been found to localise to the mitochondria where it is 
thought to partake in de novo thymidylate synthesis (Anderson et al. 2011). 
DHFRL1’s activity has been shown to be dramatically lower than that of DHFR 
(McEntee et al. 2011). The presence of a second less active dihydrofolate enzyme 
which localises to the mitochondria may have implications for health and disease.  
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Although there is only an 8% difference in the protein sequences of DHFR and 
DHFRL1, it is thought that these differences contribute to the apparent different 
activities of the enzymes (McEntee et al. 2011). Further investigation is needed into 
the specific amino acid differences between DHFR and DHFRL1 to begin to 
understand their functional relevance. 
 One carbon metabolism is reliant on the provision of one carbon donor molecules 
which largely come in the form of formate originating in the mitochondria. It is 
estimated that up to 75% of the one carbon donor molecules required for 
cytoplasmic one carbon metabolism are derived from the mitochondria (Pike et al. 
2010). Methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like 
(MTHFD1L) is the only enzyme capable of catalysing the last step in the production 
of formate in the mitochondria (Tibbetts and Appling 2010). MTHFD1L and other 
mitochondrial folate related enzymes Serine hydroxymethyltransferase 2 (SHMT2) 
and methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2 (MTHFD2) 
have recently been associated with proliferation and mortality within cancer. (Jain 
et al. 2012, Selcuklu et al. 2012, Nilsson et al. 2014). There is evidence to suggest 
that the mitochondrial folate pathway is a driving force in cancer cell proliferation 
(Jain et al. 2012). The enzyme MTHFD1L is of particular interest in relation to this 
with it being responsible for the provision of formate for cytoplasmic one carbon 
metabolism (Pike et al. 2010). The aim of this of this research thesis is to investigate 
the role which mitochondrial folate related enzymes play within the cell and the 
implications of this in relation to health and disease, with a particular emphasis on 
cancer. 
1.1 Folic Acid and Metabolism 
Folic acid is an essential water soluble vitamin also known as vitamin B9. Folic acid is 
the synthetic form of the naturally occurring folate. The recommended daily 
allowance (RDA) for folic acid is 400µg per day and 600µg per day for pregnant 
women (Bailey and Gregory 1999). Folate is found naturally in dark green leafy 
vegetables, pulses and grains. Folic acid the synthetic variety of folate, is found in 
vitamin supplements and fortified foods such as breads and cereals.  Both synthetic 
folic acid and naturally occurring folate may be referred to with the generic term 
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folate.   Due to the essential nature of folate, both its consumption and the genes 
that metabolise it have been implicated in many diseases such as Neural tube 
defects (NTDs), Cancer, Cardiovascular Disease (CVD) and Alzheimer’s (Parle-
McDermott et al. 2009, Kirke et al. 2004, Sugiura et al. 2004, Jain et a.l 2012). In 
order to fully understand the mechanisms by which folate and its related genes are 
involved in the aetiology of such diseases a comprehensive view of the way in which 
folate is metabolised is needed. 
1.1.1 Overview of One Carbon Metabolism 
Folate is metabolised via the metabolic pathway known as one carbon metabolism. 
One carbon metabolism is a complex system of interdependent metabolic pathways 
which results in the synthesis of purines, thymidylate and the remethylation of 
homocysteine to methionine for cellular methylation reactions (Fox and Stover 
2008). One carbon metabolism is compartmentalised within the cell between the 
mitochondria, the nucleus and the cytoplasm, Figure 1.1   
Once folate is recruited into the cell it undergoes polyglutamation by the enzyme 
Folyl polyglutamatesynthase (FPGS) which involves the addition of up to eight 
glutamate molecules to prevent efflux from the cell.    Folic acid is first metabolised 
by the enzyme Dihydrofolate Reductase (DHFR) to dihydrofolate (DHF) with NADPH 
as a co-factor. DHF is then reduced to tetrahydrofolate (THF), the biologically active 
form of folate. THF in the mitochondria is converted into 5,10 Methylene-THF by 
condensation of formaldehyde produced from the catabolism of glycine, serine, 
sarcosine and dimethylglycine, Figure 1.1 (Stover 2009). The 5,10 methylene-THF is 
then oxidised by the enzyme MTHFD2/L to form 10-formyl-THF which can then 
either be used to formylate MET-tRNA for protein synthesis within the 
mitochondria or it can be hydrolysed by the enzyme MTHFD1L to THF and formate 
(Stover 2009). Formate originating from the mitochondria is estimated to provide 
up to 75% of the one carbon units for cytoplasmic one carbon metabolism (Pike et 
al. 2010). Purines are produced by the incorporation of 10-formyl THF (produced 
from formate and THF) into the C2 and C8 carbons of the purine ring in the 
cytoplasm. 10-formyl THF can be reduced to 5,10 methylene-THF which is utilised 
by Thymidylate Synthase (TYMS) for the conversion of deoxy uridine 
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monophosphate (dUMP) to deoxy thymidine monophosphate (dTMP) in the 
cytoplasm, nucleus and mitochondria for thymidylate synthesis (Stover 2009). 5,10 
methylene-THF can also be produced by the enzymatic conversion of serine and 
THF; the cleavage of serine in this reaction also serves to produce the amino acid 
glycine. 5, 10 methylene THF is further reduced to 5- methyl-THF which serves in 
the re-methylation of homocysteine to methionine for cellular methylation of DNA 
and proteins. In the nucleus 5,10 methylene-THF transfers its one carbon unit to 
dUMP generating dTMP which also results in the regeneration of DHF, Figure 1.1 
(Stover 2009, Fox and Stover 2008).  
As can be seen from Figure 1.1 the metabolism of folic acid is a complex process 
involving many enzymatic reactions resulting in the production of very important 
components for the cell, such as DNA bases and methyl donor groups (Fox and 
Stover 2008).  Folic acid is an essential nutrient so its consumption and metabolism 
are of the utmost importance to the cell. Both low folate status and alterations in 
folate metabolising enzymes have been associated with disease development, as 
explored below in section 1.2. 
 
 
 
1.2 Folate and Disease 
Figure 1.1 Compartmentalisation of folate metabolism. Folate metabolism is compartmentalised 
between the nucleus, cytoplasm and the nucleus. The active form of folate, THF, along with activated one 
carbon units undergo a series of enzymatic conversions which results in the production of purines, 
thymidylate and the re-methylation of homocysteine to methione. Paralogous enzymes are represented 
in the same colour; for example the MTHFD gene family consisting of mitochondrial MTHFD1L, MTHFD2, 
MTHFD2L and cytoplasmic MTHFD1 are all denoted in blue. * Denotes the main One Carbon Metabolism 
products.  Image edited from Fox and Stover 2008. 
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 Folate plays an integral role within the cell and without its consumption the health 
and wellbeing of the cell/tissue/person is compromised and disease states can 
arise. Folate metabolism results in the production of crucial products for the cell 
without which the cell cannot survive. Any disruption or alteration in folate intake 
or metabolism can have a deleterious effect; it is for this reason that folate has 
been implicated in playing a role in many diseases, as outlined below.  
1.2.1 Neural Tube Defects 
 One of the most well-known conditions associated with low folate status are neural 
tube defects (NTDs). Folate is needed in times of rapid growth such as in the case of 
embryogenesis; perturbations in either folate consumption or metabolism can 
result in the development of congenital malformations such as NTDS (Fekete et al. 
2010). NTDs occur when the neural tube in a developing embryo fails to close 
properly, resulting in a range of conditions which vary in severity, including 
anencephaly, spina-bifida, encephalocele, cranioschisis and iniencephaly (Botto et 
al .1999). Periconceptional folic acid intake has been shown to reduce the 
occurrence of NTDs by up to 72% (MRC Vitamin Research group 1991). The 
identification of the link between folate consumption and a decrease in NTDs 
resulted in the widespread fortification of many foods such as grains, cereals and 
milk both mandatorily and voluntarily throughout the world.  The Centre for 
Disease Control and Prevention estimates that one third of flour produced 
throughout the world is fortified with folic acid (Centre for Disease Control and 
Prevention 2008). The Food Safety Authority of Ireland (FSAI) recommended 
mandatory fortification of our flour in 2006 due to the high incidence of NTD’s 
(Food Safety Authority of Ireland 2006). However, in 2009 the FSAI decided to not 
proceed with mandatory fortification due to the decrease in NTD’s which went from 
1-1.5 to 0.93 per 1000 births (Food Safety Authority of Ireland 2009). This decrease 
in NTD occurrence was attributed to the fact that folate consumption had increased 
by 30% between 2006 and 2009 due to liberal voluntary fortification of a range of 
food products with folic acid in Ireland during the preceding years  (Flynn et al. 
2008).   However, a recent publication by McDonnell et al (2015) found that 
between 2009 and 2011 NTD incidence in Ireland has increased to 1.04 per 1000 
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births.  This increase in NTD rate is not statistically significant but does highlight the 
need for continued monitoring. 
Aside from dietary factors there are also genetic elements at play in NTD 
development. It has been shown that people of different genetic origins appear to 
have different NTD rates; for instance Irish people experience a higher incidence 
than many other ethnic groups (Frey and Houser 2003). There have been over 80 
genes implicated to varying degrees in NTD development (Green et al. 2009). 
Polymorphisms in folate related genes have been shown to impact the risk of NTD 
development; genes of particular interest are outlined below. 
The folate metabolising enzyme MTHFR has a common polymorphism MTHFR 
677C<T (Frosst et al. 1995). The homozygous TT variant of the gene results in the 
production of a thermo labile unstable enzyme. Both the TT and CT variants are risk 
factors for NTD development (Kirke et al. 2004). A 19 bp Deletion Insertion 
Polymorphism (DIP) in a noncoding region of the gene of the DHFR gene has also 
been associated with NTD risk. There have been conflicting reports as to the effect 
or functionality of this polymorphism with Johnson et al (2004) associating it as a 
risk factor for NTD development and Parle-McDermott et al (2007) associating it as 
protective against NTD development. In addition, a DIP in the MTHFD1L gene 
(rs3832406) and a single nucleotide polymorphism (SNP) in the MTHFD1 gene 
(R653Q) have also been associated as risk factors for NTD development (Parle-
McDermott et al. 2009, Brody et al. 2002).  
The exact mechanisms underlying the role of folate and its metabolising enzymes in 
NTD development are not fully understood. However, it appears that NTD risk and 
folate are closely linked (Beaudin and Stover 2009). NTD development appears to 
be multi-factorial with both genetics and environmental factors such as nutrition 
and folate status all contributing to the overall risk (either increasing or decreasing) 
(Beaudin and Stover 2009, Copp and Greene 2010).  
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1.2.2 Cardiovascular Disease 
Folate status has also been implicated in playing a role in Cardiovascular Disease 
(CVD). CVD is the number one single cause of death worldwide (WHO 2015b).  One 
of the leading types of CVD is coronary heart disease (CHD).There has been much 
debate over the role, if any, that folate plays in Coronary heart disease (CHD) 
development. Elevated homocysteine levels are associated with CHD risk (Marcus et 
al. 2007). Whether elevated homocysteine is causal or consequential of CHD is still 
up for debate. Early observational studies into the effect of homocysteine-lowering 
vitamins such as folate (recall how folate is required for the re-methylation of 
homocysteine to methionine) were positive (Clarke et al. 1991). A recent meta-
analysis of 8 trials comprising of a total of 37,485 individuals involving B vitamin 
supplementation on the risk of CHD found there was no effect of B vitamin 
supplementation (inclusive of folate) on either CHD or stroke risk (Clarke et al. 
2011). However, that the Meta analysis carried out by Clarke et al (2011) measured 
the occurrence of secondary events so the role of folic acid in primary prevention 
remains to be further elucidated. 
In addition to the role of dietary folate, polymorphisms in folate related genes have 
also been associated with CHD risk. Work by Samani et al (2007) identified a 
polymorphism (rs6922269) within the MTHFD1L gene as a risk factor for CHD 
development, with as much as 23% increased risk associated per copy of the risk 
allele. The MTHFR 677C<T polymorphism is known to cause elevated homocysteine 
in individuals who are homozygous TT and has been implicated in CHD risk.  A meta-
analysis by Klerk et al (2002) found that individuals who were homozygous TT had a 
significantly increased risk of CHD compared to CC wild type homozygotes, 
particularly in a low folate setting. A more recent meta-analysis by Husemoen et al 
(2014) into the effect of the MTHFR 677C<T polymorphism on CVD found no causal 
relationship between homocysteine and CVD, consistent with the findings of Clarke 
et al (2011). However Husemoen et al (2014) couldn’t exclude a causal relationship 
between the MTHFR polymorphism and ischemic heart disease.  
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1.2.3 Neurodegenerative Diseases 
Folate status has also been linked to neurodegenerative diseases such as 
Alzheimer’s and Parkinson’s. Elevated homocysteine levels have been shown to 
correlate with poor cognitive function, Alzheimer’s and dementia (Seshadri et al. 
2002). Bryan et al (2002) found that folic acid supplementation resulted in improved 
memory processing. A randomised double blind control trial by Durga et al (2007) 
found that folic acid supplementation resulted in increased cognitive function. 
However, a Cochrane review into folic acid supplementation with or without 
Vitamin B 12 found that there is no consistent evidence to support or refute the 
role which folic acid and vitamin B 12 may play in dementia and Alzheimer’s disease 
(Malouf et al. 2008).  
As with many multi-factorial diseases, there is no one source or definitive cause of 
neurodegenerative disease; aside from nutrition genes are also thought to play a 
role in disease development. It is thought that the polymorphisms in both the 
MTHFD1L and MTHFR genes impact on homocysteine levels, with elevated 
homocysteine levels being associated with neurodegenerative diseases.  A genome 
wide association study (GWAS) identified a single nucleotide polymorphism (SNP) 
rs11754661 in the MTHFD1L gene as being significantly associated with late onset 
Alzheimer’s disease in a Caucasian population (Naj et al. 2010). Work by Ren et al 
(2011) found a similar association of the MTHFD1L SNP in a Han Chinese population. 
However, work by Ramirez-Lorca et al (2011) failed to find an association in a 
Spanish population, indicating that the effect may be population specific.  The 
MTHFR 677C<T polymorphism has also been implicated as playing a role in 
neurodegenerative diseases. A recent meta-analysis by Zhu et al (2012) identified 
the 677C<T polymorphism of the MTHFR gene as being a risk factor for the 
development of Parkinson’s disease. The findings outlined above again highlight the 
difficulty in identifying and confirming one specific contributor in the development 
and progression of multi-factorial diseases such as neuro-degenerative diseases and 
heart disease.  
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1.3 Folate and Cancer 
Cancer is a leading cause of mortality worldwide. An average of 36,000 new cases of 
cancer were registered with the Irish National Cancer Registry between 2010-2012. 
The incidence of cancer in Ireland between 2010-2012 was 790 male and 747 
female cases per 100,000 people per year.  Although the incidence rate of cancer 
has increased between 1994-2012 the mortality rates have decreased by 1.4% and 
1.1% for men and women respectively (National Cancer Registry 2014). The 
increased incidence and decreased mortality in Ireland over the last number of 
years demonstrates the positive impact cancer research has had on the 
advancement of techniques for cancer detection and treatment. 
The role which folate and folate metabolising genes play within cancer 
development and progression is complex and has a history spanning over 60 years 
(Miller 2006).  Cancer is another example of a multi-factorial disease, with genetics 
and environmental factors at play with exposure to chemicals and toxins, lifestyle 
factors and nutrition all affecting the risk or chance of cancer development. From a 
dietary point of view, much controversy exists over the role which folates play in 
cancer development, with evidence to support it both as a cancer preventative and 
a cancer causing agent (Terry et al. 2002, Larsson et al. 2004 Lajous et al. 2006, Cole 
et al. 2007). From a genetic point of view the primary folate metabolising enzyme 
DHFR has been targeted with anti-folate chemotherapy drugs in the treatment of 
cancer for many years (Visentin et al. 2012). However, our knowledge regarding 
folate genes and cancer is currently evolving with much renewed interest in the 
area, particularly towards mitochondrial folate genes which is the main focus of this 
research thesis. In order to get a comprehensive view of the relationship between 
folate and cancer, information regarding dietary folate intake and cancer risk and 
development is discussed below.  
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1.3.1 Dietary Folate and Cancer 
 Folate appears to exert a double mechanistic action on cancer growth and 
development. Due to the fact that folate metabolism leads to the production of 
DNA bases which are required in high amounts by rapidly proliferating cancer cells it 
can be easily understood how folate consumption can aid in cancer progression. 
Although folates promote the growth of pre-existing cancer there is much evidence 
to support that folate intake lowers cancer development risk i.e., the appearance of 
the primary tumour (Farber 1947, Giovanucci et al. 1998). Studies such as the 
nurse’s study who recorded the dietary folate intake by semi quantitative 
questionnaire of 121,700 women over a 15 year period found that folate intake was 
correlated with a decreased cancer risk, with 400µg intake per day having a relative 
risk value of 0.69 (Giovannucci et al. 1998). Similar studies into the role of folate 
and primary cancer incidence by Terry et al (2002), Larsson et al (2004) and Lajous 
et al (2006) all correlated dietary folate intake with a decrease in cancer risk. 
 A clinical trial set up by Cole et al (2007) in 1994 set out to further prove the 
protective effect of folate in cancer, specifically in colon cancer. The trial was set up 
to assess the preventative effect of folic acid on the re-occurrence of adenomas (a 
pre-cancerous lesion in the colon) in individuals with a recent history of them. The 
results of the trial were quite un-expected, as it was found that folic acid 
consumption was associated with an increase in cancer risk (although this was not 
primary prevention). Cole et al (2007) found that folic acid supplementation was 
associated with increased adenoma incidence and an increased incidence of 
advanced lesions (Cole et al. 2007). The findings of the adenoma trial led to great 
concern about the implications of folate fortification of our food and this finding 
was highlighted by the FSAI as a one of the reasons for not undertaking mandatory 
folate fortification in 2009 (FSAI 2009). Figueiredo et al (2009) analysed the 
adenoma trial data in regard to the development of prostate cancer and found that 
men who received folic acid had an increased risk of developing prostate cancer 
relative to those who received a placebo. Analysis of clinical trial data from Norway 
by Ebbing et al (2009) found that those who received folic acid had an increased 
incidence of cancer and increased mortality relative to those who received a 
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placebo. In order to clarify the role of folates in cancer development a meta- 
analysis was undertaken by Vollset et al (2013) into the site specific cancer 
incidence in 50,000 individuals. The meta-analysis found that collectively there was 
no significant effect of folic acid supplementation either increasing or decreasing 
cancer risk over a 5 year period. Although, the authors did note that there was a 
slight increase in cancer risk in those supplemented with folic acid but that the 
increase could just as easily be contributed to random chance.  
There are plausible molecular mechanisms to support folates as increasing and 
decreasing cancer risk. It appears that a delicate balance of folate is required. Folate 
deficiency disrupts the conversion of dUMP to dTMP leading to a shortage of 
thymidylate and an accumulation of uracil. Thymidylate is not strictly required for 
DNA synthesis as uracil can take its place (Blount et al. 1997, MacFarlane et al. 
2011). The incorporation of uracil into DNA results in a number of excision and 
repair steps which if performed repeatedly can lead to chromosomal aberrations 
and strand breaks which may lead to carcinogenesis (Duthie 1999). In addition to 
this, a deficiency in folate may also impact cellular methylation as the folate 
derivative 5-methyl-THF is required for the conversion of homocysteine to 
methionine which in turn is converted to S-adenosylmethionine (SAM, referred to 
as Adomet in Figure 1.1) for cellular methylation reactions (Fox and Stover 2008). 
DNA methylation is associated with repression of gene expression.  Hypo-
methylation of important genes such as proto-oncogenes is a known feature of 
many cancers (Liang et al. 2015, Soes et al. 2014, Choi and Lee 2013). Hyper-
methylation of tumour suppressor genes has also been associated with cancer: 
increased folate intake leads to the availability of methyl donor groups in theory 
allowing for hyper-methylation and repression of important genes (Berdasco and 
Esteller 2010). However, folate status and DNA methylation is not simply a cause 
and effect relationship. Evidence suggests that the effect nutrient availability has on 
DNA methylation is site specific and may depend on many factors such as gene, 
tissue, age etc. (Parle-McDermott and Ozaki 2011). 
The relationship between folate and cancer is complex; folate deficiency can result 
in genetic damage and increases primary cancer risk, whereas folate consumption 
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when cancer has already been established results in accelerated growth and 
progression of the cancer (Kim 2007). Apart from folate consumption/status, more 
recent research has identified that the expression level of a number of 
mitochondrial folate enzymes is associated with increased proliferation and 
mortality rate in cancer.  This is described further in Section 1.4 and is explored 
further in this research thesis. 
 
1.4 Folate Metabolising Enzymes in Cancer and Health and Disease 
The metabolism of folate by one carbon metabolism is reliant on the faithful activity 
of a plethora of enzymes, with one enzymes product acting as the next enzyme’s 
substrate. One thing which is quite obvious from Figure 1.1 is that the 
compartmentalisation of folate metabolism within the cell has led to the evolution 
of a number of enzymes which share commonality but operate in different cellular 
locations. Genes or proteins that share function and sequence identity are known as 
paralogues and were created via gene duplication events (Koonin 2005). A number 
of paralogues operate in one carbon metabolism; for example, the enzyme serine 
hydroxymethyltransferase (SHMT) is responsible for the cleavage of serine to 
glycine. This reaction however, is carried out by different enzymes depending on 
cellular location, with SHMT2 carrying out reactions in the mitochondria and SHMT1 
and SHMT2 α carrying out reactions in the cytoplasm and the nucleus (Anderson et 
al. 2012). The products of folate metabolism, purines, thymidylate and methionine 
are of paramount importance to the cell and are essential for the cell to grow and 
divide (Fox and Stover 2008). 
The mitochondrion encompasses a number of key enzymes involved in one carbon 
metabolism.  Figure 1.2 illustrates mitochondrial enzymes and demonstrates the 
roles carried out by these enzymes.  The importance of mitochondrial folate 
enzymes is currently being uncovered within the scientific community. This is 
highlighted by the fact that the presence and functionality of two novel 
mitochondrial enzymes dihydrofolate reductase like 1 (DHFRL1) and 
Methylenetetrahydrofolate Dehydrogenase (NADP+ Dependent) 2-Like (MTHFD2L) 
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was only discovered in 2011 (McEntee et al. 2011, Bolusani et al. 2011). Anderson 
et al. (2011) discovered the presence of a mitochondrial de novo thymidylate 
synthesis pathway with the newly discovered DHFRL1 enzyme thought to play a 
significant role in this pathway. McEntee et al (2011) demonstrated that the novel 
DHFRL1 enzyme is capable of reducing DHF to its biologically active form THF, albeit 
with a much reduced efficiency relative to DHFR. In addition to this, in 2012 
mitochondrial folate enzymes were shown to correlate with cancer cell proliferation 
and mortality but cytoplasmic folate enzymes showed no such correlation (Jain et 
al. 2012). However, this was not the first time that mitochondrial folate enzymes 
were associated with cancer. The MTHFD1L enzyme was associated with cancer as 
early as 2004 by Sugiura et al (2004). As outlined above in section 1.2 MTHFD1L has 
been shown to play a role in many diseases such as NTDs, CHD and 
neurodegenerative diseases. The focus of this research thesis is on mitochondrial 
folate enzymes with a particular focus on MTHFD1L (due to its previous associations 
with cancer and human disease) and on DHFRL1, a newly discovered enzyme by the 
Nutritional Genomics group in 2011.  
 
 
 
 
1.4.1 DHFRL1 and the Human DHFR Gene Family 
Figure 1.2 Mitochondrial One Carbon Metabolism. MTHFD1L is responsible for the 
conversion of 10-formyl-THF to formate which is then used as source of one carbon 
donor molecules in the cytoplasm. DHFRL1 is responsible for the reduction of DHF to 
THF for de novo thymidylate synthesis. SHMT2 cleaves serine to form glycine which is 
then further metabolised to form CH2F (also referred to as 5,10-methylene THF) which 
is used for thymidylate synthesis and as a substrate for MTHFD2/MTHFD2L. Genes of 
particular interest MTHFD1L and DHFRL1 are highlighted in purple. Genes of interest 
are denoted by*. Image edited from Scotti et al (2013). 
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Dihydrofolate Reductase (DHFR) is a folate metabolising enzyme responsible for 
initiating the one carbon metabolism enzyme cascade by reducing Dihydrofolate 
(DHF) to its biologically active form Tetrahydrofolate (THF) (Stover 2009). Up until 
2011 it was widely accepted that the DHFR gene family consisted of one functional 
gene (DHFR) and four non-functional pseudogenes. The functional DHFR gene 
consists of six exons interspersed by five introns. In contrast, the four other 
members of the DHFR gene family are intronless and are thought to have originated 
from the re-integration of processed mRNA (Anagnou et al.  1984). Publications by 
McEntee et al (2011) and Anderson et al (2011) have changed the landscape of the 
DHFR gene family as we know it. It was proven that the former pseudogene DHFRP4 
is an expressed enzyme known as dihydrofolate reductase like 1 or DHFRL1. Thus, 
proving that there is in fact nothing “pseudo” about DHFRL1 (DHFRP4) (McEntee 
2011, Anderson 2011). The DHFR gene family is dispersed among the genome with 
DHFR, DHFRP1, DHFRP2, DHFRP3, and DHFRL1 (formerly DHFRP4) located on 
chromosomes 5, 18, 6, 2 and 3, respectively; see Figure 1.4 (Anagnou et al. 1988).  
 
The role of DHFRL1 within the cell is thought to be in the provision of THF for de 
novo thymidylate synthesis within the mitochondria. The presence of de novo 
thymidylate synthesis within the mitochondria was confirmed by Anderson et al 
(2011).  Both McEntee et al (2011) and Anderson et al (2011) reported that DHFRL1 
was found to translocate to mitochondria despite the lack of a mitochondrial 
targeting sequence. This is in contrast to the DHFR enzyme which is thought to 
reside in the cytoplasm and the nucleus (Stover 2009). The enzymes DHFRL1, 
SHMT2 and TYMS are all involved in mitochondrial de novo thymidylate synthesis. 
DHFRL1 converts DHF to THF, one carbon activated molecules derived from serine 
and THF by SHMT2 are converted to thymidylate by (TYMS).  Anderson et al (2011) 
demonstrated that de novo thymidylate synthesis is important to maintain 
mitochondrial DNA integrity (mtDNA). glyA Chinese hamster ovary (CHO) cells 
lacking the SHMT2 enzyme had 40% increased level of uracil in their mtDNA than 
the wild type (WT) cells.  It was also found that transfection of the DHFRL1 gene 
into glyC CHO cells, an uncharacterised cell line auxotrophic for glycine, rescued the 
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glycine auxotrophy (Anderson et al. 2011). These results confirm the functional 
effects of DHFRL1 on mitochondrial one carbon metabolism. 
 On analysis of the amino acid residues of the DHFR and DHFRL1 enzymes, McEntee 
et al (2011) found that they share 92% homology, see Figure 1.3. Despite the 
homology between the two enzymes McEntee et al (2011) have demonstrated that 
the activity of DHFRL1 is much reduced in comparison to DHFR. DHFR has been 
shown to have a Km of 20.1µM for DHF, whereas DHFRL1 has been shown to have a 
much reduced affinity for DHF with a Km of 209.3µM. McEntee et al (2011) found 
that DHFRL1 was capable of compensating for DHFR knockout in both a mammalian 
and a bacterial system. DHFRL1 may also have a role in the control and expression 
of DHFR. Control and expression of the DHFR enzyme is tightly regulated, as 
disruption of DHFR supply can have serious effects on one carbon metabolism 
(Martianov 2007). At a post transcriptional level DHFR has been found to auto 
regulate its own expression by binding its own mRNA, thus preventing translation. 
One of the most significant findings in relation to DHFRL1 is the fact it has been 
shown to not only auto regulate its own expression by binding of its own mRNA but 
it is also capable of binding the mRNA of DHFR. Likewise DHFR has also found to be 
capable of binding the mRNA of DHFRL1 (McEntee et al. 2011).  DHFR has been 
targeted with anti-folate chemotherpeutics in the treatment of cancer for over sixty 
years (Miller 2006). Treatment of cancer with the anti-folate drug methotrexate 
initially results in an up regulation of the DHFR enzyme due to the fact that the 
methotrexate binds the DHFR enzyme causing disassociation of the mRNA, leading 
to translation of the released mRNA (Ercikan-Abali et al. 1997).  The different 
affinities of DHFR and DHFRL1 for folate suggest that they may have different 
affinities to anti-folate inhibitors. If methotrexate is not an effective inhibitor of 
DHFRL1 it could potentially hold onto the mRNA of DHFR effecting its expression. 
Investigation into the expression of DHFRL1 in cancer would help in its evaluation as 
a viable chemotherapy target. It would also provide further insight into the 
expression of mitochondrial folate enzymes in cancer, which shall be discussed 
further in section 1.4.2. Differential expression such as in the case of over 
expression of enzymes proteins etc., is a desirable feature of chemotherapeutic 
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targets. Overexpression of genes and proteins generally gives an advantage to a 
cancer cell. Blocking this overexpression can have a deleterious effect on the cancer 
cell leading to cell death e.g. HER2 overexpression and its targeted treatment with 
Trastuzumab (Herceptin) in the treatment of breast cancer (Vogel et al. 2002). 
There are 15 amino acid differences between the human DHFR and DHFRL1 
enzymes. Single amino acid changes in the DHFR enzyme have previously been 
shown to impact the sensitivity of the enzyme to anti-folates. Indeed, site directed 
mutagenesis of amino acid residue 31 of the DHFR enzyme from a phenylalanine to 
a serine has been shown to result in an 11 fold reduction in catalytic efficiency and a 
100 fold reduced affinity for the anti-folate methotrexate (Schweitzer et al. 1989). 
Similarly, it has been shown that mutating the leucine at position 22 of the DHFR 
enzyme to a phenylalanine results in an 88 fold reduced affinity for methotrexate 
(Ercikan-Abali et al. 1996). Both positions 22 and 31 of the DHFRL1 enzyme are the 
same as DHFR, so it is unlikely that these residues would be a source of diversity 
between the enzymes. It is not fully known what the impact of the amino acid 
differences in DHFRL1 and DHFR has on the enzymes. It is known that DHFRL1 has a 
reduced affinity for folate in comparison to DHFR.  Due to the number of amino acid 
differences in DHFRL1 (relative to DHFR) it is likely that the differences impact the 
enzyme in many ways both structurally and functionally. McEntee et al (2011) 
noted that the arginine at position 24 of the DHFLR1 enzyme may be a source of the 
significant differences observed in this enzyme.   Gao et al (2013) performed 
predictive protein modelling into the conformation of the DHFRL1 enzyme which 
revealed that its structure may be closer to that of E.coli DHFR than to human 
DHFR.  Molecular dynamic simulations into substrate enzyme binding affinities 
indicated that mutating the arginine at position 24 of the DHFRL1 enzyme to a 
tryptophan (as found in DHFR) would restore DHFRL1’s binding affinity for folate 
(Gao et al. 2013) Further characterisation and investigation into the impact of 
specific amino acid differences between DHFR and DHFRL1 is needed in order to 
determine the contributions of the amino acids to the overall structure and function 
of the enzymes. In addition, analysis of DHFRL1’s expression in a cancer cell line 
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model will allow for the further characterisation of the emerging mitochondrial 
driven role within cancer, which shall be explored further in section 1.4.3. 
 
CLUSTAL O(1.2.1) multiple sequence alignment 
 
 
DHFR        MVGSLNCIVAVSQNMGIGKNGDLPWPPLRNEFRYFQRMTTTSSVEGKQNLVIMGKKTWFS 
DHFRL1      MFLLLNCIVAVSQNMGIGKNGDLPRPPLRNEFRYFQRMTTTSSVEGKQNLVIMGRKTWFS 
            *   ******************** *****************************:***** 
 
DHFR        IPEKNRPLKGRINLVLSRELKEPPQGAHFLSRSLDDALKLTEQPELANKVDMVWIVGGSS 
DHFRL1      IPEKNRPLKDRINLVLSRELKEPPQGAHFLARSLDDALKLTERPELANKVDMIWIVGGSS 
            ********* ********************:***********:*********:******* 
 
DHFR        VYKEAMNHPGHLKLFVTRIMQDFESDTFFPEIDLEKYKLLPEYPGVLSDVQEEKGIKYKF 
DHFRL1      VYKEAMNHLGHLKLFVTRIMQDFESDTFFSEIDLEKYKLLPEYPGVLSDVQEGKHIKYKF 
            ******** ******************** ********************** * ***** 
 
DHFR        EVYEKND 
DHFRL1      EVCEKDD 
            ** **:* 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 Clustal Omega alignment of DHFR and DHFRL1. There are 15 amino acid 
differences between DHFR and DHFRL1. The areas in yellow are the sequences 
required for catalytic activity of DHFR. Residues thought to be important for folate, 
NADPH and methotrexate binding are denoted in red (McEntee et al 2011). 
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                                                    DHFR Gene Family 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Chromosomal Location of the Human DHFR Gene Family. The two 
expressed enzymes DHFR and DHFRL1 are denoted in red and are located on 
chromosomes 3 and 5 respectively. The DHFR pseudo-genes, DHFRP1, DHFRP2 
and DHFRP3 are denoted in green and are located on chromosomes 18, 6 and 
2, respectively. 
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1.4.2 The Human MTHFD Gene family 
Methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like (MTHFD1L) is 
a mono-functional mitochondrial folate metabolising enzyme. MTHFD1L forms part 
of the MTHFD gene family consisting of the tri-functional cytoplasmic enzyme 
MTHFD1, and the bi-functional mitochondrial enzymes MTHFD2 and MTHFD2L, see 
Figure 1.5 (Tibbetts and Appling 2010). The MTHFD gene family is integral to the 
metabolism of folate via one carbon metabolism. Within the cytoplasm, the tri 
functional enzyme MTHFD1 utilises the one carbon units released from the 
mitochondria in the form of formate in three different ways. Formate is 
incorporated into the activated one carbon units cycle by its conversion to 10-
formyl-THF by MTHFD1, thus providing the required substrate for purine synthesis. 
MTHFD1 can also reduce formate to 5,10-methylene-THF, where it can utilised in 
either thymidylate bio-synthesis or incorporated into the methyl cycle for the re-
methylation of homocysteine to methionine (Tibbetts and Appling 2010). Within the 
mitochondria the enzymes MTHFD1L and MTHFD2/2L perform the 3 enzymatic 
reactions which the cytoplasmic MTHFD1 performs. MTHFD2 as stated previously is 
a bi-functional enzyme with 5,10-methenyl-THF (CH+-THF) cyclohydrolase and 5,10-
methylene-THF (CH2-THF) dehydrogenase activity.  MTHFD2 expression is absent in 
normal adult mammalian cells with the expression of the gene found in malignant 
transformed cells and in developing embryonic tissue where it is found to be 
essential (Tibbetts and Appling 2010).  In 2011 Bolusani et al (2011) discovered the 
existence of the MTHFD2L gene responsible for the 5,10-methenyl-THF (CH+-THF) 
cyclohydrolase and 5,10-methylene-THF (CH2-THF) dehydrogenase activity  within 
the mitochondria of normal adult mammalian cells .   
It is estimated that up to 75% of cytoplasmic one carbon units originate in the 
mitochondria (Pike et al. 2010). The MTHFD1L gene performs the crucial last step in 
the supply of one carbon units for cytoplasmic one carbon metabolism by the 
conversion of 10-formyl-THF to formate (Tibbetts and Appling 2010). Since its 
discovery, MTHFD1L has been shown to play a role in many diseases such as NTDs, 
CHD and neurodegenerative diseases, as outlined in section 1.2.  Most recently 
MTHFD1L has been associated with cancer, in particular the proliferation of rapidly 
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growing cancer cells. It appears that MTHFD1L, MTHFD2 and SHMT2 may work in 
conjunction with one another to allow for rapid proliferation and growth of cancer 
cells. Outlined below in section 1.4.3 is information regarding MTHFD1L and the 
appearance of a mitochondrial driven role within cancer.  
1.4.3 Emergence of a Mitochondrial Driven Role in Cancer 
 MTHFD1L was first associated with cancer by Sugiura et al (2004) who found the 
gene to be up regulated in colon adenocarcinoma. Gene expression was analysed in 
117 normal colon samples and 77 adenocarcinoma colon samples.  It was found 
that MTHFD1L was 1.45 fold increased in benign adenoma tissue compared to 
normal colon tissue. However, the increase in MTHFD1L expression was more 
pronounced in the adenocarcinoma tissues with a 2.38 fold increase observed.  The 
up-regulation of MTHFD1L in colon cancer was confirmed by examining its 
expression in normal colon cell lines (CCD841CoN) and cancerous colon cell lines 
(SW620 and HCT116). Once it was established that the over expression of MTHFD1L 
was linked to colon cancer, the authors set out to investigate what effect (if any) 
overexpressing MTHFD1L gene would have on the normal HEK 293 cell line.  
Interestingly it was found that over expression of MTHFD1L in HEK 293 led to 
increased “colony formation” or increased cell growth. Selcuklu et al (2012) found 
MTHFD1L to be up-regulated in breast cancer, where it is thought to be a target of 
miR 9, a micro RNA thought to possess tumour suppressor activity. Selcuklu et al 
(2012) also found MTHFD2 to be up regulated in breast cancer and found that the 
overexpression of miR 9 resulted in impaired cell growth and increased apoptotic 
activity. Most recently Jain et al (2012) associated MTHFD1L with cancer. The 
authors analysed the consumption and release (CORE) of 219 metabolites in the 
NCI-60 panel of cancer cell lines. Glycine consumption was found to be markedly 
increased in highly proliferative cancer cells whereas slowly proliferating cells were 
found to release glycine; see Figure 1.6. Glycine is a non-essential amino acid as it 
can be synthesised within the cell. Expression of the mitochondrial enzymes 
MTHFD1L, MTHFD2 and SHMT2 involved in the synthesis of glycine were associated 
with rapidly proliferating cancer cells whereas their cytoplasmic counterparts 
showed no such correlation, see Figure 1.6. It was established that glycine 
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consumption was a unique feature of rapidly proliferating cancer cells as normal 
cells with equivalent doubling times were found to release glycine (Jain et al. 2012). 
 Furthermore, Inhibition of SHMT2, a key enzyme in glycine biosynthesis, was found 
to greatly affect rapidly proliferating cells in the absence of glycine, whereas slowly 
proliferating cells remained largely unaffected. These findings indicate that glycine 
and its associated synthesising enzymes play a crucial role in driving cell growth and 
rapid proliferation.  Moreover, Expression levels of these mitochondrial enzymes 
MTHFD1L, SHMT2 and MTHFD2 were analysed in a cohort of 1300 breast cancer 
patients. It was found that patients with above median level expression of 
mitochondrial enzymes (MTHFD1L, SHMT2 and MTHFD2) experienced greater 
mortality. These findings suggest that MTHFD1L and mitochondrial enzymes may 
play a key role in cancer growth and progression (Jain et al. 2012).   
More evidence of the mitochondrial driven role in cancer cell growth and 
proliferation comes from Lehtinen et al (2013), who found that MTHFD2 was 
associated with increased mortality and poor outcome in breast cancer patients. 
Interestingly, it was shown that MTHFD2 may play a role in cancer invasion, 
migration and metastasis (Lehtinen et al. 2013). Most recently, A meta-analysis of 
available gene micro array sets by Nilsson et al (2014) encompassing over 20,000 
genes and 1,981 tumour types in 19 cancer types identified MTHFD2 as the most 
highly scored protein associated with cancer. It was also found that knockdown of 
the MTHFD2 gene resulted in cell death in human cancer cells. Moreover, high 
expression of MTHFD2 was associated with increased mortality in breast cancer 
patients, consistent with previous associations of mitochondrial folate enzymes and 
increased mortality (Nilsson et al. 2014). 
The uncovering of the up regulation of the mitochondrial folate pathway and its 
association with cancer presents us with the opportunity to further decipher the 
molecular mechanisms which occur during malignant transformation and cancer 
cell proliferation. Vasquez et al (2013) recently associated the expression of 
mitochondrial folate enzymes with increased methotrexate sensitivity in leukaemia 
patients, independent of DHFR expression. A biomarker for this mitochondrial 
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molecular gene signature would enable the stratification of patients based on their 
molecular profile into targeted drug therapies, hopefully leading to improved 
patients outcomes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 MTHFD Gene family domain structure. MTHFD1 is trifunctional with 
dehydrogenase, cyclohydrolase and 10-formyl THF synthetase activity.  The 
dehydrogenase, cyclohydrolase domain of MTHFD1L is inactive meaning that it is 
monofunctional with 10-formyl THF synthetase activity.  MTHFD2 and MTHFD2L are both 
bifunctional enzymes with dehydrogenase and cyclohydrolase activity. The blue domain 
represents the mitochondrial targeting sequence of MTHFD1L, MTHFD2 and MTHFD2L. 
Image taken from Tibbetts and Appling (2010). 
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Figure 1.6. A. Correlation of metabolites with cell doubling times in the nci-60 panel. 
Glycine is highlighted as significant p < 0.05. B. Correlation of the nci-60 panel 
proliferation rate and expression of metabolic enzymes with MTHFD1L, MTHFD2 and 
SHMT2 are significantly correlated with proliferation rate but their cytoplasmic 
counterparts MTHFD1 and SHMT1 are non-significant. Image taken from Jain et al 
(2012). 
 
A. 
B. 
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1.5 Aims and Objectives 
The overall aim of this thesis was to begin to elucidate the molecular mechanisms of 
mitochondrial folate enzymes in human disease.  This aim was addressed through 
the following questions: 
 Aim 1: Does manipulation of MTHFD1L expression have an impact on 
formate levels and cell growth? (Chapter 3). 
Objectives: Formate analysis by gas chromatography mass 
spectroscopy (GC-MS) in HEK 293 cells lines with modulated 
MTHFD1L expression. 
 Aim 2: What is the functional relevance of amino acid 24 in DHFRL1? 
(Chapter 4) 
Objectives: Expression of recombinant DHFR, DHFRL1 and the 
mutant DHFR W24R and the DHFRL1 R24W proteins in an 
E.coli expression system. Analysis of the effect of these 
mutations on protein solubility and structure.  
 Aim 3: Are folate enzymes differentially expressed in cancer 
metastasis? (Chapter 5). 
Objectives: RT-qPCR analysis of the folate related genes, 
DHFRL1, DHFR, MTHFD1, MTHFD2, MTHFD1L, SHMT1, 
SHMT2, TYMS, ATIC  in primary and metastatic cancer cell 
lines. 
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Chapter 2 
Methods and Materials 
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2.0 Materials 
2.0.1 Protein Production and Analysis 
Sigma Aldrich: Bis-acrylamide 40% w/v (Cat No. A9926), Ammonium Persulfate (Cat 
No. A3678-100G), Sodium Dodecyl Sulphate (Cat No. 71725), Dimethyl Sulfoxide 
(DMSO) (Cat No. D8418), EDTA (Cat No. EDS), Imidazole (Cat No. I5513), LB Broth 
(Cat No. L3033), Kanamycin (Cat No. K4000) Ampicillin (Cat No. A0166), Agar (Cat 
No. A5306), Yeast Extract (Cat No. Y1333), Tryptone (Cat No. T7293), NaCl (Cat No. 
S7653), L- Arabinose (Cat No. A3256),Gluthathione Agarose Beads (Cat No. G4510), 
Gluthathione (Cat No. G6013), Acetic Acid (Cat No. A6283), 2- Meracaptoethanol, 
(Cat No. M6250), Bradford Reagent (Cat No. B6916), Bovine Serum Albumin (Cat 
No. A3294),Glycine (Cat No. G8898), Tween (Cat No. P1379), Triton X (Cat No. 
X100), ColorBurst protein ladder (Cat No. C1992-1VL), His Select Nickel Affinity Gel 
(Cat No. P6611), Anti-Rabbit HRP secondary antibody (Cat No. A0545). 
Clontech: HisTALON™ Gravity Column Purification Kit (Cat No. 635654) 
Invitrogen: Bl21AI One Shot Chemically Competent Cells (Cat No. C6070-03),pDEST 
15 Plasmid Vector (Cat No. 11802-014), pDEST 17 plamsid vector (Cat No11803-
012).  BP Clonase Enzyme (Cat No. 11789-020), LR Clonase Enzyme (Cat No. 11791-
020), pDONR 221 (Cat No. 12536-017). 
Bioline: Alpha Gold Efficiency Competent Cells (Cat No. BIO– 85027). 
Thermo Scientific: 4- 20% w/v Tris Glycine Gels (Cat No. 25269), Super Signal West 
Femto Reagent (Cat no. 34096), Western Blot Stripping Buffer (Cat No. 46430), 
Western Blotting Filter Paper (Cat No. 84783), Carbenicillin (Disodium Salt) (Cat No. 
BP2648-5), Coomassie Brilliant Blue G250 Dye (Cat No 20279), PageRuler Plus 
Prestained Protein Ladder (Cat. No 26619),  Pierce 1-Step Transfer Buffer (Cat No. 
84731), PVDF Transfer Membrane (Cat No. 88518).  
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2.0.2 Molecular Biology 
Agilent: QuikChange Lightning Multi Site-Directed Mutagenesis Kit (Cat No. 
210518).  
Sigma Aldrich: Agarose (Cat No. A9539), Orange G Loading Dye (Cat No. O3756), 
RNA Loading Dye (Cat No. R1386), Taq Polymerase 5U/µl (D4545), DNAse treatment 
kit (Cat No: AMPD1-KIT). 
Promega: dNTP’s (Cat No. U1515) 
New England Biolabs: 100bp ladder (Cat No. N3231L), 1kB DNA Ladder (Cat No. 
N0468S),. 
Bioline: Plasmid Isolation Kit (Cat No. BIO-52026), RNA Extraction Kit (Cat No. BIO-
52072), Random Hexamers (Cat No. BIO- 38028), Bioscript (Cat No. BIO-27036), 
Oligo dT (Cat No. BIO- 38029), Ribosafe RNAse inhibitor (Cat No.  Bio-65027), Sensi 
Mix One Step Kit (Cat No. 76001).  
Applied Biosystems: Taq man RT-qPCR assays (Cat no. 4331182) MTHFD1 (Hs 
01068268_g1), MTHFD2 (Hs 00759197_s1), SHMT1 (Hs 00244618_m1). 
Roche: Universal Probe Library 1-90 (Cat No. 04683633001). 
2.0.3 Cell Culture 
Sigma Aldrich: Trypsin EDTA (Cat No. T4049), Sodium Pyruvate (Cat No. S8636), 
Dulbecco’s Modified Eagle Medium (DMEM) (Cat No. D5796), Cell Freezing Medium 
(Cat No. C6039), Propidium iodide (Cat No. P4864), Isopropyl β-D-1-
thiogalactopyranoside (IPTG) (Cat No. 15502), Fetal Bovine Serum (FBS) (Cat No. 
F9665). 
Lennox: Puromycin Dihydrochloride (Cat No. CA 2856 0010) 
Gibco: Trypan Blue (Cat No. 15250-061), Phosphate Buffer Saline 10X (Cat No. 
14200). 
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Greiner Bio One: Tissue Culture Flasks 75cm2 (Cat No. 658175CI), Tissue Culture 
Flasks 25 cm2 (Cat No. 690175 CI), 6 Well Plates (Cat No. 657160), Cell Scrapers (Cat 
No. 541070G). 
Promega: Cell Titre 96 Non-Radioactive Cell Proliferation Assay (MTT) (Cat No. 
G4100). 
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2.0.4 Equipment 
 Eppendorf pipettes (P10, P100, P1000) and Gilson Pipettes (P20) were used 
for micropipetting. 
 Nano drop 100 Thermo Scientific  
 GeneGnome Syngene Bio-imager 
 DNR Mini-Bis Pro Bio-Imaging System 
 Roche Lightcycler® 480 
 Tecan i600 spectohotometer  
 Theremo Scientific Pierce G2 Fast Blotter 
 Thermo Scientific Forma Steri-Cycle Co2 Incubator  
 Innova®43 Incubator Shaker Series New Brunswick Scientific 
 Applied Biosystems GeneAmp® PCR System 9700  
 Thermo Scientific Forma Steri-Cycle Co2 Incubator  
 Bioair Safeflow 1.2 Laminar Flow Biosafety Cabinet 
 Branson Digital Sonifier  
 
2.0.5 Stock Solutions 
 Coomassie Blue Stain: 2.5g Coomassie, 100ml Acetic Acid, 300ml Methanol, 
600ml H2O. 
 Coomassie Blue De-stain – 100ml Acetic Acid, 300ml Methanol, 600ml H2O. 
 LB Broth – 5 grams of tryptone, 5 grams of NaCl, 2.5grams of yeast extract, 
500ml of H2O. 
 LB Agar – 15g of agar per litre of LB Broth 
 Tris Glycine Running Buffer (10 X):  15.14 grams of Tris HCL, 5 grams of SDS, 
71.3 grams of glycine (pH 8.3). 
 Transfer Buffer (1 X) – 100 mL 10 X Transfer Buffer, 200 mL Methanol, 700 
mL dH2O.  
 Sample buffer ( 4X)– 2.4 mL 1M Tris / HCl (pH 6.8), 4 mL Glycerol, 1 g SDS, 4 
mg Bromophenol blue, 500 µL betamercaptoethanol, 3.1 mL dH2O (pH 6.8). 
 TBS (10 X): 24.23 grams of Tris HCL, 80.06 grams of NaCl, 1 L of H2O (pH 7.6). 
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 TBS-T: 50 mLs of 10 X TBS, 450 mL of H2O, 250 μl Tween 20. 
 5% w/v Milk Blocking Buffer:  2.5 grams of Non Fat Milk Powder, 50ml of 1 
X TBST. 
 Bacterial Lysis Buffer: 50 mM Potassium Phosphate (pH 7.8), 400 mM NaCl, 
100 mM KCl, 10 % w/v Glycerol, 0.5 % w/v Triton X-100, 10 mM Imidazole 
(pH 7.8). 
 Orange G (10 X): 0.1gram Orange G, 20 grams of sucrose, 50 ml of H20   
 TBE (10 X): 48.44 grams of Tris HCL, 12.37 grams of Boric Acid, 1.5 grams of 
EDTA, 500 mls of H2O(pH 8.2). 
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2.1 Methods 
2.1.1 Plasmid Preparations 
A single colony of bacteria containing the desired plasmid of interest was picked 
and used to inoculate 5ml LB Broth containing a selective agent (100µg/ml 
ampicillin).  The broth was incubated at 37°C shaking at 220 RPM overnight. The 
overnight culture was centrifuged at 1500 x g for 10 minutes to pellet the bacterial 
cells. The Plasmid DNA was then extracted from the bacteria using the Bioline 
Plasmid isolation kit (Cat No. BIO-52026) as per manufacturer’s instructions. 
2.1.2 Quantification of DNA and RNA 
The Thermo Scientific Nano Drop 1000 apparatus was used to quantitate DNA and 
RNA. A 1 µl volume of DNA or RNA was loaded onto the pedestal of the apparatus 
and measured at 260nm. Nucleic acids free from contamination by either salt of 
organic compounds should have a 260:280 ratio of between 1.8-2.0. 
 
2.1.3 Agarose Gel Electrophoresis 
Agarose was added to 1 X Tris-Borate-EDTA (w/v) and boiled in a microwave oven 
until completely dissolved. The mixture was then cooled under running water until 
it was “hand hot”. A 5μl volume of Ethidium bromide (10μg/ml) was added to a 
150ml agarose gel (0.33 μg/ml). The agarose gel was set in a mould and wells were 
created using a standard gel comb.  The DNA samples were mixed with Orange G 
loading dye and loaded into the wells. The appropriate DNA ladder was also loaded 
(either 100bp or 1kb). RNA was mixed with RNA loading buffer (Sigma Aldrich Cat 
No. R1386) and heated to 70 °C for 10 minutes; the tube containing the RNA was 
then put on ice prior to loading onto the agarose gel. Agarose gels were set at 90 
volts for 40-50 minutes until resolved. Agarose gels were imaged and photographed 
under UV light with DNR Mini-Bis Pro Bio-Imaging System 
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2.1.4 Bacterial Cell Transformation 
 The pDEST 17 Plasmids (DHFRL1, DHFR or mutants DHFRL1 R24W and DHFR W24R ) 
were transformed into BL21 AI One shot bacterial cells using the heat shock 
method. For each plasmid transformation one vial of the BL21 AI Bacterial cells was 
incubated with approximately 10ng of plasmid DNA in a final volume of 5µl for 30 
minutes on ice. The cells were then placed in a water bath at 42 °C for 30 seconds to 
heat shock.  Cells were immediately returned to ice and 250 µl of pre-warmed S.O.C 
(Invitrogen Cat No. C6070-03) medium was added. Cells were then placed in an 
incubator at 37° C shaking at 220 RPM for 1 hour. Cells were then plated on LB agar 
with a selective agent (100µg/ml ampicillin). Plates were incubated at 37 °C 
overnight.  
  2.1.6 Site Directed Mutagenesis 
Site directed mutagenesis was performed to mutate the tryptophan at position 24 
of the DHFR enzyme to an arginine (W24R) and to mutate the arginine at position 
24 to a tryptophan in the DHFRL1 enzyme (R24W).  The Agilent QuikChange 
Lightning Site-Directed Mutagenesis Kit was used to introduce the mutations 
(Product no. 210518). Primers were designed as per the instruction manual, see 
Table 1 page 33. The following reaction was set up to introduce the mutations into 
the DHFR and DHFRL1 genes: 
 5 l of 10× reaction buffer 
  100 ng of pDEST 17 template (either DHFR or DHFRL1) 
 125 ng of oligonucleotide primer #1 X l (DHFR/DHFRL1) 
 125 ng of oligonucleotide primer #2 (DHFR/DHFRL1) 
 1 l of dNTP mix  
 1.5 l of QuikSolution reagent  
 H2O was added to a final volume of 50 l 
 Lastly 1 l of QuikChange Lightning Enzyme 
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The site directed mutagenesis reactions were then incubated as follows: 
 95°C for 2 minutes 
 95°C 20 seconds 
 60°C 10 seconds 
 68°C 30 seconds 
  68°C 5 minutes 
Dpn I Digestion was carried out to digest the parental non mutant plasmid DNA. 
This was performed by the addition of 2 l of Dpn I restriction enzyme to both the 
DHFR W24R and DHFRL1 R24W reactions. The digestion reaction was gently mixed 
and then incubated at 37°C for 5 minutes to digest the parental plasmid DNA. The 
mutated plasmids were then transformed into XL10 –Gold ultra-competent cells as 
follows. XL10 –Gold ultra-competent cells were thawed on ice and 2l of -ME mix 
from the site directed mutagenesis kit was added, the cells were swirled gently and 
incubated on ice for 2 minutes. 2l’s of the Dpn I treated plasmid DNA was added to 
the cells and incubated on ice for 30 minutes. The cells were then heat shocked for 
30 seconds at 42°C and then returned to ice for 2 minutes. 500l of preheated NZY+ 
broth was then added to each tube. The tubes were then incubated at 37°C for 1 
hour with shaking at 225 RPM.  50l’s and 150l’s of each transformation were 
plated onto Lb ampicillin plates (100g/ml). The transformation plates were 
incubated overnight a 37°C overnight. A plasmid preparation was performed as per 
section 2.1.1 and the isolated plasmids were sent for Sanger sequencing to confirm 
that the mutations had been inserted. 
 
 
 Sequence 
DHFR W24R 
 
For:GAACGGGGACCTGCCCAGGCCACCGCTCAGGAA 
Rev:TTCCTGAGCGGTGGCCTGGGCAGGTCCCCGTTC 
DHFRL1 R24W For:GAACGGGGACCTGCCCTGGCCGCCGCTCAGGAA  
Rev:TTCCTGAGCGGCGGCCAGGGCAGGTCCCCGTTC 
 
 
X 18 cycles 
Table 1.0 DHFRL1 and DHFR Site Directed Mutagenesis Primers  
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2.1.7 Induction of Recombinant Protein Expression 
Using the tip of a p10 pipette a single colony containing the plasmid pDEST 17 
(DHFR, DHFRL1 or mutants W24R, R24W) was selected and cultured overnight in LB 
broth (ampicillin 100μg/ml) shaking at 220rpm at 37oC. The next day a 1/20 dilution 
of the overnight culture into fresh LB broth was performed. The dilution allows the 
cells to quickly return to logarithmic growth. After approximately 1 hour and 40 
minutes 1ml of culture was removed and placed in a spectrophotometer and 
measured at 600nm. The culture must have an optical density of between 0.4-0.5 
(mid log phase) in order to proceed to the next step. The cultures were then split in 
two with 0.2% w/v of L-arabinose added to one of the cultures in order induce 
expression of the target protein, the un-induced culture acted as a control. In order 
to identify the time period at which the cells produce the greatest amount of 
protein, 1ml samples of induced and un-induced samples were taken at 0 hours, 2 
hours, 4 hours, 6 hours and 24 hours after L-arabinose addition. Whole bacterial cell 
lysate was analysed for each time point by mixing with 4 X SDS PAGE buffer and 
heating to 99°C for 5 minutes and analysed by SDS PAGE as per section 2.1.9. After 
the desired time period of induction the cultures were centrifuged at 2,200 X G for 
30 minutes at 4oC. The LB broth was poured off and the pelleted cells were stored 
at -20 oC and used for purification as per 2.1.11 or were used for solubility analysis.  
For solubility analysis the cell pellets were weighed and B-PER Bacterial Protein 
Extraction Reagent (Cat no. 78243) was added in a ratio of 4mls/gram weight of 
bacteria. The bacterial samples were then lysed by sonication on ice in the Branson 
Digital sonifier apparatus at 30% amplitude for 3 X 10 seconds with a 30 second 
cooling period in between each sonication round. The bacterial/B-PER samples were 
then incubated at room temperature for 20 minutes and then centrifuged for 30 
minutes at 10,000 x g at 4°C. This separated the samples into the soluble and 
insoluble fractions. All fractions were analysed by SDS and Western blot as per 2.1.9 
and 2.1.10.  
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2.1.8 Purification of His Tagged DHFRL1 by His-Talon Affinity Purification  
Samples Fractionation: Pelleted induced BL21 AI bacterial samples containing 
pDEST 17 were re-suspended in HisTALON xTractor Buffer in a ratio of 2ml of buffer 
per 100mg of cell pellet. Samples were incubated for 15 minutes on ice. The 
bacterial samples were then lysed by sonication on ice in the Branson Digital 
sonifier apparatus at 30% amplitude for 3 X 10 seconds with a 30 second cooling 
period in between each sonication round. Samples were then centrifuged for 20 
minutes at 10,000 x g at 4°C. The supernatant containing the soluble protein 
fraction was removed  an aliquot was saved for SDS PAGE and Western blot analysis 
the remaining soluble fraction was applied to the His-Talon affinity column. 
Affinity Purification: All buffers were de-gassed prior to use by using 0.2µm 
membrane filter. The affinity resin was equilibrated with 6 bed volumes (6ml) of 
equilibration buffer, the buffer flowed off by gravity and was discarded. The 
clarified protein fraction was applied to the column in 5ml fractions; the flow 
through was collected and placed in a tube on ice. The first wash step was 
performed using 8 column volumes (8ml) of wash buffer, the wash step fraction was 
collected and stored on ice. The second was step was performed with 7 column 
volumes (7ml) of wash buffer this fraction was collected and stored on ice. The 
target recombinant His tagged protein was eluted using 6 ml of elution buffer 
collected in 1 ml fractions. Each 1ml fraction of eluted target protein was stored in 
500 µl of glycerol to prevent damage of the protein by freeze thaw from storage at -
20°C. All protein fractions were analysed by SDS PAGE and or Western Blot. 
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2.1.9 SDS Page Analysis Both pre-cast (Thermo Scientific Cat No. 25269) and 
“homemade” SDS PAGE gels were used for protein analysis. 
 SDS PAGE gel recipe: To make a 10% w/v polyacrylamide gel the following 
was added. Resolving Gel: 4ml of H20, 3.3ml of 30% w/v acrylamide, 2.5ml 
of 1.5M trizma base, 100ul of 10% w/v SDS, 100ul of 10% w/v APS and 4ul 
of TEMED. Once the gel is poured into the mould a layer of 70% w/v ethanol 
was added to ensure that the gel sets evenly. When the resolving get was 
set the ethanol was poured off and the stacking gel was added. Stacking 
Gel: 3.4ml of H2O, 830ul of 30% w/v acrylamide, 630ul of 1m trizma base at 
pH 6.8, 50ul of 10% w/v SDS, 50ul of 10% w/v APS and 5ul of temed. A 12 
well comb is added to the stacking gel in order to provide well’s for the 
samples to be analysed. 
 Protein sample preparation: Protein samples to be analysed were mixed 
with 4X sample buffer and heated at 95 °C for 5 minutes. The denatured 
protein samples were loaded onto an SDS PAGE gel (Thermo Scientific 4-
20%) or a “homemade” 10% w/v SDS PAGE gel. 
  SDS PAGE analysis: The SDS PAGE gels were run at 100 volts until samples 
had passed through the stacking layer of the gel. The voltage was then 
increased to 120 volts. The gel was run for the appropriate time for the 
ladder to resolve sufficiently which was approximately ~ 1 hour for the pre 
cast gels and 2 hours for the “homemade” gels. The SDS PAGE gel was then 
either used for western blot analysis (see below) or stained in coomassie 
blue for two hours while rocking gently. The SDS PAGE gels were then 
destained in destaining solution and then visualised and photographed 
under white light using the Mini Bis Pro Gel imager. 
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2.1.10 Western Blot Analysis 
Two transfer methods were used for western blot analysis, the Biorad Mini 
Transblot Cell and the Thermo Scientific G2 Fast blotter. 
 Thermo Scientific G2 Fast blotter  
The PVDF membrane was placed in the methanol for 30 seconds to charge. 
The  PVDF membrane, the SDS PAGE gel and filter paper were then 
equilibrated in the Pierce 1 step transfer buffer for 10 minutes. The cassette 
for Pierce G2 fast blotter was assembled with the aforementioned pre-
soaked materials, see figure 2.0 below. A roller was used in between the 
addition of each layer to eliminate any air bubble which could interfere with 
the transfer. The transfer was then set at 25 volts for 7 minutes. 
 
 
 
 
 
 
 
Figure 2.6 Schematic of Thermo Scientific G2 Fast Blotter.  Transfers were set up 
with two layers of pre-soaked filter paper with PVDF membrane pre charged with 
methanol and soaked in transfer buffer with the SDS PAGE gel on top with two 
additional layers of filter paper over the gel. (Image taken from the fast blotter 
user manual May 2015 http://www.medical-
supply.ie/products/attachments/62288%20Thermo%20Pierce%20G2%20Fast%20
Blotter.pdf) 
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  Biorad Mini Transblot  Cell 
 
The PVDF membrane was placed in the methanol for 15 seconds to “pre 
wet”. The PVDF membrane, the SDS PAGE gel, fibrous pads from the mini 
trans blot system and filter paper were then equilibrated in transfer buffer 
for 15 minutes at 4 °C. The cassette for the mini trans blot transfer system 
was assembled with the aforementioned pre-soaked materials. The ice block 
and stirring bar were added to the transfer tank. The transfer was set at 100 
volts for 60 minutes in a 4 °C cold room. 
 Primary Antibody addition: To confirm the transfer the membrane was then 
stained with ponceau S. The ponceau S stain was removed by washing with 
TBST. The membrane was then blocked for 1 hour gently rocking at room 
temperature in a 5% w/v milk TBST solution.  The blocking buffer was then 
removed and the primary DHFR or his antibody was then added at a 
1/10,000 dilution in a 5% w/v milk TBST solution and left at 4 °C gently 
rocking overnight. 
 Secondary Antibody addition: The primary antibody was then removed and 
three consecutive 15 minute washes with TBST were performed to ensure 
removal of excess unbound primary antibody.  The anti-rabbit secondary 
antibody was then added at a 1/50,000 dilution in TBST solution at room 
temperature and left to rock gently for one hour. The membrane was then 
further washed with TBST (3 x 15 minutes).  
 Western Blot Imaging: The working solution of the Signal West Femto 
reagent was then prepared and 1ml was then applied to the membrane. The 
membrane was then imaged with the Gene Gnome Instrument (Syn Gene). 
2.1.11 Bradford Assay 
The Bradford assay allows for the quantification of protein in an unknown sample. 
The assay was carried out in a 96 micro well plate and the Tecan i600 
spectrophotometer.tohotometer was used to measure the absorbance of the 
protein samples and standards. 
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 Protein standards were made up at 25µg, 125µg, 250µg, 500µg, 750µg, 
1000µg, and 1500µg of bovine serum albumin (BSA). 
 5µl of each standard and protein of unknown concentration was added to a 
96 well micro-plate in duplicate. 
 250µl of Bradford reagent was added to the samples and standards. The 
plate was wrapped in tinfoil, rocked gently for 30 seconds to mix and then 
incubated for 15 minutes at room temperature. 
 The absorbance of the samples and standards was then read at 595nm.   
 The concentration and absorbance of the standards was then plotted in 
Microsoft Excel. The equation of the line was then used to determine the 
concentration of the unknown protein samples. 
2.2 Cell Culture 
2.2.1 HEK 293 MTHFD1L Over expressed and Knockdown Cell Lines 
Previously generated HEK 293 cells with modulated levels of MTHFD1L were utilised 
in this research thesis. The MTHFD1L knockdowns 1 and 2 were generated by 
knocking down the MTHFD1L gene using shRNA down regulation which could be 
essentially “turned on” by the addition of the inducer molecule IPTG. The MTHFD1L 
overexpressed HEK 293 contained a plasmid vector pcDNA 3.2 which constitutively 
over expressed the MTHFD1L gene. Human Embryonic Kidney 293 (HEK 293) cells 
were cultured in Dulbecco’s modified Eagle medium DMEM with 10%  fetal bovine 
calf serum, 200mM L-glutamine in a 5% CO2 incubator at 37°C. The HEK293 shRNA 
MTHFD1L knockdown lines (1 and 2) and the associated non targeting shRNA 
control were grown in normal HEK 293 medium supplemented with puromycin (5 
µg/ml) as a selective agent and with IPTG (200 µM) to induce the shRNA down 
regulation. The MTHFD1L overexpressed cell line and the empty vector control were 
grown in normal HEK293 medium supplemented with 500 µg/ml of the selective 
agent G418. Cells were cultured in 10ml of medium and seeded in 75 cm2 tissue 
culture flasks. Cells were passaged by removing culture media, rinsing with 2mls of 
Trypsin-EDTA then incubating the cells with 3ml of Trypsin-EDTA at 37 °C for 5- 10 
minutes. The trypsin is neutralised by the addition of 3ml of complete DMEM. Cells 
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are then centrifuged at 500 X G for 5 minutes to pellet the cells. Pelleted cells were 
then re-suspended in cell culture medium and seeded in 75 cm2 tissue culture flasks. 
2.2.2 Intracellular and Cell Medium Formate Quantification 
In order to test the effect that altering the level of the MTHFD1L gene has on its 
metabolite production formate the HEK 293 cell lines with modulated levels of the 
MTHDFD1L gene were utilised. Prior to collection of samples all microfuge tubes 
were washed in ultra-pure H2o to reduce the risk of formate contamination from 
the plastic. Optimisation was performed with the cell lines in order to identify the 
ideal seeding density for growth over five days. It was identified that a density of 2 X 
106 was optimum. For formate quantification HEK 293 cell lines with altered 
MTHFD1L expression and associated controls (1.MTHFD1L overexpressed, 2. 
MTHFD1L over expressed empty vector control, 3. MTHFD1L shRNA knockdown 1, 
4. MTHFD1L shRNA knockdown 2,5. Knockdown control of non-targeting shRNA,6. 
normal HEK293 cells) were set up set up at a cell density of 2 X 106 in triplicate and 
seeded in 75 cm2 tissue culture flasks. 300 µl’s of cell culture medium was removed 
from the each cell line in duplicate every 12 hours for 5 days and stored at -80 °C. 
After 5 days had elapsed flasks set up in duplicate for each cell line were trypsinized 
and cells were counted (as per section 2.2.4). The cell pellet of each cell line was 
stored at -80 °C. The third flask set up of each cell line was used for RNA extraction 
to confirm MTHFD1L expression by RT-qPCR (as per section 2.3). All medium 
samples and cell pellets collected for the 5 day experiment were sent on dry ice to 
Dr Sean Brosnan in the University of Newfoundland, St. John’s Canada for formate 
analysis by gas chromatography mass spectroscopy (GS-MS).   Two approaches 
were taken in the normalisation of intracellular formate levels within the MTHFD1L 
over expressed and knockdown HEK 293 cell lines. Formate concentration for each 
replicate was divided by its corresponding protein concentration (Obtained via 
Bradford assay) or number of cells present on final day of experiment. Replicate 
values were averaged and the standard deviation values were obtained. The 
normalised formate values were plotted in Microsoft Excel for the MTHFD1L over 
expressed and knockdown cell lines. Statistical significance was determined by 
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Student’s t-test using Microsoft Excel. The formate cellular medium concentrations 
were normalised to the volume of medium in each flask at the time of collection. 
 
2.2.3 SW480 and SW620 Cell lines 
SW480 and SW620 cells were cultured in Dulbecco’s modified Eagle medium DMEM 
with 10% fetal bovine calf serum, 200mM L-glutamine in a 5% CO2 incubator at 37 
°C. . Cells were passaged by removing culture medium, rinsing with 2mls of Trypsin-
EDTA then incubating the cells with 3ml of Trypsin-EDTA at 37 °C for 5- 10 minutes. 
The trypsin is neutralised by the addition of 3ml of complete DMEM. Cells are then 
centrifuged at 500 X G for 5 minutes to pellet the cells. Pelleted cells were then re-
suspended in cell culture medium and seeded in 75 cm2 tissue culture flasks. 
2.2.4 Cell Enumeration 
Cell viability counts were performed by the addition of the trypan blue at a 1:4 
concentration; the cells were then left at room temperature for 5 minutes. The cells 
were then added to a haemocytometer and visualised at 100x magnification under 
a microscope. The number of live cells per square of the haemocytometer was then 
counted. Live cells appear white and the dead cells appear blue. The number of live 
cells was then calculated per ml of cells by multiplying by the dilution factor and 
then by 104. 
2.3 RT-qPCR Analysis 
2.3.1 RNA Extraction and cDNA Synthesis 
Cell pellets were washed with 1ml of PBS and RNA was extracted using the Bioline 
RNA extraction kit as per manufacturer’s instructions. The extracted RNA was 
quantified using the Nano drop 1000 (Thermo Scientific). The quality of the RNA 
was assessed by agarose gel electrophoresis. For DNAse treatment of RNA the 
following was performed, 1µl of Sigma 10x reaction buffer (R6273-1ML) and 1µl of 
Sigma DNAse 1(D5307 1000u/ml) to 2 µg’s of RNA in a final volume of 10 µl. The 
DNAse reaction was incubated for 10 minutes at room temperature. The reaction 
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was inactivated by the addition of 1 µl of Sigma stop solution (S4809-1ML) and the 
RNA was heated to 70 °C for 10 minutes. Reverse transcription was performed by 
the addition of 2 µl (50 ng/ μl) of Bioline random hexamers primers (RHP-111C) and 
4 µl (50µm) of oligo (dT) 18 primer mix (ODT-110L) to the DNAse treated RNA and 
incubated at 70 °C for 5 minutes, tubes were the placed on ice for 1 minute. Then 
remaining constituents of the reaction were added as follows, 1 x Bioline reaction 
buffer (MB-1091), 1μl of ribonuclease inhibitor (40,000u/ml R2520-2.5KU), 1μl of 
Bioline Bioscript (200u/µl, BIO-27036). The cDNA reaction was then incubated on 
the thermocycler as follows: 
 10 minutes at 25 °C 
 60 minutes at 42 °C 
  15 minutes at 70 °C 
  hold at 4 ° C.  
The cDNA was then either stored at -20 °C or used for the genomic DNA 
contamination assay and subsequent real time PCR analysis. 
 
2.3.2 Genomic DNA Contamination Assay 
Prior to RT-qPCR analysis of cDNA the MTHFD1 R653W intron flanking PCR assay 
was performed in order to ensure that the RNA from which the cDNA was 
synthesised was free of genomic DNA. The intron spanning assay allows for the 
detection of genomic DNA. The expected size of the PCR products of cDNA free 
from genomic DNA contamination is 232bp. The expected size of the PCR products 
containing genomic DNA is 330 bp. Contaminated cDNA would be represented by 
two PCR bands at 232 bp and 330bp. Although all RT-qPCR assays were intron 
spanning, genomic DNA may still interfere non-specifically and this assay acts as an 
extra control. A  PCR master mix was made as per table 1.2. See Table 1.1 below for 
primer sequences.  
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MTHFD1 R653Q Sequence 
Forward Primer 5′- CACTCCAGTGTTTGTCCATG -3′ 
Reverse Primer 5′- GCATCTTGAGAGCCCTGAC-3′ 
 
 
Reagent 1X reaction 
10 X PCR Buffer 5µl 
MgCl2 3µl 
2.5 mM DNTP 4µl 
Forward Primer 0.3µl 
Reverse Primer 0.4µl 
cDNA 1 µl 
Taq Polymerase 0.2µl 
H2O 36.1µl 
 
 
 
 
 
The PCR reaction was placed in the Applied Biosystems GeneAmp® PCR System 
9700 set at the following: 
 
 
 95°C for 3 min 
  94°C for 30 s 
 58°C for 1 min 
 72°C for 1 min 
 72°C for 10 min. 
 PCR products were analysed on a 1% w/v agarose gel by electrophoresis, as per 
section 2.1.3 
 
Table 1.1 MTHFD1 R653Q Primer Sequences 
Table 1.2PCR Master mix 
35 Cycles 
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2.3.3 Reverse Transcriptase Polymerase Chain Reaction (RT-qPCR) 
 
RT-qPCR assays were carried out in white 96 well plates in the Roche Lightcycler® 
480 machine. RT-qPCR assays were carried out using the Roche Universal Probe 
Library (UPL) and Applied Biosystem’s Taq Man primer probe mix.  A PCR master 
mix was made up for each gene to 15 μl and 1 μl of cDNA was added per reaction, 
as per Table 1.3. See Table 1.4 for primer sequences. The comparative E-method 
was used to determine the fold change between target genes relative to a reference 
gene (Tellman 2006). 
 
 
 
 
Each gene was analysed in triplicate and a negative control was also set up with 1 μl 
of H2O in place of cDNA.  The PCR reaction was up as follows: 
 
 95°C for 5 min 
 95°C for 30 sec 
 60°C for 30 sec 
 72°C for 1 sec  
Applied Biosystems Taq man assays were used in the analysis of MTHFD1 (product 
no. Hs01068268_g1), MTHFD2 (product no. Hs00759197_s1) and SHMT1 
(HS00244618). 
 
Reagent 1 X Reaction 
SensiMixII 8 μl 
Probe 0.16 μl 
Forward primer (0.2 μM/μl) 0.16 μl 
Reverse primer (0.2 μM/μl) 0.16 μl 
H₂O 5.52 μl 
45 Cycles 
Table 1.3 PCR master mix 
46 
 
                                         DHFR Primers, UPL Probe # 24 
Forward Primer    5’GGGGGAAAGCTGGAGTATTG3’ 
Reverse Primer 5’ACTATGTTCCGCCCACACAC 3’ 
                                         DHFRL1, UPL Probe #89 
Forward Primer 5’CGGACCTTAGAAAGTCACACATC3’ 
Reverse Primer 5’GCGAAATTCCCTTCTTCAAA 3’ 
                                             MTHFD1L, UPL Probe #42 
Forward Primer    5’GAGCTCTGAAGATGCATGGAG 3’ 
Reverse Primer 5’TGCTTCTGGAGGTTACAGCA 3’ 
                                          SHMT2, UPL Probe #83 
Forward Primer 5’ TTGCTGCCCTAGACCAGAG 3’ 
Reverse Primer 5’GACCAGCTGCCCACATCT 3’ 
                                         TYMS, UPL Probe #43 
Forward Primer 5’ CCCAGTTTATGGCTTCCAGT 3’ 
Reverse Primer 5’GCAGTTGGTCAACTCCTGT 3’ 
                                         GUS, UPL Probe #57 
Forward Primer 5’  ACGCCAGCTTCAAAGCAA 3’ 
Reverse Primer 5’ TCACAGGAGAATCACTTCAACC  3’ 
                                          ALDH51, UPL Probe #64 
 
Forward Primer  5' TCG AGA ACA GGG AAT AAC ATT G 3' 
 
Reverse Primer  5' TGA TTT GGA TCC ATT GTT GC 3' 
 
                                               ATIC, UPL Probe #89 
       
Forward Primer 5’ GAGGGACTGCAAAAGCTCTC 3’ 
 
Reverse Primer 5’ GGA AATCCCGTCAACTCAGA 3’ 
 
 
 
 
 
 
Table 1.4 Primer Sequences and UPL probes for RT-qPCR Assays 
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Expression on Formate 
Production and Cell 
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3.0 Introduction 
The main aim of this chapter is to characterise the effects altered 
Methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like (MTHFD1L) 
expression has on HEK 293 cells. MTHFD1L is a monofunctional enzyme involved in 
folate metabolism. MTHFD1L is located in the mitochondria and is responsible for 
the crucial last step in the provision of one carbon units for the cytoplasm by the 
conversion of 10-formyl-THF to formate (Tibbetts and Appling 2010). Formate is 
utilised in one carbon metabolism in the production of purines, thymidylate and the 
re-methylation of homocysteine to methione, a donor group for cellular 
methylation reactions (Fox and Stover 2008). It is estimated that up to 75% of 
formate for one carbon metabolism originates in the mitochondria (Pike et al. 
2010). 
 As discussed in section 1.2 folate is associated with many multifactorial diseases, 
aside from folate consumption genetic polymorphisms and gene expression of 
folate metabolising enzymes also contribute to the risk of disease such as neural 
tube defects (NTD’s), cancer, Cardiovascular disease (CVD) and neurological 
diseases (Kirke et al. 2004, Samani et al. 2007, Cole et al. 2007). A delicate balance 
between formate supply and demand must be maintained within the cell for 
effective maintenance of one carbon metabolism. This is demonstrated by the work 
of Parle-McDermott et al (2009) who found that a deletion insertion polymorphism 
(DIP) (rs3832406) which effects alternative splicing of the MTHFD1L gene resulting 
in increased levels of the MTHFD1L enzyme is associated with Neural Tube Defect 
(NTD) risk. Impairment of folate metabolising enzymes is generally associated with 
increased NTD risk, the fact that a polymorphism in the MTHFD1L gene which 
results in greater enzyme levels is associated with NTD risk highlights the 
importance of metabolic balance (Kirke et al. 2004). It is thought the increased 
levels of MTHFD1L results in an increase in formate which causes a disruption to the 
flow and balance between cytoplasmic and mitochondrial one carbon metabolism, 
hindering cellular proliferation. The authors also hypothesised that excess formate 
may build up to toxic levels within developing embryos disrupting cellular 
proliferation (Parle-McDermott et al. 2009). Such is the importance of the MTHFD1L 
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gene Momb et al (2012) found that its absence was embryonic lethal in mice. The 
authors also found that knocking out the gene resulted in NTD development with 
100% penetrance. Further proof of the role of the MTHFD1L gene in NTD’s comes 
from Minguzzi et al (2014) who found that a single nucleotide polymorphism (SNP) 
rs7646  within the gene affects microRNA binding resulting in increased NTD risk.  
The SNP  rs11754661 within the MTHFD1L gene has also been associated with 
Alzheimer’s disease risk in American and Han Chinese populations, but studies by 
Ramirez-Lorca et al (2011) failed to find an association in a Spanish population (Naj 
et al. 2010, Ren et al. 2011, Ramirez-Lorca 2011).  The role of the MTHFD1L gene in 
Alzheimer’s disease is thought to be due to the effect its expression has on the re-
methylation of homocysteine to methionine. Elevated levels of homocysteine have 
been associated with Alzheimer’s disease, an impairment of the MTHFD1L gene 
may cause a reduction in formate and tetrahydrofolate (THF) from the 
mitochondria therefore disrupting the remethylation of homocysteine to 
methionine (Seshadri et al. 2002, Naj et al. 2010). In addition to its role in NTD’s and 
Alzheimer’s disease, MTHFD1L has also been associated with increased risk of 
Cardiovascular disease (CVD), again with its role thought to be due to the provision 
of one carbon molecules for re-methylation of homocysteine in the cytoplasm 
(Nilesh et al. 2007, Samani et al. 2007).  
As discussed in section 1.4 MTHFD1L also has strong links to cancer growth and 
development. Sugiura et al (2004) found that MTHFD1L expression was elevated in 
colon cancer, they also found that over expressing the gene in HEK 293 cells lead to 
increased “colony formation”, indicating the gene had an effect on the growth of 
the cells. Selcuklu et al (2012) also found that enzyme to be up-regulated in breast 
cancer. Most recently Jain et al (2012) associated MTHFD1L, along with other 
mitochondrial folate enzymes Methylenetetrahydrofolate dehydrogenase (NADP+ 
dependent) 1-like (MTHFD2) and Serine hydroxy methyltranferase (SHMT2) with 
increased growth, proliferation and mortality in cancer. Moreover, findings by 
Fashfindar et al (2012) and Wang et al (2013) have found that the metabolite of 
MTHFD1L, formate may be a useful biomarker for staging and grading of tumours 
and in the detection of cancer metastasis.  
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HEK293 Cell lines with modulated MTHFD1L expression (increased and decreased) 
were previously generated in the Nutritional Genomics laboratory (Minguzzi 2013). 
Although HEK 293 cells are a non-cancerous “normal” cell line they are a good 
model for observing and characterising changes and can be utilised as a “test tube 
with a membrane”. The MTHFD1L gene was overexpressed by transfection of HEK 
293 cells with the Invitrogen plasmid pcDNA 3.2 which constitutively overexpresses 
the MTHFD1L gene. The MTHFD1L gene was knocked down by transfection of HEK 
293 cells with shRNA (short hairpin RNA), two knockdown clones were created. The 
MTHFD1L knockdown cell lines have an IPTG inducible promoter system allowing 
for down regulation of the gene when desired. The inducible promoter system in 
the MTHFD1L knockdown cell lines limited the deleterious effects down regulation 
of the gene may have on the HEK 293 cell lines. Previous proteomic analysis of the 
HEK 293 cell lines with modulated MTHFD1L expression identified that a number of 
important DNA synthesis and repair enzymes were affected by MTHFD1L expression 
(Minguzzi 2013). An example of which is thymidylate synthase (TYMS), Minguzzi 
(2013) found that when MTHFD1L was over expressed the TYMS enzyme was down 
regulated relative to the control cell line. TYMS is known to translocate to the 
nucleus and the mitochondria for de novo thymidylate synthesis (Anderson et al. 
2011 and 2012). Interestingly Minguzzi (2013) found proteins thought to be 
involved in complexing with TYMS at the nuclear lamina for thymidylate synthesis; 
Proliferating cell nuclear antigen (PCNA), Lamin A/C (LMNA) and Lamin B1 (LMNB1) 
were also down regulated (Anderson et al. 2012, Minguzzi 2013).  Intriguingly, these 
proteins showed opposite trends were they were up-regulated when MTHFD1L was 
knocked down and down regulated when MTHFD1L was over expressed (Minguzzi 
2013). It appeared that thymidylate synthesis was affected by MTHFD1L expression.  
It was hypothesised that the effects observed in the proteomic data were mediated 
by the metabolite of MTHFD1L, formate (Minguzzi 2013). Therefore one of the main 
aims of this chapter was to assess if altered MTHFD1L expression results in a 
detectable altered formate level which could have implications for formate as a 
biomarker, with secondary aims being detection of alterations in cell cycle and cell 
growth. Due to the fact that the expression of the MTHFD1L gene has been 
significantly associated with cancer cell growth and mortality, the detection of an 
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altered formate level within the HEK 293 cells with modulated MTHFD1L expression 
may have implications for the characterisation of formate as a biomarker. The 
detection and study of changes within the metabolism of a cell, tissue or organism 
is referred to as metabolomics and is fast emerging field within cancer research.  
3.0.1 Metabolomics and Cancer 
Genomics, transcriptomics, proteomics and now metabolomics are all utilised in the 
study and research of cancer in order to establish the changes that occur within the 
cell which enable it to become malignant. Aside from helping us attain a deeper 
understanding of cancer at a molecular level, these tools allow us to identify targets 
or biomarkers for the identification and treatment of cancer. Metabolic re-
programming is a hallmark of cancer (Ward and Thompson 2012). Detecting 
changes in metabolites within cancer versus normal tissue can allow for an un-
invasive means of cancer diagnosis and in some cases the development of targeted 
therapies (Patel and Ahmed 2015).  
Metabolite profiling is often said to be the most reliable and coherent snap shot of 
the cell. Detection of changes at a DNA, transcription or protein level are indeed 
very valuable, however it thought that metabolic profiling is the closest 
representation to the phenotype of the cell/tissue, see Figure 3.1 (Patel and Armed 
2015, Fien 2002) . Changes at a DNA or at a transcription level within a cell are not 
always represented at a protein or metabolic level due to regulatory processes 
within the cell. One of the earliest known changes detected in the metabolism of 
cancer cells is their propensity towards sugar as an energy source and aerobic 
glycolysis as an energy means (Warburg et al. 1927).  Indeed, it is well documented 
that cancer cells readily consume sugar and this change in cancer cell metabolism 
can be used in conjunction with positron emission tomography (PET) scanning in the 
detection of tumours throughout the body particularly in the lungs (Vansteenkiste 
et al. 2002).   
The main techniques employed for metabolite analysis are nuclear magnetic 
resonance spectroscopy (NMR) and mass spectrometry (MS). Mass spectrometry 
involves ionization of a compound and analysis based on the mass to charge ratio. 
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Different separation methods can be used in conjunction with mass spectrometry 
such as liquid chromatography (LC-MS), capillary electrophoresis (CE-MS) and gas 
chromatography (GC-MS) (Patel and Ahmed 2015).The method used in this chapter 
for formate analysis was GC-MS, see Figure 3.2 for GC-MS schematic.  
 
 
 
 
 
 
 
 
3.0.2 Aims 
 
Figure 3.1  “Omics”. There are four different molecular levels  in which cells/tissue 
can be analysed and studied, DNA, RNA, protein and metabolic. The metabolite 
level is said to be the closest to the phenotype of the cell. (Image taken from 
http://www.metabolomics.bbsrc.ac.uk/background.htm) 
 
Figure 3.2 GC-MS Schematic for metabolite analysis. Samples are separated, 
ionized and molecules are detected by their mass to charge ratio. Accurate 
quantification of a metabolite can be achieved by the inclusion of an isotype 
dilution of the target metabolite (Lamarre et al 2014). Image edited from 
(Last et al 2007). 
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3.0.2 Aims 
The main aim of this chapter was to characterise the effects altered MTHFD1L 
expression has on HEK 293 cells, with a view to assessing: 
 If altered MTHFD1L expression results in a detectable altered formate level 
in HEK 293 cells. The premise of this was two-fold; 1. This would allow for 
the assessment of formate as a biomarker for MTHFD1L expression in regard 
to cancer. 2. This finding would allow for confirmation of the previous work 
by Dr Minguzzi who suggested that formate supply within the cell mediated 
the changes observed in DNA repair and synthesising enzymes in HEK 293 
cells with altered MTHFD1L expression (Minguzzi 2013).    
 The effect altered MTHFD1L expression has on the cell growth and the cell 
cycle in HEK 293 cells.  
 
3.0.3 Objectives 
In order to characterise the effect altered MTHFD1L expression has on HEK 293 cells 
the following procedures were undertaken. 
 Cell cycle analysis of the MTHFD1L knockdown HEK 293 cell lines by flow 
cytometry using propidium iodide staining. 
 Analysis of Formate in the MTHFD1L over expressed, knockdown and 
associated controls in both the cell medium of each cell line and 
intracellularly by GC-MS. 
 Normalisation of formate levels to cell number and protein concentration 
for intracellular analysis and to medium volume for extracellular cell 
medium analysis. 
 Cell proliferation analysis by cell counting.  
 Confirmation of MTHFD1L in modulated HEK 293 cells by rt-qPCR. 
 
 
54 
 
3.1 Results 
3.1.1 Cell Cycle Analysis of MTHFD1L Knockdown Cell Lines 
 Flow cytometric analysis was under taken in order to ascertain if knocking down 
the MTHFD1L gene had an effect on the cell cycle of the HEK 293 cells. Cells were 
permeabilised and fixed using ethanol and then stained using propidium iodide. 
Propidium Iodide is a DNA intercalating agent which also acts as a DNA fluorophore 
when excited in the range of 488 nm (Pozarowski and Darzynkiewicz 2004). 
Propidium iodide is impermeable to the cell membrane hence the need for ethanol 
permeabilastion. Cell cycle analysis by flow cytometry allows for the determination 
of what percentage of cells are in a given phase of the cell cycle.  It can be seen 
from Figure 3.2 below, cell cycle analysis results in two gaussian peaks representing 
the G1 and G2/M phases respectively. The S phase of the cell cycle shares an 
overlap with both the G1 and G2/M phases. When the percentage of each cell in a 
given cell cycle phase are compared for the MTHFD1L knockdowns (1 and 2) and the 
associated non targeting shRNA control, very little difference was observed, see 
Figures 3.2 and 3.3.  
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Figure 3.3 Cell Cycle Analysis by Flow Cytometry of MTHFD1L Knockdowns. A. The number 
of cells is represented on the y axis of the graph while the relative florescence of the cells is 
represented on the X axis. Cells which are in the G1 phase of the cell cycle have 1 copy of 
DNA, as the cell progresses through to the S phase of DNA synthesis the florescence 
increases accordingly. Cells in the G2 phase of the cell cycle are said to have twice as much 
DNA content and therefore twice the amount of florescence when compared to G1 cells. 
Very little difference can be observed between the shRNA control and knockdowns 1 and 
2.B.The percentage of cells in each phase of the cell cycle can be seen. There appears to be 
very little difference between the two MTHFD1L knockdowns 1 and 2 the control cell line 
shRNA control in regards to percentage of cells in each phase of the cell cycle.  
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3.2. Intracellular Formate Analysis in HEK 293 Cells with Modulated MTHFD1L 
3.2.1 Intracellular Formate Analysis in MTHFD1L Over expressed Cells 
As per section 2.2.2 of Chapter 2 the HEK 293 cell lines with modulated MTHFD1L 
expression were set up at 2 x 106 in triplicate for 5 days. The pcDNA 3.2 empty 
vector HEK293 cell line acts a control for the MTHFD1L overexpressing cells. 
Unfortunately during the first day of the formate analysis experiment the empty 
vector cell line cells did not attach as well to the cell culture tissue flask in 
comparison to the MTHFD1L overexpressed cells. This resulted in fewer cell 
numbers in the empty vector cell line compared to the overexpressed. In order to 
act as an extra control normal HEK 293 cells were included in the analysis of the 
overexpressed cells. When intracellular formate levels are normalised to protein 
concentration it appears that the MTHFD1L overexpressing cell line has a 2.89 fold 
higher formate concentration when compared to the empty vector control. When 
the MTHFD1L over expressing cell line is compared to the normal HEK 293 cells it 
has 1.23 fold higher formate level, see Table 3.1 for fold differences and see Figure 
3.4 for relative differences. Consistent with normalisation to protein concentration 
the MTHFD1L over expressing cells appear to have an increased formate 
concentration with it being 1.85 fold higher when compared to the empty vector 
control when normalised to cell number. When compared to the normal HEK 293 
cells the MTHFD1L over expressing cell line has a 1.74 fold increased formate 
concentration, see Table 3.1 and Figure 3.5. When the intracellular formate data 
was normalised to protein concentration and cell number statistical analysis 
indicated that the increased formate level observed in the MTHFD1L overexpressing 
cells was statistically significant relative to the empty vector cells, see Table 3.1. 
However, relative to the normal HEK 293 cells statistical analysis indicated that the 
increased formate level in the MTHFD1L overexpressing cells was non-significant. 
The experiment would need to be repeated in order to conclusively identify if the 
MTHFD1L overexpressing cells have a statistically significant higher formate level 
than the controls. Despite the discordance with the statistical analysis results clear 
trends can be observed and it appears that overexpressing the MTHFD1L gene has 
had an effect on the metabolism of the HEK 293 cells 
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Fold 
Difference 
 
Fold 
Difference 
 Cell Line Protein¥ p Value* Cell Numberɨ p Value* 
Overexpressed 2.89 0.005 1.85 0.007 
Empty Vector Control 1 
 
1 
 
 
Fold 
Difference 
 
Fold 
Difference 
 Overexpressed 1.23 0.068 1.74 0.190 
Normal HEK 293 1 
 
1 
            *As determined by T test (Significance ≤ 0.05)      
          ¥ See Figure 3.4 for graphical representation of formate concentration (µM) per µg of protein. 
          ɨ See Figure 3.5 for formate concentration (µM) per cell                                                                                
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Figure 3.4 Formate Levels of MTHFD1L Overexpressed Cell line Normalised to Protein 
Concentration.   It can be seen that Intracellular formate values obtained for the MTHFD1L 
overexpressed cell line appears to be much higher when compared to the formate values 
obtained for the empty vector with a 2.89 fold over expression (p=0.005) calculated as per Table 
3.1.  The formate level differences between the MTHFD1L over expressed and the HEK 293 cells 
indicate that the MTHFD1L had an increased formate level relative to the normal HEK 293 cell 
line, with a 1.23 fold increased concentration observed (p=0.068). However, the HEK 293 cells 
are grown in the absence of the selective agent G418 so are not the true control for the 
overexpressed cells but due to issues with the empty vector cell attachment, as explained 
previously in section 3.2.1 they included as an extra control. 
Table 3.1 Fold difference in Formate concentration normalised to protein and cell 
number 
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Figure 3.5 Formate Levels of MTHFD1L Overexpressed Cell line Normalised to Cell 
Number.   It can be seen that when the formate levels are normalised to cell number 
that the formate level for MTHFD1L over expressing cells appears to be higher when 
compared to both the empty vector control with a 1.85 fold increased level calculated 
as per Table 3.1 (p=0.007) and the normal HEK 293 cells with a 1.74 fold increased 
level as per table 3.1 (p=0.190).  
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3.2.2 Intracellular Formate Analysis in MTHFD1L Knockdown Cells 
The MTHFD1L knockdown cell lines were set up as per section 2.2.2 of Chapter 2. 
When intracellular formate levels are normalised to protein concentration it 
appears that the MTHFD1L shRNA knockdowns 1 and 2 have a -1.58 and -1.69 
reduced formate concentration when compared to the non-targeting shRNA 
control, see Table 3.2 for fold differences and and Figure 3.6 for relative differences.  
These results indicate that knocking down the MTHFD1L gene has had a direct 
effect on intracellular formate concentration. When intracellular formate levels are 
normalised to cell number it appears that the MTHFD1L shRNA knockdowns 1 and 2 
have a -1.02 and a -1.31 fold reduced formate concentration when compared to the 
non-targeting shRNA control, see Table 3.2 and Figure 3.7. When the intracellular 
formate data was normalised to protein concentration statistical analysis indicated 
that the changes observed were significant, Table 3.2. However, upon normalisation 
of the data to cell number statistical analysis indicated the changes observed in the 
MTHFD1L knockdown cell lines were non-significant.  The experiment would need 
to be repeated in order to conclusively identify if the formate level of the MTHFD1L 
knockdown cell lines is statistically significantly lower than the shRNA control. 
Again, due to time constraints this could not be carried out. Despite the 
inconsistencies with the statistical analysis results and data normalisation clear 
trends can be observed and it appears that knocking down the MTHFD1L gene had 
an effect on formate production particularly in knockdown 2. 
 
             
           *As determined by T test (Significance ≤ 0.05)        
            ɫ See Figure 3.6 for graphical representation of formate concentration (µM) per µg of protein. 
            Ї See Figure 3.7 for formate concentration (µM) per cell.  
  
Fold 
Difference   
Fold 
Difference 
 Cell Line Proteinɫ P Value* Cell NumberЇ p Value* 
Knockdown 1 -1.58 0.007 -1.02 0.409 
Knockdown 2 -1.69 0.003 -1.31 0.106 
shRNA Control 1 
 
1 
 
Table3.2. Fold difference in Formate concentration normalised to protein and cell 
number 
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Figure 3.6 Formate Levels of MTHFD1L Knockdown cell line Normalised to protein.   It 
can be seen that when the formate levels are normalised to protein concentration, that 
the formate level for MTHFD1L knockdown cell lines 1 and 2 appears to be lower when 
compared to the shRNA control with a -1.58 (p=0.007) and -1.69 (p=0.003) fold reduced 
formate concentration calculated (as per Table 3.2), respectively. The knockdowns 1 
and 2 also appear to have a lower formate level relative to the normal HEK 293 cells. 
Although the normal HEK 293 cells are not the true control for the knockdown cell 
lines; the lower intracellular formate level observed in the knockdowns relative to the 
normal HEK 293 cells provides further evidence that knocking down the MTHFD1L gene 
has had an effect on the HEK 293 cells. 
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Figure 3.7 Formate Levels of MTHFD1L Knockdown cell line Normalised to cell 
number.   When formate levels are normalised to cell number the MTHFD1L 
knockdown 2 has a -1.31 fold lower lower formate level p=.0.106  (as per Table 3.2) 
compared to the control shRNA control. The MTHFD1L knockdown 1 has a marginally 
reduced formate concentration (-1.02 fold as per Table 3.2) relative to the shRNA 
control p=0.409.  
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3.3 Formate Cellular Medium Analysis in HEK 293 Cells with Modulated MTHFD1L 
3.3.1 Cell Medium Formate Analysis in MTHFD1L Overexpressing cells 
The formate concentration in the cell medium of each cell line was monitored by 
collecting aliquots of medium every 12 hours for 5 days of growth, as per section 
2.2.2 of Chapter 2. This allowed for the determination of formate concentration 
throughout the experiment as opposed to a final formate concentration. It can be 
seen from Figures 3.8 and 3.9 that both the MTHFD1L overexpressing cell line and 
the normal HEK 293 cells have similar formate level distribution patterns 
throughout the 5 day experiment.  However, the formate level for the MTHFD1L 
over expressing cells peaks between days 2.5 and 3, and then begins to decline. 
Whereas the formate level for the normal HEK 293 cells peak at days 3 and 3.5 and 
like the MTHFD1L overexpressing cells then begins to decline.  The cell medium 
formate level for the empty vector control cells, unlike the MTHFD1L over 
expressing and normal HEK 293 cells can be seen to increase steadily throughout 
the five day experiment. The different pattern in formate levels observed for the 
empty vector control may be due to the issues with growth and attachment of the 
cells in the first day of the experiment as explained above.   
It can be seen from Figure 3.9 that the MTHFD1L over expressing cell line has the 
highest overall cellular medium formate concentration. This result is in concordance 
with the intracellular formate analysis with MTHFD1L over expressing cells also 
having the highest formate level, relative to the empty vector control and the 
normal HEK 293 cells.  
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Figure 3.8 Formate Cellular Medium Concentrations. Sections A, B and C show the cell 
medium formate level for the MTHFD1L overexpressed, empty vector control and the normal 
HEK 293 cells throughout the 5 day experiment. It can be seen in section A and C that the 
formate distribution patterns are similar for both the MTHFD1L overexpressed and HEK 293 
cells. The MTHFD1L overexpressed cell’s medium concentration peaks at 216 µM of formate 
on day 3. The normal HEK 293 cell line has a peak formate concentration on day 3.5 with a 
concentration of 199 216 µM of formate    The Empty vector control formate medium levels 
can be seen to increase steadily throughout the 5 days of growth, with the highest formate 
concentation observed on day 5 at 161µM of formate. 
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Figure 3.9 Cellular Medium Formate Concentrations for MTHFD1L Overexpressed Cell Line.  The 
MTHFD1L over expressed and normal HEK 293 cell lines appear to have a similar formate distribution 
pattern. However it can be seen that the MTHFD1L overexpressed cell line has a higher cellular 
medium formate concentration in comparison to the HEK 293 cells from days 1 to 3.5 where it then 
begins to decline. The MTHFD1L overexpressed cell line also reaches the highest maximal value over 
all for the cellular medium formate concentration. The empty vector cells denoted by the red line 
appear to have consistently increasing formate concentration which may be attributed to the 
recovery and growth of the cells as mentioned previously.  
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3.3.2 Cell Medium Formate Analysis in MTHFD1L Knockdown Cells 
The cellular medium formate analysis for the MTHFD1L knockdown cells and 
associated control indicated that knocking down the MTHFD1L had an effect on 
formate concentration within the cell medium. It can be seen from Figures 3.10 and 
3.11 that both the MTHFD1L knockdown cells lines 1 and 2 exhibited a similar 
formate distribution pattern throughout the 5 day experiment. The non-targeting 
shRNA control appears to have an increasing formate concentration throughout the 
5 day experiment where it then appears to plateau.   
Figure 3.11 shows that the MTHFD1L knock down cell lines appear to have a much 
lower cellular medium formate concentration when compared to the non-targeting 
shRNA control.  The shRNA control formate level starts off at a similar level to the 
MTHFD1L knockdowns, however by day 1.5 the formate level appears to increase 
well above that of the MTHFD1L knockdowns.  
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Figure 3.10 Formate Cellular Medium Concentrations. Sections A, B and C show the cell 
medium formate level for the shRNA control and the MTHFD1L knockdowns 1 and 2 throughout 
the 5 day experiment. It can be seen in section B and C that both the MTHFD1L knockdown cell 
lines 1 and 2 have a similar formate distribution patterns. The formate level of both the 
MTHFD1L knockdown cell lines increases steadily, plateaus and the declines. The formate level 
of the shRNA control cell line also increases steadily but does not exhibit a decline unlike the 
two knockdown cell lines. 
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Figure 3.11 Formate Cellular Medium Concentrations.   The shRNA control cell line, 
as denoted by the blues line, reaches the highest formate concentration over the 5 
days of growth. The MTHFD1L knockdowns 1 and 2 have a similar formate 
distribution to each other throughout the 5 days of growth. The similarity between 
the two MTHFD1L knock down cell lines indicates that knocking down the MTHFD1L 
gene has affected the cells formate production. 
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3.4 Growth Analysis in HEK 293 Cells with Modulated Expression of MTHFD1L 
Growth analysis of the HEK 293 cells with modulated MTHFD1L expression was 
achieved by counting the cell number for each cell line after a 5 day period of 
growth. Differential expression of the MTHFD1L gene was found to impact cell 
growth in HEK 293 cells.  From Figure 3.12 it can be observed that the MTHFD1L 
over expressing cells had increased growth when compared to the normal HEK 293 
cells and the empty vector control, see Table 3.3 for fold differences. It can be seen 
form Figure 3.13 knocking down MTHFD1L  within the HEK 293 cells resulted in 
decreased cell growth in comparison to the control, see Table 3.4 for fold 
differences.  
 
 
 
 
 
 
 
       
    
 
 
 
 
 
 
Cell Line Cell Growth 
Overexpressed 5.6 
Empty Vector Control 1 
 Fold Difference 
Overexpressed 1.14 
Normal HEK 293 ctrl 1 
 Fold Difference 
Cell Line Cell Growth 
Knockdown 1 -1.81 
Knockdown 2   -1.3 
shRNA Control 1 
Table 3.3. Fold difference in growth rate of the MTHFD1L over 
expressed cell line relative to the empty vector control and the 
normal HEK 293 cells. 
Table 3.4. Fold difference in growth rate of the MTHFD1L 
Knockdown cell lines relative to the shRNA control 
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Figure 3.12 Growth of MTHFD1L Over expressed cells and associated control. 
It can be seen that MTHFD1L over expressed cells grew faster than both the 
HEK 293 cells and the empty vector control. The empty vector growth rate 
appears to be lower than the overexpressed and the normal HEK 293 cells. The 
empty vector control may have been affected by the initial attachment issues 
that occurred, or it may be that the selective agent G418 in which the cells are 
grown in has an effect on the growth rate of the cells and the overexpression 
of the MTHFD1L allows the cells to overcome this effect. 
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Figure 3.13 Growth of MTHFD1L knockdown cells and associated 
control. It can be observed that the MTHFD1L knockdown cell lines 1 
and 2 grew slower than the non-targeting shRNA control. Knock down 
1 had -1.81 fold decreased growth and knockdown 2 had -1.3 fold 
decreased growth relative to the shRNA control. 
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3.5 Confirmation of MTHFD1L Expression in the Knockdown and Overexpressed 
Cell lines 
RT-qPCR expression analysis of the MTHFD1L gene was carried in all of the HEK 293 
cells with modulated expression of the MTHFD1L gene and associated controls as 
per section 2.2.2 and 2.3 of Chapter 2. This analysis confirmed that the MTHFD1L 1 
knockdown cell lines 1 and 2 had decreased MTHFD1L expression, having only 25% 
and  35% MTHFD1L expression relative to shRNA control cell line, respectively, see 
Figure 3.14 below. The MTHFD1L over expressed cell line contained pcDNA 3.2 
vector which constitutively over expressed an “optimised” version of the MTHFD1L 
gene. The MTHFD1L overexpressed clone was optimised for codon expression in 
humans, meaning that the DNA sequence was different from the MTHFD1L gene 
but the amino acid and resultant protein had the same sequence as the MTHFD1L 
gene (Minguzzi 2013). RT-qPCR was carried out to detect the expression of the 
MTHFD1L overexpressed gene and endogenous MTHFD1L expression in both the 
MTHFD1L over expressed cell line and the empty vector see Figures 3.14, 3.15 and 
3.16. The optimised MTHFD1L gene was confirmed as over expressed. 
 
 
 
 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
HEK 293 shRNA control Knockdown 1 Knockdown 2
R
e
la
ti
ve
 E
xp
re
ss
io
n
 
Normalised MTHFD1L Expression 
Figure 3.14 MTHFD1L expression in knockdowns and controls. 
Expression level of the MTHFD1L gene in knockdowns 1 and 2 is 
approximately 25% and 35% that of the shRNA control. MTHFD1L 
gene expression for each cell line was normalised to GUS gene 
expression. 
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Figure 3.16 Relative Expression of endogenous MTHFD1L expression in the 
MTHFD1L  overexpressed cell line and the empty vector. It can be seen that 
endogenous expression of the MTHFD1L gene is much the same between the 
empty vector control and the MTHFD1L overexpressing clone. Endogenous 
MTHFD1L expression is slightly lower in the MTHFD1L Opt clone but not 
significantly so. 
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3.6 Discussion 
MTHFD1L is an essential enzyme responsible for the provision of one carbon donor 
molecules in the form of formate for cytoplasmic one carbon metabolism (Momb et 
al. 2012). MTHFD1L has been implicated in playing a role in many diseases such as 
NTD’S, CVD, Alzheimer’s and cancer (Parle-McDermott et al. 2009, Minguzzi et al. 
2014, Naj et al. 2010, Ren et al. 2011, Nilesh et al. 2007, Samani et al. 2007). In 
addition to this MTHFD1L has recently been implicated as playing a significant role 
in cancer proliferation and mortality (Sugiura et al. 2004, Jain et al. 2012). There is 
evidence to suggest that MTHFD1L is working in conjunction with other 
mitochondrial folate enzymes, SHMT2 and MTHFD2 in highly proliferative cancers 
(Jain et al. 2012, Nilsson et al. 2014). The up-regulation of the mitochondrial folate 
pathway is highly advantageous to a growing cancer cell with the mitochondrial 
enzymes providing the necessary components in the form of formate and glycine 
for the cell to grow divide and proliferate. The Warburg effect is a phenomenon 
known to occur in cancer cells, where energy production is switched from the 
energy efficient method of oxidative phosphorylation to the less energy efficient 
aerobic glycolysis (Warburg et al. 1927). The possible mechanisms behind the up-
regulation of the mitochondrial folate pathway shall be discussed in detail in 
Chapter 5.  
MTHFD1L’s recent association with cancer growth, proliferation and mortality 
means that a biomarker for its expression would be extremely desirable (Jain et al. 
2012, Nilsson et al. 2014, Selcuklu et al. 2012).  The HEK 293 cells with modulated 
MTHFD1L expression act a good model for gauging formate levels both 
intracellulary and extracellulary. When the intracellular formate concentration was 
measured for the MTHFD1L over expressing cell line it was found that with 
normalisation to both cell number and protein concentration its formate level was 
2.89 and 1.85 fold higher, respectively, relative to the empty vector control, Figure 
3.4, 3.5. The normal HEK 293 cells were included as an extra control for the 
MTHFD1L over expressing cell line due to issues which occurred with the empty 
vector control cell line. The differences observed in normalisation between the 
normal HEK 293 cell line and the empty vector control cell line may be due to two 
Figure 3.15 Relative Expression of MTHFD1L over expressed human 
optimised clone.  The MTHFD1L opt gene can be seen to be 
overexpressed. This is notable as the relative expression as denoted on the 
y axis is much greater than the normal HEK 293 cell line and the MTHFD1L 
knockdowns 1 and 2 as seen in Figure 3.14 Relative expression of the 
MTHFD1L optimised gene is also much greater than the expression of the 
normal MTHFD1L gene gene observed in Figure 3.16. As expected no 
expression of the MTHFD1L opt gene was detected in the empty vector 
control.  
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factors. One is that the empty vector is the true control and mimics the effect of the 
pcDNA 3.2 vector and the associated effects that would be exerted on the cells from 
having been transfected and grown in the G418 selective agent. It may be that the 
differences in formate level between the MTHFD1L overespressing cells and the 
empty vector are a true representation of the expression system and the effect that 
up regulating the MTHFD1L gene has on HEK 293 formate levels. Another factor 
which may be responsible for the discrepancies between the formate levels of the 
normal HEK 293 cells and the empty vector control is the fact that the empty vector 
cells did not attach as well as the MTHFD1L overexpressing and normal HEK 293 
cells. However, normalisation to protein level in addition to cell number should 
have controlled for the difference in cell number. The experiment would have to be 
repeated to conclusively ascertain the effect of overexpressing the MTHFD1L gene 
relative to the empty vector control in HEK 293 cells. Unfortunately due to time 
constraints repetition of the experiment was not possible. 
The MTHFD1L knockdown cell lines 1 and 2 exhibited lower intracellular formate 
concentration when normalised to protein and cell number. When the formate level 
of knockdown 1 was normalised to protein and cell number it had a -1.58 and a -
1.02 fold decreased expression, respectively, when compared to the shRNA control. 
When the formate level of knockdown 2 was normalised to protein and cell number 
it had a -1.69 and a -1.31 fold decreased expression, respectively, when compared 
to the shRNA control. Although there are differences observed with the two 
normalisation methods, as evidenced by the statistical significance results in Table 
3.2, an overall detectable decrease in formate concentration was observed, 
specifically for knockdown 2. The detection of altered formate levels supports 
Minguzzi’s (2013) hypothesis that formate (either increased or decreased) mediated 
changes in expression of a number key enzymes within the MTHFD1L modulated 
HEK 293 cells (Minguzzi 2013).  In relation to formate as a biomarker for MTHFD1L 
expression, both the knockdown and overexpressed cell lines provide further 
evidence that altered MTHFD1L gene expression effects formate production. 
It was not known whether the intracellular formate levels would necessarily 
correlate with the cellular formate medium concentrations. However, consistent 
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with the intracellular formate data the MTHFD1L over expressed cells reached the 
highest maximal formate value when compared to the empty vector control and the 
normal HEK 293 cells. In Figure 3.8, it can be seen that the distribution pattern of 
formate was similar in the HEK 293 and the MTHFD1L over expressed cell line. 
Although the pattern is similar the over expressed MTHFD1L cell line has a much 
higher formate level on days 1 through 3 were the normal HEK 293 cells appears to 
peak on day 3.5. The fact that the cellular medium formate level in the MTHFD1L 
over expressing cells is higher than the normal HEK 293 cells from day one indicates 
that the overexpression of the MTHFD1L gene is having an effect on the metabolism 
of the cell. As can be seen in Figure 3.10 cell medium formate concentration for the 
MTHFD1L knockdowns 1 and 2 appears to be much lower than the shRNA control. 
The shRNA control’s formate level appears to increase steadily and is seen to 
plateau on days 4.5 and 5. The MTHFD1L knockdown cell lines 1 and 2 cell medium 
formate level peaks between days 3 and 3.5 where it then begins to decline. These 
results demonstrate that altering MTHFD1L gene expression has resulted in a 
detectable change in the extra-cellular formate concentration. The detection of 
differences in formate level in the extracellular environment of the cell is very 
exciting and may have implications for the use of formate as a biomarker in the 
detections of altered MTHFD1L expression in diseases such as cancer. 
In agreement with this finding a paper by Wang et al (2013) found formate to be 
significantly elevated in the mucosae of patients with oesophageal cancer versus 
healthy individuals when analysed by Nuclear Magnetic Resonance  (NMR), (p 
0.0005). Most interesting of all is that they found that the level of formate could be 
correlated to the stage and progression of the cancer at stages II,III,IV with 
significance of p 0.001, p 0.001 and p 0.0001 respectively. Wang et al (2013) also 
found that other metabolites involved in one carbon metabolism, uracil, methionine 
and glycine were also significantly linked to the stage and progression of 
oesophageal cancer, p <0.0001, p <0.0001 and p <0.0001, respectively.  Farshidfar 
et al (2012) also found that metabolomic analysis of serum samples from patients 
with adenocarcinoma identified that formate levels were significantly increased in 
patients with liver metastasis (p0.0005) (Farshidfar 2012). 
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Further confirmation that up regulating and knocking down the MTHFD1L had a 
significant impact on the HEK 293 cells comes from the fact that their growth rate 
was altered. The MTHFD1L knockdowns 1 and 2 had a growth rate of -1.81 and -1.3 
fold that of the shRNA control, or in percentage terms knockdowns 1 and 2 had a 
growth rate that was reduced by 45% and 23% respectively. The MTHFD1L 
overexpressed cell lines had a 1.14 fold higher growth rate when compared to the 
normal HEK 293 cell line. The increased growth rate observed in the MTHFD1L over 
expressed HEK 293 cell line is in concordance with findings in the literature whereby 
Sugiura et al (2004) found that up regulating MTHFD1L resulted in “increased 
colony formation” in HEK 293 cells. Jain et al (2012) also showed a correlation with 
increased cell growth rate and expression of the MTHFD1L gene in various cancers. 
The fact that knocking down the MTHFD1L gene resulted in decreased cell growth in 
the HEK 293 cell lines is indeed very promising and provides evidence that the 
development of targeted therapies against MTHFD1L could be very effective in 
cancers which exhibit MTHFD1L over expression.  
Previous work on the HEK 293 MTHFD1L cell lines found that the expression of the 
enzyme TYMS (thymidylate synthase) was decreased upon MTHFD1L over 
expression (Minguzzi 2013).  TYMS is responsible for the production of the DNA 
base thymine. Minguzzi (2013) hypothesised that formate may act as a sensor for 
nucleotide supply. HEK 293 cells are a non-cancerous “normal” cell line. The 
decrease in TYMS expression in the HEK 293 MTHFD1L over expressed cell line was 
thought to be protective to prevent increased DNA synthesis and abnormal cell 
proliferation (Minguzzi 2013). When thymine is limited uracil is incorporated into 
DNA in its place. Consequently the incorporation of uracil in  the place of 
thymidylate may cause strand breaks and subsequent abnormalities with DNA 
replication, increasing the risk of cancer development (Blount et al. 2002). The work 
by Wang and colleagues (2013) may demonstrate a similar scenario as in the 
MTHFD1L over expressed HEK293 cell line, as they observed an increased formate 
level indicating that MTHFD1L is up regulated. The fact that they observed an 
increased uracil level may be hypothetically due to the fact that MTHFD1L up 
regulation caused a decrease in TYMS gene expression levels and thymidine 
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concentration, in turn up regulating uracil concentration to take the place of 
thymidine; see Figure 3.17. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.17 Scenario of the knock on effects MTHFD1L up regulation. Previous work in the 
HEK 293 cells found that Methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-
like (MTHFD1L) over expression resulted in decreased thymidylate synthase (TYMS) 
enzyme levels. A decrease in TYMS enzyme levels may result in an increase in uracil 
concentration and may explain the observed increase in uracil concentration in 
oesophageal cancer by Wang et al (2013) (image edited from niclot et al 2006). 
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MTHFD1L is not solely responsible for formate production; however, it does 
produce up to an estimated 75% of formate required for the cell (Pike et al. 2010). 
The fact that increasing and decreasing MTHFD1L expression at genetic level 
resulted in changes in both intracellular and extra-cellular formate indicates that 
formate could be used as a biomarker for MTHFD1L expression in regard to cancer. 
MTHFD1L, along with other mitochondrial folate related enzymes, has been 
significantly associated with high growth and proliferation rates in cancer. MTHFD1L 
expression has also been associated with increased mortality in cancer patients 
(Jain et al. 2012, Sugiura et al. 2004). Work by Lamarre et al (2012) has 
demonstrated urinary and plasma formate as an accurate biomarker for vitamin 
B12 and folate deficiency in rats.  As previously discussed, work by Wang et al 
(2013) has shown that formate level can be significantly correlated with stage and 
progression of oesophageal cancer (Wang et al. 2013).  Results from this chapter 
have demonstrated that changes in MTHFD1L expression results in changes in 
formate concentration in both the intracellular and extracellular environment of the 
cell. The extra cellular environment is the ideal place for biomarker identification as 
the biomarker itself may then be excreted into bodily fluids such a blood, urine, 
mucus etc.  Although urinary and plasma formate is an indication of folate and 
vitamin B 12 status, it is not known whether an increase in MTHFD1L expression, 
such as in the case of cancer would result in detectable urinary or plasma formate 
changes. However, what is known is the work by Farshidfar et al (2012) who found 
that formate was detected in the serum of patients and was correlated with liver 
metastasis. The results in this chapter provide further support for formate as a 
biomarker for MTHFD1L expression. As mentioned previously MTHFD1L is thought 
to be up-regulated in conjunction with other mitochondrial folate enzymes MTHFD2 
and SHMT2 and all three enzymes have been associated with highly proliferative 
cancers (Jain et al. 2012). Vasquez et al (2013) recently associated the expression of 
SHMT2 and MTHFD2 with increased methotrexate sensitivity in leukaemia patients, 
independent of DHFR expression. Vasquez et al (2013) also identified that 25% of 
cancers have an up-regulation of folate related enzymes. This information taken 
collectively means that formate may be a biomarker for not just MTHFD1L 
expression but for expression of other folate related enzymes MTHFD2, and SHMT2. 
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It is notable that MTHFD1L is the rate limiting step in the mitochondria to convert 
10-formylTHF to formate (Tibbets and Appling 2010). Therefore, in a cancer setting 
the detection of elevated formate levels may be indicative of the up-regulation of 
not only MTHFD1L, but of SHMT2 and MTHFD2, given recent findings from Jain et al 
(2012). If formate is an accurate biomarker for MTHFD2 and SHMT2 expression the 
findings by Vasquez et al (2013) on the expression of these enzymes with the 
increased methotrexate sensitivity in cancer patients is of particular relevance. 
Therefore, one might hypothesise that up-regulation of formate may also act as a 
biomarker to identify individuals who would benefit from methotrexate treatment. 
To conclude, the HEK 293 cells with modulated MTHFD1L expression allowed for 
the analysis of changes at the metabolite level which stemmed from controlled 
alterations at the expression level of the MTHFD1L gene. Measuring both the 
intracellular formate levels and cellular medium formate concentration levels 
allowed for a comprehensive view of the formate status of each cell line with 
altered MTHFD1L expression. Using two methods for formate data normalisation, 
protein concentration and cell number also allowed for a robust assessment of the 
formate status of each cell line. In addition to this, analysis of extra cellular formate 
in the cell medium of each cell line allowed for a time lapse view of the formate 
level in a given cell line. These results demonstrate that overexpressing the 
MTHFD1L gene in HEK 293 cell resulted in an increased intracellular formate level 
between 1.23-2.89 fold, increased extra-cellular formate level and an increased cell 
growth rate by 1.14 fold. Knocking down the MTHFD1L gene in HEK 293 cells 
resulted in an intracellular formate level of between -1.02-1.69 fold that of the 
control and decreased extra-cellular formate level. Knocking down the MTHFD1L 
gene also resulted in a 23% and 45% reduction in growth rate in HEK 293 cells. 
These results provide support for the hypothesis that altered formate levels in the 
MTHFD1L HEK 293 cell lines mediated changes in DNA repair and synthesising 
enzymes (Minguzzi 2013). They also provide further evidence of the impact 
expression of the MTHFD1L gene has on the growth rate of cells. Most importantly 
this work provides further evidence for the use of formate as a biomarker for 
MTHFD1L expression in cancer. 
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4.0 Introduction 
In 2011 it was discovered that there is a second dihydrofolate reductase (DHFR) 
enzyme, dihydrofolate reductase like 1 (DHFRL1). DHFRL1 shares 92% homology 
with the DHFR enzyme (McEntee et al. 2011, Anderson et al. 2011). DHFR is 
involved in folate metabolism via the one carbon metabolism biochemical pathway. 
DHFR reduces folic acid and dihydrofolate (DHF) to its biologically active form 
tetrahydrofolate (THF) using NADPH as a co-factor for the reaction. One carbon 
metabolism results in the production of purines, thymidylate and methyl donor 
groups for cellular methylation reactions (Fox and Stover 2009). Although there is 
only an 8% amino acid difference between the two enzymes, it has been shown that 
DHFRL1 activity is 10 times less than that of DHFR (McEntee et al. 2011).  McEntee 
et al (2011) have demonstrated that DHFRL1 is capable of compensating for DHFR 
knockout in both a bacterial and a mammalian system. DHFRL1 may also play a role 
in the control of expression of both itself and of DHFR. DHFR is known to bind its 
own mRNA to prevent translation; it has also been shown that DHFRL1 is capable of 
binding its own mRNA and the mRNA of DHFR (McEntee et al. 2011). In the 
treatment of cancer DHFR has been the target of anti-folate chemotherapy for over 
60 years (Miller 2006). The discovery of a second DHFR enzyme, DHFRL1, means 
that the novel enzyme could also potentially be a chemotherapeutic target in the 
treatment of cancer in a similar manner as DHFR. Treatment of cancer with the anti-
folate drug methotrexate initially results in an up regulation of the DHFR enzyme 
due to the fact that the methotrexate binds the DHFR enzyme causing 
disassociation of the mRNA leading to translation of the released mRNA (Ercikan-
Abali et al. 1997). The different affinities of DHFR and DHFRL1 for folate suggest 
that they may have different affinities to anti-folate drugs which could potentially 
impact the control of expression of both DHFR and DHFRL1. 
DHFRL1 has been shown to translocate to the mitochondria where it partakes in 
mitochondrial one carbon metabolism (McEntee et al. 2011, Anderson et al. 2011). 
DHFRL1 is involved in the de novo thymidylate synthesis pathway within the 
mitochondria. DHFRL1 is responsible for the reduction of DHF to THF in the 
mitochondria. THF and one carbon activated molecules derived from serine by the 
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enzyme serine hydroxymethyltransferase 2 (SHMT2) are converted to thymidylate 
by the enzyme thymidylate synthase (TYMS). This reaction also serves to regenerate 
DHF for further cycles of thymidylate synthesis (Anderson et al. 2011). The presence 
of a de novo thymidylate pathway within the mitochondria was only confirmed in 
2011 (Anderson et al. 2011). Thymidylate is the only non-essential DNA base with 
uracil taking its place when thymidylate supply is limited (MacFarlane et al. 2011). 
Mitochondrial derived thymidylate is thought to be necessary to maintain the 
integrity of mitochondrial DNA (mtDNA) by preventing the incorporation of uracil 
(Anderson et al. 2011).  mtDNA damage and TYMS inhibition has previously been 
associated with apoptosis. Due to these previous associations Anderson et al (2011) 
hypothesised that inhibition of thymidylate synthesis may result in increased 
mtDNA damage and cell death.  As stated previously, DHFRL1 could potentially be a 
chemotherapeutic target. If Anderson et al’s (2011) hypothesis is true DHFRL1 
would be an ideal target in the treatment of cancer. Further investigation would be 
needed to assess the possibility of DHFRL1 as a viable target in the treatment of 
cancer.  
4.1 Amino Acid differences between DHFRL1 and DHFR 
Of the 15 amino acid differences between DHFRL1 and DHFR only one amino acid at 
position 24 is thought to be important for the binding of DHF and NADPH (McEntee 
et al. 2011). The DHFR enzyme has a tryptophan (W) at position 24 whereas DHFRL1 
has an arginine (R). McEntee et al (2011) noted the W24R amino acid change as 
significant and hypothesised that it may be a source of the DHFRL1’s reduced 
catalytic activity. The tryptophan at position 24 is highly conserved in the DHFR 
enzyme across many species. Indeed work by Beard et al (1991) found that site 
directed mutagenesis of the tryptophan at position 24 of human DHFR to a 
phenylalanine caused a 25 fold reduced affinity of the enzyme for DHF and  a 21 
fold reduced affinity for NADPH. The phenylalanine substitution also resulted in a 
50% decrease in DHFR enzyme stability and a dramatic reduction in enzyme 
efficiency (Beard et al. 1991). Similarly work on mouse DHFR has also shown the 
importance of the tryptophan at position 24 of the enzyme.  Thillet et al (1988) 
performed site directed mutagenesis on mouse DHFR, producing a number of 
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mutants one of which resulted in a tryptophan (W) to arginine (R) substitution at 
position 24. The W24R mutation in mouse DHFR resulted in over a 100 fold reduced 
affinity for folate, with the wild type enzyme having a Km of 0.09µM for folate 
whilst mutant had a Km of 10 µM. The authors also found that introducing a W24R 
mutation in mouse DHFR affected its ability to bind methotrexate, a known anti-
folate drug used frequently in chemotherapeutic regimens. It is thought that the 
tryptophan at position 24 forms a hydrogen bond with methotrexate and that 
switching this amino acid to an arginine disrupts this binding.  Thillet et al (1988) 
found that the W24R mutation in mouse DHFR resulted in it having a Ki of 300nM 
for methotrexate whereas the wild type enzyme has a Ki of 0.004nM; this results in 
the DHFR mutant (W24R) having a 75,000 fold reduced affinity for methotrexate 
(Thillet et al. 1988). Although this work was carried out in mouse DHFR, this could 
have some bearing on the human DHFRL1 enzyme where an arginine is found at 
position 24 in the conserved catalytic activity site in place of the highly conserved 
tryptophan residue.  
Gao et al (2013) performed a molecular dynamics simulation as to the effect of 
mutating the arginine at position 24 in DHFRL1 to a tryptophan. Free energy 
calculations into enzyme substrate affinity found that the calculated values were in 
concordance with experimental values for DHFR and DHFRL1. Most interestingly the 
calculated values for DHFRL1 R24W  indicated that the mutation recovers the 
binding affinity for DHF to that of DHFR. Molecular modelling also indicated that 
wild type DHFRL1 has a conformation which is more similar to E.coli DHFR that to 
human DHFR.  
  Despite shared genetic homology, there are distinct differences between the 
paralogous enzymes DHFR and DHFRL1. DHFRL1 has been shown to translocate to 
the mitochondria to partake in the de novo synthesis of thymidylate (Anderson et 
al. 2011). Whereas, DHFR is thought to primarily reside in the cytoplasm partaking 
in cytoplasmic one carbon metabolism. Both enzymes are capable of the reduction 
of DHF to its biologically active form THF; however, their abilities to perform this 
function are somewhat different. DHFRL1’s activity has been shown to be only one 
tenth that of DHFR (McEntee et al. 2011). In addition, molecular dynamic simulation 
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into the structure and conformation of the DHFRL1 enzyme indicates that its 
structure may be different from DHFR’s (Gao et al. 2013). Investigation into the 
effects of the amino acid differences between the enzymes is needed in order to 
identify specific residues which may contribute to the diversity between the 
enzymes. 
4.2 Aims/Objectives 
The main aim of this chapter was to investigate the effects of specific amino acid 
differences between DHFR and DHFRL1in order to begin to understand their 
functional relevance. 
Objectives: 
 Predictive protein modelling of DHFR, DHFRL1 and examination of amino 
acid substitutions in DHFRL1 R24W and DHFR W24R to ascertain the effect if 
any on predicted binding or folding.  
 Expression of recombinant DHFR and DHFRL1 with purification of the 
recombinant enzymes.   
 Analysis of the recombinant proteins using SDS PAGE and Western blot. 
 Site directed mutagenesis to introduce the DHFRL1 R24W and the DHFR 
W24R mutations into the DHFRL1 and DHFR genes.  
 Optimisation of expression of the DHFRL1 R24W and the DHFR W24R 
mutant proteins. Analysis of the effect of these mutations on protein 
expression and solubility.  
 
 
 
 
 
 
85 
 
4.3 Results 
4.3.1 Identification of Important Amino Acid Differences between DHFR and 
DHFRL1 
Since there are 15 amino acid differences between DHFR and DHFRL1, and there is a 
possibility of two amino acids at each of the 15 sites. Mathematically there are up 
to 215 (33,000) possible amino acid combinations that could theoretically be 
responsible for the differences in enzyme activity between the two proteins. 
Therefore a rational approach had to be taken to identify amino acids which may be 
of particular importance. A Clustal Omega alignment of the amino acid sequences of  
DHFRL1  and DHFR from human, cow, rat, mouse, chicken and chimpanzee was 
undertaken in order to identify conserved amino acids across species which are 
likely to be important. One amino acid which was found to be highly conserved in 
the DHFR enzyme was a tryptophan (W) at position 24. Figure 4.1 shows that 
DHFRL1 has an arginine (R) at position 24, whereas DHFR has a tryptophan at 
position 24 in all 6 species examined. In addition to this, McEntee et al (2011) had 
previously noted this residue may be of particular importance in regard DHFRL1’S 
reduced activity. Work by Gao et al (2013) also provided strong evidence in the 
form of predictive modelling as to the relevance of the tryptophan at position 24.  
In order to further assess the importance of the amino acids at position 24 of 
predictive modelling was undertaken using Swiss-Model (Arnold et al. 2006, Bordoli 
et al. 2009, Biasini et al. 2014). Interestingly the protein modelling predicted that 
the DHFRL1 wild type protein did not have a conserved NADPH binding site, Figure 
4.2. As mentioned previously NADPH is a co-factor for the DHFR enzyme in its 
reduction of folate. Mutating the amino acid at position 24 in DHFRL1 from an 
arginine (R) to tryptophan (W) failed to restore the NADPH binding site. 
Interestingly changing the tryptophan at position 24 of the DHFR protein to an 
arginine resulted in the loss of the NADPH binding site, as determined by the 
predictive modelling, see Figure 4.3.  Predictive modelling alone is not conclusive 
for the loss or conservation of the NADPH binding site in the DHFR and DHFRL1 
proteins. However, these results provided further evidence as to the amino acid at 
position 24 being a likely candidate for causing the differences observed between 
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the DHFR and DHFRL1 proteins and for these reasons it was selected for 
experimental analysis.  
CLUSTAL O(1.2.1) multiple sequence alignment 
 
 
CHICKEN         -VRSLNSIVAVCQNMGIGKDGNLPWPPLRNEYKYFQRMTSTSHVEGKQNAVIMGKKTWFS 
BOS TAURUS      MVRPLNCIVAVSQNMGIGKNGNLPWPPLRNEFQYFQRMTTVSSVEGKQNLVIMGRKTWFS 
MOUSE           MVRPLNCIVAVSQNMGIGKNGDLPWPPLRNEFKYFQRMTTTSSVEGKQNLVIMGRKTWFS 
RATTUS          MVRPLNCIVAVSQNMGIGKNGDLPWPLLRNEFKYFQRMTTTSSVEGKQNLVIMGRKTWFS 
DHFRL1          MFLLLNCIVAVSQNMGIGKNGDLPRPPLRNEFRYFQRMTTTSSVEGKQNLVIMGRKTWFS 
DHFR            MVGSLNCIVAVSQNMGIGKNGDLPWPPLRNEFRYFQRMTTTSSVEGKQNLVIMGKKTWFS 
CHIMPANZEE      MVGSLNCIVAVSQNMGIGKNGDLPWPPLRNEFRYFQRMTTTSSVEGKQNLVIMGKKTWFS 
                 .  **.****.*******:*:** * ****::******:.* ****** ****:***** 
 
CHICKEN         IPEKNRPLKDRINIVLSRELKEAPKGAHYLSKSLDDALALLDSPELKSKVDMVWIVGGTA 
BOS             IPEKNRPLKDRINIVLSRELKEPPKGAHFLAKSLDDALELIEDPELTNKVDVVWIVGGSS 
MOUSE           IPEKNRPLKDRINIVLSRELKEPPRGAHFLAKSLDDALRLIEQPELASKVDMVWIVGGSS 
RATTUS          IPEKNRPLKDRINIVLSRELKEPPQGAHFLAKSLDDALKLIEQPELASKVDMVWVVGGSS 
DHFRL1          IPEKNRPLKDRINLVLSRELKEPPQGAHFLARSLDDALKLTERPELANKVDMIWIVGGSS 
DHFR            IPEKNRPLKGRINLVLSRELKEPPQGAHFLSRSLDDALKLTEQPELANKVDMVWIVGGSS 
CHIMPANZEE      IPEKNRPLKGRINLVLSRELKEPPQGAHFLSRSLDDALKLTEQPELASKVDMVWIVGGSS 
                ********* ***:******** *:***:*::****** * : *** .***::*:***:: 
 
CHICKEN         VYKAAMEKPINHRLFVTRILHEFESDTFFPEIDYKDFKLLTEYPGVPADIQEEDGIQYKF 
BOS             VYKEAMNKPGHVRLFVTRIMQEFESDAFFPEIDFEKYKLLPEYPGVPLDVQEEKGIKYKF 
MOUSE           VYQEAMNQPGHLRLFVTRIMQEFESDTFFPEIDLGKYKLLPEYPGVLSEVQEEKGIKYKF 
RATTUS          VYQEAMNQPGHLRLFVTRIMQEFESDTFFPEIDLEKYKLLPEYPGVLSEIQEEKGIKYKF 
DHFRL1          VYKEAMNHLGHLKLFVTRIMQDFESDTFFSEIDLEKYKLLPEYPGVLSDVQEGKHIKYKF 
DHFR            VYKEAMNHPGHLKLFVTRIMQDFESDTFFPEIDLEKYKLLPEYPGVLSDVQEEKGIKYKF 
CHIMPANZEE      VYKIPRCSL--------------------------------------------------- 
                **:                                                          
 
CHICKEN         EVYQKSVLAQ 
BOS TAURUS      EVYEKNN--- 
MOUSE           EVYEKKD--- 
RATTUS          EVYEKKD--- 
DHFRL1 HUMAN    EVCEKDD--- 
DHFR HUMAN      EVYEKND--- 
CHIMPANZEE      ---------- 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Clustal Omega Alignment of human DHFRL1 and DHFR amino acid protein 
sequences. The tryptophan at amino acid position 24 appears to be highly conserved 
across, chicken, cow, mouse, rat, chimpanzee and human DHFR. However, the 
tryptophan is not conserved in the DHFRL1 enzyme as an alanine is found at position 24 
of the protein.  
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Figure 4.2 DHFRL1 WT and DHFRL1 R24W predicted protein structures.  Predictive 
modelling indicates that DHFRL1 is capable of binding folic acid but the binding site for 
NADPH, a co-factor required for the reduction of folate is not conserved. Changing the 
amino acid of the DHFRL1 protein to that of the DHFR protein at position 24 from an 
arginine to a tryptophan fails to restore the NADPH binding site in the DHFRL1 protein.  
 
88 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 DHFR WT and DHFR W24R predicted protein structures. The single amino acid 
change at position 24 from a tryptophan (W) to an arginine (R) results in the loss of the 
NADPH binding site of the DHFR enzyme. Indicating the amino acid change affects the 
folding and conformation of the DHFR enzyme. 
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4.3.2 Expression and Purification of Recombinant DHFR and DHFRL1 
DHFR and DHFRL1 ultimate orf clones in pDONRTM221 were recombined with 
pDESTTM 17 the resultant plasmid DNA was sequenced then transformed into the 
BL21 AI E.coli cells. The pDEST 17 vector encodes a His tag comprising of 6 histidine 
residues; this enables purification of the target proteins by affinity chromatography 
with either a nickel or cobalt column.  The pDEST 17 vector encodes an inducible 
promoter; addition of L-arabinose to this system induces expression of the target 
protein. In the lab Dr Linda Hughes had previously shown the optimum temperature 
for protein induction was 37°C and the optimum concentration of the inducer 
molecule L- arabinose was 0.2% w/v. To examine the optimum time to collect the 
induced protein, 1ml was collected from induced and uninduced bacterial cultures 
at 2, 4 and 6 hours post induction, as per section 2.1.7 of Chapter 2. The samples 
were lysed in 4X SDS PAGE loading dye and analysed by SDS PAGE. It was found that 
the quantity of the target DHFRL1 and DHFR fusion proteins increased over time 
with its expression being highest 6 hours post induction, see Figures 4.4 and 4.5. 
To purify the target DHFRL1 and DHFR his tagged proteins a His-TALON column 
containing immobilised cobalt was used. Prior to purification the bacterial cell 
pellets were weighed and the HisTALON xTractor Buffer was added in a ratio of 
2mls of buffer per 100mg of bacteria and cells were lysed, as per section 2.1.8 of 
Chapter 2. Purification of the DHFR protein was successful, with the largest amount 
of protein being eluted in fraction 2. In contrast purification of the DHFRL1 protein 
yielded a small quantity of impure protein. Figure 4.6 shows that there is a number 
of contaminating proteins bands in the eluted fractions of the DHFRL1 protein. 
What is also of note is that, despite the fact the induction of the DHFRL1 protein 
appeared to be quite strong as analysed by whole cell lysate, there appears to be 
very little target DHFRL1 in the soluble protein fraction. Western blot analysis with 
an antiDHFR antibody confirmed that the purified protein fractions were DHFR and 
DHFRL1, see Figure 4.7 and 4.8. The presence of contaminating bands in the elution 
fractions of the DHFRL1 protein is likely due to the fact that there was very little 
DHFRL1 protein in the soluble fraction; this may have allowed native E.coli proteins 
to non-specifically bind to the column. Repeating the experiment showed that the 
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DHFR protein could be successfully purified by affinity chromatography whereas 
purification of the DHFRL1 protein even under increasing salt concentrations could 
not yield a clean purification.  It became evident that the insolubility of the DHFRL1 
recombinant protein was resulting in too little soluble protein being available for 
purification. Evidence pointing towards solubility issues came from the fact that 
good protein induction was observed in the whole cell lysate but very little protein 
was observed in the soluble protein fractions.  DHFR and DHFRL1 only differ from 
each other by 15 amino acids.  It was hypothesised that one or a number of the 
different amino acids contributed to the poor solubility of the DHFRL1 protein.  
 
 
 
 
 
 
 
 
 
Figure 4.4 Time points of Induction of DHFRL1 HIS protein analysed by SDS PAGE and 
Stained in coomassie blue. Whole bacterial cell lysate was collected at 0, 2, 4 and 6 
hours post induction in order to ascertain the optimum protein collection time point. 
Lane 1 contains the protein ladder. Lanes 2 and 3 contain DHFRL1 protein at 0 hours 
induced and un-induced. Lanes 4 and 5 contain DHFRL1 protein induced and un-induced 
at 2 hours. Lanes 6 and 7 contain DHFRL1 protein induced and un-induced at 4 hours. 
Lanes 8 and 9 contain DHFRL1 protein induced and un-induced at 6 hours. It can be seen 
that the largest amount of the target DHFRL1 protein is present at the 6 hour time point. 
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Figure 4.5 Time points of Induction of DHFR protein analysed by SDS PAGE. Whole 
bacterial cell lysate was collected at 0, 2, 4 and 6 hours post induction in order to 
ascertain the optimum protein collection time point. Lane 1 contains the protein 
ladder. Lanes 2 and 3 contain DHFR protein at 0 hours un-induced and induced. 
Lanes 4 and 5 contain DHFR protein un-induced and induced at 2 hours. Lanes 6 and 
7 contain DHFR protein un-induced and induced at 4 hours. Lanes 8 and 9 contain 
DHFR protein un-induced and induced at 6 hours. It can be seen that the largest 
amount of the target DHFR protein is present at the 6 hour time point. 
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Figure 4.6 His-Talon Purification of DHFRL1 analysed by SDS PAGE. The SDS PAGE gel 
was stained with coomassie blue and visualised under white light. Lane 1 contains a 
protein ladder. Lane 2 contains the un-purified soluble protein fraction; little to no 
induced protein band can be seen in this fraction. Lane 3 contains the flow through 
fraction. Lanes 4 and 5 contain wash 1 and 2 fractions. Lanes 6 to 11 contain elution 
fractions 1-6 respectively. It appears that the purification process resulted in the 
enrichment of the target DHFRL1 His fusion protein as seen in lane 7. Although the 
target protein appears to have been enriched, it still remains quite impure. 
Target Protein 
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Figure 4.7 Western Blot analysis of Purified DHFRL1 with an antiDHFR antibody. Lane 1 
contains the soluble induced protein fraction; a faint band can be observed, indicating there 
was very little target protein in the soluble fraction. Lanes 2, 3 and 4 contain the wash step 
fractions, lanes 5-10 contain elution fractions 1-6. Lane 11 contains the Sigma DHFR kit 
enzyme as a positive control. Consistent with SDS PAGE analysis, the majority of the target 
protein is present in elution fraction 2 where it appears to have been enriched as seen in 
lane 6. 
 
25 kDa 
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Figure 4.8 Western Blot analysis of Purified DHFR with an antiDHFR antibody. Lane 1 
contains the soluble induced protein fraction; it can be seen that there is a large abundance 
of the DHFR protein in the soluble fraction. Lanes 2, 3 and 4 contain the wash step fractions, 
lanes 5-10 contain elution fractions 1-6. It can be seen that the majority of purified protein 
is in lanes 6 and 7, which contain elution fractions 2 and 3. Lane 11 contains the Sigma DHFR 
kit enzyme as a positive control.. 
 
25 kDa 
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4.3.3 Site Directed Mutagenesis of DHFR and DHFRL1 
The R24W and the W24R mutations were inserted into the DHFRL1 and the DHFR 
genes, respectively by site directed mutagenesis as per section 2.1.6 of Chapter 2. 
The pDEST17 plasmids encoding the newly mutated DHFR and DHFRL1 genes were 
sent for Sanger sequencing to confirm that the mutations were correctly inserted. A 
Clustal Omega alignment was performed on the sequencing results against the 
DHFRL1 and the DHFR sequences to confirm the mutations were inserted in the 
correct positions; see appendices C1 and D1. The DNA sequencing results for the 
DHFRL1 R24W and the DHFR W24R were converted to the amino acid sequences. A 
Clustal Omega was performed which confirmed that the mutations in the DNA 
sequences resulted in the desired R24W and W24R changes in the amino acid 
sequence; see appendices C2 and D2.  
4.3.4 Optimisation of DHFRL1 R24W and DHFR W24R Expression 
The DHFRL1 R24W and the DHFR W24R pDEST 17 vectors were transformed into 
the BL21 AI cells for protein expression as per section 2.1.4 of Chapter 2. Expression 
was induced at 37°C with 0.2% w/v L-arabinose.  A 1ml volume of culture was taken 
from the induced and un-induced cultures at 2, 4 and 6 hours to confirm that the 
optimum time point for protein collection was 6 hours, as with the wild type 
DHFRL1 and DHFR. The bacterial cell pellet was lysed in 4X SDS PAGE loading dye 
and analysed by SDS PAGE. It can be seen in Figure 4.9 that the amount of target 
protein increased over time with the largest amount of protein seen at 6 hours post 
induction, as was seen for the wild type DHFRL1 and DHFR proteins.  
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Figure 4.9 Induction of DHFRL1 R24W at 2, 4, 6 hours analysed by SDS PAGE and stained 
with coomassie blue. Whole bacterial cell lysate was collected at 2, 4 and 6 hours post 
induction in order to confirm the optimum protein collection time point. Lane 1 contains a 
protein ladder. Lanes 2 and 3 contain the induced and un-induced samples at 2 hours. 
Lanes 4 and 5 contain the induced and un-induced samples at 4 hours. Lanes 6 and 7 
contain the induced and un-induced samples at 6 hours. The target DHFRL1 R24W protein 
appears to increase over time with it being most abundant 6 hours post induction. 
       1           2            3              4            5             6           7        
Target 
Protein 
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4.3.5 Induction of Wild type DHFRL1, DHFR and Mutants 
Induction of the wild type (WT) proteins DHFRL1 and DHFR and the mutant DHFRL1 
R24W and DHFR W24R was undertaken with a view to assess if introducing the 
mutations had any effect on protein solubility. The target proteins were induced for 
6 hours at 37°C with 0.2% w/v L-arabinose in the BL21 AI cells. Cells were 
fractionated into soluble and insoluble protein fractions in B-per complete reagent 
(4mls/gram of bacteria) combined with freeze thaw and sonication, as per section 
2.1.7 of Chapter 2. SDS PAGE gels were equally loaded with 18 µl of protein lysate 
(lysed in B-per at 4ml/gram of bacteria) and 6µl 4X sample buffer. SDS PAGE and 
western blot analysis showed that the amino acid mutations at position 24 had an 
effect on the DHFR enzyme but not on DHFRL1. Figure 4.10 shows that a strong 
protein band is present in the soluble fraction at the correct size for DHFR, as was 
seen previously. The protein bands present in the soluble fractions for the DHFR 
W24R, DHFRL1 WT and the DHFRL1 R24W are much weaker. The DHFRL1 WT and 
R24W mutant have very strong induction bands that are apparent in the insoluble 
protein fractions, confirming previous hypothesis that solubility of the DHFRL1 
protein was the reason for its poor purification. Western blot analysis with an anti-
His antibody confirmed the SDS PAGE results. Due to the fact that there was such a 
large abundance of the target proteins, particularly for the insoluble fractions the 
PDVF membrane actually became scorched as soon as the substrate was added 
meaning that a luminescent image was not captured in time. However, white light 
images of the scorched PVDF membranes were captured, which confirm the SDS 
PAGE results, see Figures 4.11 and 4.12.  The protein solubility results provide 
further evidence as to the importance of the 24th amino acid residue of the DHFR 
and DHFRL1 proteins. 
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Figure 4.10. SDS PAGE analysis of DHFR, DHFRL1 and mutants soluble and insoluble 
fractions. A. Contains the soluble protein fractions. A strong induction band is present 
at 25 kDa for the wild type (WT) DHFR protein. Little to no induction bands can be seen 
for the DHFR W24R, DHFRL1 R24W and the DHFRL1 WT in the soluble protein fraction. 
B. represents the insoluble protein fractions. The DHFR W24R mutation resulted in 
little to no soluble induced protein but a large abundance of induced target protein in 
the insoluble fraction. Although there is still a presence of insoluble protein in the 
DHFR WT a strong induction band still persists in the soluble fraction. The induced 
proteins for DHFRL1 WT and R24W mutants appears to be all in the insoluble fractions. 
A 
B 
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Figure 4.11 Western blot analysis of the soluble protein fractions of DHFR, DHFRL1 and 
mutants.  Western blot analysis confirmed that the induced band at 25 kDa was indeed the 
DHFR WT protein. A. It can be seen that the PVDF membrane is being scorched due to the 
abundance of target protein as indicated by the apparent “hole” in the DHFR WT band. B. 
Imaging of the membrane under white light visualises the extent of staining and confirms that 
there is a large abundance of the DHFR protein in the soluble fraction. 
A B 
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Figure 4.12 Western blot analysis of the insoluble protein fractions of 
DHFR, DHFRL1 and mutants.  Unfortunately due to the large abundance of 
target His tagged proteins the PVDF membrane became scorched almost 
immediately such that the luminescence could not be visualised. Despite 
this, white light images of the PVDF membrane confirmed the SDS PAGE 
results. A large abundance of DHFR W24R protein can be seen in its 
corresponding labelled lane. The induced proteins for DHFRL1 WT and R24W 
mutants appears to be all in the insoluble fractions. A portion of the DHFR 
WT protein appears to be in the insoluble protein fraction; however a large 
portion of soluble DHFR is present as seen in previous images. 
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4.4 Discussion 
The conversion of folate to its biologically active form tetrahydrofolate (THF) is one 
of the most important biochemical reactions carried out within the cell. The 
metabolism of folate results in the production of DNA and methyl donor groups for 
cellular methylation reactions (Fox and Stover 2008). Such is the importance of 
folate metabolism that it is targeted with anti-folate chemotherapy drugs in the 
treatment of cancer (Miller 2006).  The enzyme DHFRL1 is found to be a less active 
version of the DHFR enzyme, a systematic site directed mutagenesis approach is 
needed to decipher which amino acids contribute to the differences in enzyme 
activity (McEntee et al. 2011). If the low level of activity seen for DHFRL1 is 
physiologically relevant then the enzyme could potentially be a chemotherapeutic 
target by the use of anti-folate drugs in the treatment of cancer in much the same 
way as DHFR. The DHFR and DHFRL1 enzymes are 92% identical, despite their 
similarity DHFRL1 has been shown to have a much reduced affinity for DHF 
(McEntee et al. 2011). This suggests that DHFRL1 may also have a reduced affinity 
for anti-folate chemotherapy drugs such as methotrexate.  
In order to identify key residues that may be responsible for the differences 
between the DHFR and DHFRL1 enzymes an amino acid alignment was performed 
with DHFRL1 and DHFR from 6 species. The Clustal Omega amino acid alignment 
revealed that the tryptophan at position 24 of the DHFR enzyme was highly 
conserved in all species tested (human, rat, mouse, chicken, cow and chimpanzee) 
but the DHFRL1 enzyme had an arginine in the same position. The highly conserved 
nature of the tryptophan suggests that it is integral to the function of DHFR in its 
binding and reduction of DHF to THF. 
Predictive protein modelling indicated that the DHFRL1 enzyme did not have its 
NADPH (a co-factor for the reduction of folate) binding site conserved. Predictive 
modelling alone is not enough to confirm that this is the case. However, the 
predictive modelling revealed that changing the tryptophan (W) at position 24 of 
the DHFR enzyme to an arginine (as found in DHFRL1) would result in the loss of the 
enzymes NADPH binding site. Interestingly the predictive modelling found that 
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changing the arginine to a tryptophan in the DHFRL1 enzyme failed to restore its 
NADPH binding site, indicating that further amino differences between the enzymes 
also contribute to its loss.  This information was viewed in regard to the importance 
of the position of the 24th amino acid and its function in the structural conformation 
of the enzyme. 
In order to further investigate the differences between the DHFR and DHFRL1 
enzymes pDEST 17 plasmids encoding the genes were transformed into bacterial BL 
21 AI cells.  It was ascertained that the optimum conditions for expression were at 
37°C, with 0.2% w/v L-arabinose and that the optimum time for protein collection 
was 6 hours post induction. Expression of both the DHFR and DHFRL1 recombinant 
proteins was confirmed in whole cell lysate by SDS PAGE. Purification of the His 
tagged DHFR enzyme using His-Talon cobalt columns was achieved successfully; 
however purification of the DHFRL1 enzyme yielded only a small quantity of impure 
enzyme, despite good protein expression in the whole bacterial cell lysate samples. 
Evidence suggested that the insolubility of the DHFRL1 recombinant protein was 
resulting in too little soluble protein being available for purification. 
Site directed mutagenesis was performed and a DHFRL1 mutant with a tryptophan 
(W) at position 24 was created and a DHFR mutant with an arginine (R) at position 
24 was also created. Expression of all four enzymes, DHFR WT, DHFRL1 WT, DHFR 
W24R and DHFRL1 R24W was successfully undertaken. Solubility of the 
recombinant proteins was used as a measure of protein structure, as the solubility 
of recombinant proteins produced in E.coli has previously been shown to depend on 
the structure of the protein. (Idicula-Thomas and Balaji 2005). Separating the 
induced bacterial cells into soluble and insoluble protein fractions confirmed that 
the DHFRL1 enzyme was predominantly insoluble, thus providing an explanation as 
to why expression  in the whole bacterial cell lysate was high but  the enzyme failed 
to purify from the soluble fraction. It was also found that introducing the R24W 
mutation alone had no effect on protein solubility as the mutant was just as 
insoluble as the wild type. The protein modelling software showed a single amino 
acid change would not restore the NADPH binding site and these data show that a 
single amino acid change cannot make the protein more soluble. Interestingly, 
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mutating the tryptophan to an arginine in the DHFR enzyme resulted in the enzyme 
becoming predominantly insoluble. The protein modelling software predicted that 
this single amino acid change could result in the loss of DHFR’s NADPH binding site, 
so in this instance a single amino acid change could have a big impact. Since not 
enough expressed recombinant protein could be purified for kinetics analysis, the 
NADPH binding site was not experimentally assessed in this instance but the results 
do confirm that an effect was caused by the mutation. The wild type DHFR enzyme 
had a strongly expressed protein band in the soluble protein fraction and, therefore 
purifies well.  Although it can be clearly seen that some of the DHFR protein remains 
insoluble enough of the protein is soluble for purification. Unfortunately there is not 
enough soluble protein available for adequate purification of DHFRL1 or the mutant 
DHFRL1 R24W and DHFR W24R. Both predictive modelling and solubility results 
indicate that the amino acid at position 24 may have an effect on enzyme structure. 
Predictive binding calculations by Gao et al (2013) found that the binding modes of 
DHFRL1 and DHFR to its substrate DHF are different. Arginine is quite a long 
positively charged amino acid and is thought to extend deeply into the binding 
pocket of the DHFRL1 enzyme (Gao et al. 2013).  Predictive modelling by Gao et al 
(2013) indicates that the pterin ring of DHF forms a hydrogen bond with arginine at 
position 24 of the DHFRL1 protein and that this residue also forms two hydrogen 
bonds with NADPH. Modelling by Gao et al (2013) indicates that the R24W mutation 
in the DHFRL1 enzyme would result in the mutant binding and interacting with DHF 
in much the same way as DHFR. The data presented in this chapter indicates that 
the DHFRL1 R24W mutant does not behave any more like DHFR in terms of its 
solubility than the wild type DHFRL1 enzyme indicating that further amino acids 
may also play a role in the solubility and structure of the enzyme. 
Expression of recombinant proteins in an E.coli system is a relatively cheap and 
convenient method of protein production in comparison to a mammalian system. 
However, it does have its drawbacks such as the inability to perform post 
translational modifications and specific folding of proteins. As stated previously, 
solubility was used a measure of protein structure as it has previously been shown 
that the solubility of a recombinant protein in an E.coli system can depend on its 
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structure (Idicula-Thomas and Balaji 2005).  However, solubility of a recombinant 
protein may also be affected by other issues such as toxicity induced by 
heterologous protein production. The host bacteria can sequester the protein in 
insoluble inclusion bodies to minimise the toxic effects (Palomares et al, 2004, Saida 
2007).Perhaps the DHFRL1 protein is somehow toxic to the E.coli cells, causing it to 
be insoluble. In addition to this, high expression of non-native proteins such as in 
the case of producing the human enzymes DHFR and DHFRL1 may saturate foldases 
within bacteria, causing misfolded insoluble proteins (Palomares et al. 2004). 
However, it appears that this is not the case in this instance as the expression level 
of the DHFRL1 and the DHFRL1 R24W mutant enzymes appear to be lower than that 
of DHFR. The data suggests that amino acid differences between DHFR and DHFRL1 
cause the enzymes to have different solubilities and therefore different structural 
conformations. This may explain why the BL 21 AI cells can produce soluble DHFR 
protein but not DHFRL1 protein. It is possible that the amino acid differences 
between DHFR and DHFRL1 result in the bacteria being unable to properly fold the 
DHFRL1 enzyme resulting in it being insoluble. Furthermore, mutating the amino 
acid at position 24 of the DHFR enzyme may cause similar structural changes as 
observed in DHFRL1, resulting in the enzyme being insoluble.  
These results give an insight into the significance of the amino acid differences 
between DHFR and DHFRL1. The predictive protein modelling results together with 
the solubility results all point towards DHFR and DHFRL1 having different structural 
conformations. It appears that the 24th amino acid residue is of particular 
importance in the differences observed between the enzymes.  Previous 
experimental work by Beard et al (1991) found that mutating the tryptophan at 
position 24 of the DHFR enzyme to a phenylalanine causes a dramatic 25 fold 
reduction in affinity for the substrate DHF and over a 50% decrease in enzyme 
stability (Beard et al. 1991).  DHFRL1 is a potential chemotherapeutic target in the 
treatment of cancer; however the reduced affinity of the enzyme for the substrate 
also suggests that it may also have a different affinity to the widely used anti-folate 
methotrexate. Indeed work in mouse DHFR demonstrated that mutating the 
tryptophan at position 24 to an arginine resulted in the enzyme having thousands 
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fold reduced affinity for methotrexate. It is thought that the tryptophan at position 
24 forms a hydrogen bond with methotrexate and switching this amino acid to an 
arginine disrupts this binding (Thillet et al. 1988). Trimethoprim is an anti-folate 
agent against bacterial DHFR which can be used to treat urinary tract infections 
(Brogden et al. 1982). Analysis of the inhibition of the anti-folate trimethoprim on 
the mouse DHFR W24R mutation also found that the enzyme had a 15 fold reduced 
affinity for the inhibitor than the wild type enzyme (Thillet et al. 1988). Although the 
affinity of the DHFR W24R mutation for trimethoprim is still lower than that of the 
wild type, it is much less dramatic than the reduced affinity observed by the 
mutation for methotrexate. Work by Gao et al (2013) suggests that DHFRL1’s 
conformation may be closer to bacterial DHFR than to human DHFR. Perhaps 
alternative anti-folates that are known to have a much reduced affinity for human 
DHFR, such as anti-protozoals could be explored in the targeting of DHFRL1. Data 
presented in this research thesis provides further evidence as to the possible 
structural impact that the amino acid at position 24 of DHFR and DHFRL1 has on the 
enzymes. This information taken collectively suggests that alternative anti-folate 
drugs to methotrexate would need to be explored for the targeted treatment of 
DHFRL1 in cancer. The ideal scenario would be a two pronged approach with the 
targeted treatment of DHFR with methotrexate and an alternative drug for 
targeting DHFRL1. 
To conclude, it appears that amino acid differences between DHFR and DHFRL1 not 
only affect the binding and affinity of the enzymes for their substrate DHF, but may 
also impact on the folding and conformation of both enzymes. It appears that the 
24th residue of the DHFR and DHFRL1 enzymes may be a key player as to the 
differences observed between the enzymes. DHFRL1 may be a potential 
chemotherapeutic target in the treatment of cancer, although its biological 
significance does need to be further investigated. Evidence suggests that DHFRL1 
would respond to different anti-folate inhibitors than DHFR potentially allowing for 
a combinatorial treatment to target DHFR and DHFRL1.  Further investigation is 
warranted into the biological significance of the DHFRL1 enzyme and evaluation of 
the enzyme as a chemotherapeutic target.  
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5.0 Introduction 
5.1 Gene Expression and Cancer 
Regulation and control of gene expression is fundamental to maintain health within 
the cell. Cancer is the unregulated and uncontrolled growth of cells (Sher 1996). 
Cancer may arise through a number of mechanisms all of which are essentially 
caused and or result in aberrant gene expression. As previously discussed, recent 
evidence suggests that mitochondrial folate enzymes may play a significant role in 
cancer growth and development. Although the link between cancer and folate 
enzymes such as DHFR has been widely known and accepted for many years, the 
expression of the complex folate pathway and its pathological significance in regard 
to cancer appears to be coming to the forefront among the scientific community 
(Jain 2012, Selcuklu 2012, Nilsson 2014).  
Chapter 3 has shown that both knocking down and over expressing the 
mitochondrial gene MTHFD1L impacted cell growth and formate production. 
Publications by Jain et al (2012) Sugiura et al (2004) and Fashfindar et al (2012) have 
associated MTHFD1L with increased cancer cell proliferation, mortality and 
metastasis.  Jain et al (2012) also significantly associated mitochondrial MTHFD2 
and SHMT2 with cancer cell proliferation but not their paralogous cytoplasmic 
counterparts. Nilsson et al (2014) also found a significant link between the 
expression level of the MTHFD2 gene and increased mortality in breast cancer 
patients.  
Recent evidence appears to be in favour of a folate mitochondrial driven role in 
cancer growth and development. In order to further explore the role of folate 
enzymes in cancer, the expression level of a range of mitochondrial and cytoplasmic 
folate enzymes was analysed in the isogenic colon cancer cell line model SW480 and 
SW620, see Figure 5.1. The mitochondrial enzymes MTHFD1L, SHMT2 and MTHFD2 
and the cytoplasmic paralogues MTHFD1 and SHMT1 have been selected due to 
their recent associations with cancer (Jain et al. 2012, Nilsson et al. 2014). The 
mitochondrial enzyme DHFRL1 has been selected for expression analysis along with 
the cytoplasmic DHFR. Unlike DHFR, very little is known about the expression level 
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of the novel enzyme DHFRL1 in regard to cancer. The genes TYMS, ATIC and 
ALDH51A have also been selected for analysis as they were previously identified by 
Dr Stefano Minguzzi as being significantly affected by altered MTHFD1L expression 
(Minguzzi 2013). 
 The SW480 cells are a primary colon cancer cell line; the SW620 cells were derived 
from a lymph node metastasis in the same individual. The derivation and isogenic 
nature of the SW480 and SW620 cell lines makes them an excellent model for 
studying genetic differences that arise due to tumour progression and metastasis 
(Leibovitz et al. 1976). 
 
 
 
 
 
 
 
 
 
 
 Figure 5.1 Folate Enzymes Selected for expression analysis in the SW480 and 
SW620 cell lines. Genes depicted in the same colour are paralogous. Genes 
which are underlined are known to localise to other parts of the cell e.g. TYMS 
also localises to the nucleus. 
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5.2 Aims and Objectives 
The main aim of this chapter was to assess if folate related genes are differentially 
expressed in a primary and metastatic colon cancer cell line. This aim was achieved 
by the following objectives.  
 Extraction of RNA from the SW480 and SW620 cell lines. Ensuring it was free 
from genomic DNA by DNAse treating and performing a DNA contamination 
assay. 
 Selecting an appropriate reference gene for RT-qPCR analysis between the 
SW480 and SW620 cell lines. 
 Performing gene expression analysis by RT-qPCR on the SW480 and SW620 
samples for the following genes, MTHFD1L, MTHFD2, MTHFD1, DHFRL1, 
DHFR, SHMT2, SHMT1, ATIC and ALDH51. 
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5.3 Results 
5.3.1. cDNA Synthesis and the DNA Contamination Assay 
RNA was successfully extracted from the SW480 and SW620 cells and cDNA was 
synthesised as per section 2.3.1 of Chapter 2. The presence of genomic DNA can 
potentially interfere with subsequent RT-qPCR analysis of gene expression. In order 
to ensure that synthesised cDNA was free from genomic DNA, the MTHFD1 R653Q 
genomic DNA contamination assay was performed, as per section 2.3.2 of Chapter 
2. This assay is an intron spanning assay allowing for the detection of genomic DNA. 
The expected size of the PCR products of cDNA free from genomic DNA 
contamination is 232bp. The expected size of the PCR products containing genomic 
DNA is 330 bp. Contaminated cDNA would be represented by two PCR bands and 
232 bp and 330bp. It can be seen from Figure 5.2 that the synthesised cDNA is free 
from genomic DNA contamination. 
 
 
 
 
 
 
 
 
Figure 5.2 Genomic DNA Contamination Assay. 1. 100bp 
ladder 2. SW480 PCR product  3. SW620 PCR product  4. 
Positive genomic DNA control 5. Negative control. It can be 
seen that cDNA is free from genomic DNA contamination as 
PCR products in lanes 1 and 2 are at 232 bp. The PCR product 
for genomic DNA can be seen at 330bp. 
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5.3.2 Reference Gene Selection for RT-qPCR 
In order to identify the appropriate reference gene for  expression analysis of the 
SW480 and SW620 cell lines RT-qPCR was undertaken with the following genes, 
GUS, GAPDH,  RPS 13 and TBT. The relative ratio is calculated by simply dividing one 
CP value over another for a given gene. GUS was found to be the most appropriate 
reference gene for the SW480 and SW620 cell lines with a relative ratio of 0.99. RPS 
would also be a good candidate as control gene for the cell lines with a relative ratio 
of 0.98. The relative ratios for the GAPDH and TBT were 0.95 and 0.96 respectively, 
see Table 5.1. 
 
 
 
Gene Mean CP of Triplicates Standard Deviation Cell Line Relative Ratio 
GUS 26.57 0.02 SW 480 
 GUS 26.65 0.12 SW620 0.99 
RPS 13  23.71 0.06 SW 480 
 RPS 13  23.47 0.09 SW620 0.98 
GAPDH 17.55 0.05 SW 480 
 GAPDH 18.35 0.09 SW 620 0.95 
TBT 35.45 0.14 SW 480 
 TBT 36.74 0.06 SW 620 0.96 
 
 
 
 
 
 
 
 
 
Table 5.1 Reference Gene Selection for SW480 and SW620 cell lines  
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5.3.4 All target genes are differentially expressed in SW620 cells compared to 
SW480 cells 
Gene expression analysis for the 10 selected genes was successfully carried out on 
the cDNA derived from the SW480 and SW620 colon cancer cell lines as per section 
2.3.3 of Chapter 2, see Figure 5.3 and Table 5.2. The ATIC gene was found to have -
1.420 fold lower expression in the SW620 cells compared to the SW480 cells. The 
expression of ALDH51A was 1.3 fold higher in the SW620 cells compared to the 
SW480 cells. The expression of the TYMS gene appeared to -2.5 fold lower in the 
SW620 cells compared to the SW480 cells. The expression of the cytoplasmic 
MTHFD1 gene appeared to have a -1.28 fold lower in the SW620 cells compared to 
the SW480 cells. Whereas, both the mitochondrial paralogues of MTHFD1, 
MTHFD1L and MTHFD2 were found to be up regulated in the SW620 cells relative to 
the SW480 cells, by 2.17 and 1.8 fold respectively. SHMT1 was found to have -2.32 
fold lower expression in the SW620 cells, while its paralogous mitochondrial 
counterpart SHMT2 was found to have 2.98 fold higher expression when compared 
to the SW480 cell. The cytoplasmic DHFR enzyme was found to have -1.85 fold 
lower expression in the SW620 cells, though its mitochondrial paralogue DHFRL1 
was found to have a 3.36 fold higher expression when compared to the SW480 
cells. 
 
 
Gene Fold Expression of SW620 Cells compared to SW480  Gene Location 
SHMT2 2.98 Mitochondria 
MTHFD2 1.8 Mitochondria 
MTHFD1L 2.17 Mitochondria 
DHFRL1 3.36 Mitochondria 
ALDH 1.3 Mitochondria 
TYMS -2.5 Mito/Nucleus 
DHFR -1.85 Cytoplasm/Nucleus 
SHMT1 -2.32 Cytoplasm 
MTHFD1 -1.28 Cytoplasm 
ATIC -1.42 Cytoplasm 
Table 5.2 Fold Expression of genes and their cellular location in the SW620 cell 
line compared to the SW480 cell line. 
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Figure 5.3 Fold Expression results in the SW620 cells compared to the SW480 
cells. It can be seen that a trend towards higher expression of the mitochondrial 
genes is present in the SW620 cells when compared to the SW480 cells. 
Interestingly it can also be seen that the cytoplasmic genes within the SW620 
cells appear to have lower expression when compared to the SW480 cells. 
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5.4 Discussion 
The SW480 and SW620 isogenic colon cancer cell line model allows for the analysis 
of changes between a primary tumour and a secondary metastatic growth invitro 
(Leibovitz et al. 1976). RNA was successfully extracted from the cell lines, 
quantified, DNAase treated and used to make cDNA. The MTHFD1 R653Q PCR DNA 
contamination assay confirmed that the SW480 and SW620 cDNA samples were 
free from genomic DNA which could have interfered with the relative quantitative 
gene expression analysis.  
Gene expression analysis was carried out successfully for each of the 10 genes 
analysed. The data show an obvious trend towards the up regulation of 
mitochondrial folate genes in the SW620 metastatic cell line. MTHFD2, MTHFD1L, 
SHMT2, DHFRL1 and ALDH51 were found to be 1.80, 2.17, 2.98, 3.36 and 1.30 fold 
over expressed, respectively, compared to the SW480 cell line.  The up regulation of 
mitochondrial folate genes in the SW620 metastatic cell line is in concordance with 
recent findings in the literature, where folate mitochondrial enzymes have been 
correlated with proliferation and metastasis (Jain et al. 2012, Nilsson et al. 2014). 
Interestingly, cytoplasmic enzymes appeared to be down regulated in the 
metastatic SW620 cells relative to the SW480.  The fold reduced expression in the 
SW620 cells relative to the SW480 cells for the cytoplasmic genes MTHFD1, SHMT1, 
DHFR and ATIC was -1.28, -2.32, -1.85 and -1.42, respectively. There appears to be 
somewhat of an inverse relationship between the mitochondrial and cytoplasmic 
folate genes within the SW480 and SW620 cell lines; see Figure 5.4. 
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Figure 5.4 The expression patterns of mitochondrial and cytoplasmic folate related genes 
within the SW480 and SW620 cell lines. There appears to be an inverse relationship between 
the mitochondrial and cytoplasmic folate genes within the SW620 cells. As depicted, in the 
SW620 cells the mitochondrial genes appear to have an increased expression and the 
expression of cytoplasmic genes appear to have decreased relative to the SW480 cell line. 
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The origin or cause of the observed over expression of mitochondrial folate genes in 
the SW620 cells or indeed in other fast growing cancer cells is not an easy thing to 
distinguish. SHMT2 or serine hydroxymethyltransferase is a known target of the 
oncogene c-myc; nonetheless, Lee et al (2014) have data to suggest that it is 
inadequate for malignant transformation. However, work by Zhang et al (2012) 
identified that over expression of the enzyme glycine decarboxylase (GLDC) may be 
sufficient to initiate tumourigenesis in non-small cell lung cancer.  Up regulation of 
GLDC was also found to result in up regulation of SHMT1 and SHMT2 (Zhang 2012). 
The SHMT enzymes (1 and 2) are responsible for the conversion or serine to glycine 
and the conversion of THF to CH2-THF. CH2-THF is then used in subsequent reactions 
by MTHFD2 and MTHFD1L in the mitochondria and MTHFD1 in the cytoplasm in the 
production of formate; see Figure 5.5. Formate is then transported into the 
cytoplasm where it is then used as a one carbon donor for cytoplasmic one carbon 
metabolism. It is evident that up regulation of the mitochondrial folate enzymes 
SMHT2, MTHFD2 and MTHFD1L and in turn an up regulation of formate would 
confer an advantage to the SW620 cells. With formate providing extra one carbon 
molecules allowing for increased nucleotide synthesis, this would facilitate 
increased proliferation in the SW620 metastatic cell line. 
 
 
 
Figure 5.5 Glycine Biosynthesis and Formate production.  Glycolysis provides serine 
which is cleaved by SHMT1 in the cytoplasm and SHMT2 in the mitochondria. Glycine 
is utilised by MTHFD2 and MTHFD1L in the mitochondria in the production of formate. 
(Image taken from Jain et al 2012) 
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 Indeed, the notion of mitochondria playing a central role in cancer pathogenesis is 
not novel. The Warburg effect is a well-defined phenomenon in which cancer cells 
use glycolysis as opposed to oxidative respiration as a method of energy production 
(Warburg et al. 1927). The glycolytic pathway and the one carbon metabolism 
pathway are interlinked with one another (Amelio et al. 2014). One may be forgiven 
for hypothesising that the observed role of glycine production in cancer cells (as 
observed by Jain and colleagues 2012) may be a consequence of the Warburg effect 
within transformed cells. With glycolysis driving serine production which results in 
the production of glycine in the mitochondria (Amelio et al. 2014). Thus, the 
reliance of fast growing cancer cells on glycine may be a consequence of the switch 
in metabolism from oxidative respiration to glycolysis within the cell. Contrary to 
this hypothesis Zang et al (2012) have found that over expression of the 
mitochondrial enzyme glycine decarboxylase (GLDC) actually causes an up 
regulation of glycolytic enzymes and propose that over expression of GLDC actually 
promotes glycolysis and up regulation of glycine related enzymes SHMT1/2 in non-
small cell lung cancer.  In addition they found that increased GLDC expression 
results in an increase in pyrimidine production. Treatment with methotrexate in 
cells with overexpressed GLDC specifically prohibited proliferation but this did not 
occur in control cells. Most pertinent of all was that shRNA down regulation of GLDC 
in combination with methotrexate treatment was most effective at killing 
transformed cells (Zang et al. 2012).  
Whether up regulation of the glycine pathway and its related enzymes is the answer 
as to why cancer cells switch their metabolism to glycolysis or are up regulated as 
consequence of the switch in energy production, remains to be further investigated. 
For cancer cells to grow and divide nucleotides are required, whence the long 
known link between folate metabolism which results in the production of 
nucleotides and classical chemotherapeutic agents (Visentin et al. 2012). It is logical 
to see how a switch by a cell to glycolysis resulting in increased serine which results 
in increased glycine, resulting in increased formate, ultimately leading to increased 
nucleotide synthesis is extremely advantageous to a cancer cell. Though the link 
between folate metabolism and cancer is well known, our understanding of the 
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relationship between the biochemical intermediates involved in one carbon 
metabolism and their significance in regard to cancer is novel, given recent 
evidence both in the literature and in this research thesis. 
The metastatic SW620 cell line is known to be more proliferative than the parent 
SW480 cell line (Hewitt et al. 2000). The data in this chapter, in addition to 
correlating the gene signature identified by Jain et al (2012) of MTHFD1L, MTHFD2 
and SHMT2 being up regulated in proliferative cancer cells, has also identified a 
fourth enzyme DHFRL1 which may play a pivotal role in cancer proliferation (Jain 
2012). DHFRL1 has been found to be the most up regulated of the genes analysed, 
with a 3.36 fold over expression in the SW620 cells compared to the SW480 cells. As 
explained in Chapter 4, DHFRL1 is responsible for the conversion of DHF to its active 
form THF in the mitochondria (Anderson et al. 2011, McEntee et al. 2011). Due to 
the fact that DHFRL1 was only discovered in 2011, its expression level in cancer is 
largely unknown (McEntee et al. 2011, Anderson et al. 2011). Therefore, the role it 
potentially plays within cancer may have been overlooked thus far. DHFRL1 has 
been implicated in playing a crucial role in de novo thymidylate synthesis in the 
mitochondria (Anderson 2011). What is curious is that the enzyme TYMS 
(thymidylate synthase) was found to be -2.5 fold lower expressed in the SW620 cells 
in comparison to the SW480 cell line. Hypothetically, it could be that the up 
regulation of DHFRL1 within the mitochondria is heavily geared towards the 
provision of THF for formate synthesis and not thymidylate synthesis within the 
mitochondria. 
The enzymes DHFR, MTHFD1 and SHMT1 may have been found to have a lower 
expression level in the SW620 cells relative to the SW480 due to the fact their 
respective paralogues DHFRL1, MTHFD1L and MTHFD2 were up regulated. It may be 
that parts of the one carbon metabolism pathway in cytoplasm are somewhat 
depressed to allow for the up regulation of the mitochondrial pathway. The nature 
of the observed lower expression of the DNA synthesising enzymes TYMS and ATIC 
in the SW620 cell line relative to the SW480 cell line remains to be seen. Previous 
work by Minguzzi (2013) on HEK 293 cells with altered MTHFD1L expression found 
both TYMS and ATIC to have decreased expression upon MTHFD1L over expression. 
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As HEK 293 cells are a non-cancerous cell line, this decrease in expression was 
thought to be protective. 
In summary, the results obtained in this chapter provide further evidence of the 
role of mitochondrial folate enzymes in cancer cell growth and proliferation. The 
advantage of up regulating mitochondrial folate enzymes to the SW620 cells and 
indeed other cancer cells is unambiguous. The cause of the well-known higher 
proliferation rate of the SW620 metastatic cancer cells in comparison to the primary 
SW480 cell line is multi-faceted and may not be fully attributable to the up 
regulation of MTHFD1L,MTHFD2 and SHMT2 (Gao et al.  2012). However, in light of 
recent evidence from the literature and this research thesis, it may be fair to say 
that up-regulation of mitochondrial folate enzymes in the SW620 cells may have 
conferred an advantage in some part to the SW620 cells allowing for increased 
proliferation and metastasis. This may have an implication in the treatment of colon 
cancer and indeed other cancers in which this gene signature is at play. Increased 
knowledge of the myriad of complex changes which occur in cancer cells allowing 
them to proliferate and metastasise is key in the treatment of cancer. The 
development of targeted therapies against crucial enzymes in the mitochondrial 
folate pathway may provide an effective modality of treatment in highly 
proliferative aggressive cancers in the future. 
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General Discussion  
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Discussion 
One carbon metabolism is an essential biochemical pathway in which folates are 
metabolised. The metabolism of folate provides one carbon molecules for the 
production of crucial cellular components such as the DNA bases adenine, 
methylation donor groups and amino acids which are necessary for the growth, 
replication and maintenance of health within the cell (Fox and Stover, 2008). The 
essentiality of folate within the cell has meant that it has had a longstanding 
relationship with health and disease. The relationship of folate with health and 
disease is not unambiguous; it seems that health complications can arise or become 
accelerated if too much or too little folate is consumed. In addition to folate status a 
number of folate genes have also been shown to play a role in disease development 
with the most significant roles seen to be in NTDs and cancer (Parle-McDermott et 
al. 2009, Kirke et al. 2004, Sugiura et al. 2004, Jain et al, 2012).  Folate metabolism 
is compartmentalised within the cell, with the majority of biochemical reactions 
taking place in the cytoplasm and the mitochondria (Fox and Stover 2008). The 
importance of the mitochondria within one carbon metabolism has been 
highlighted over the past number of years with the discovery of novel enzymes such 
as MTHFD1L, MTHFD2L and DHFRL1 (Prasannan et al. 2003, Bolusani et al. 2011, 
McEntee et al. 2011).  
The mitochondrion is often referred to as the “power house” of the cell, where the 
vast majority of cellular metabolism and energy production takes place (Chan., 
2005). The cell is highly reliant on the mitochondria for the production of ATP, the 
energy currency within the cell. The phenomenon of some cancers cells to switch 
from the high energy producing oxidative phosphorylation to the energy inefficient 
method of aerobic glycolysis, is known as the Warburg effect (Warburg et al. 1927). 
The elucidation of this phenomenon by Otto Warburg lead to him defining cancer as 
a disease of the metabolism (Warburg et al. 1927). Although we now know there is 
much more to the etiology of cancer than a switch in energy production, Warburg’s 
theories and findings are ever more relevant today as our knowledge of the 
mitochondria and the metabolic pathways which it encompasses is ever expanding.  
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As the relevance of the mitochondria within cancer is coming to be fully appreciated 
the story of how each enzyme fits into the puzzle is becoming clearer.  In the 
mitochondria the DHFRL1 enzyme plays a role in initiating the one carbon 
metabolism pathway by converting DHF to its biologically active form THF 
(Anderson et al. 2011). The MTHFD1L enzyme is responsible for the last step in 
mitochondrial one carbon metabolism by the conversion of 10-formyl THF to 
formate (Tibbetts and Appling 2010). The mono-functional enzyme MTHFD1L is 
responsible for the production of up to 75% of one carbon donor molecules for 
cytoplasmic one carbon metabolism (Pike et al. 2010). However, the functionality of 
MTHFD1L is not unique, in that the tri-functional cytoplasmic enzyme MTHFD1 also 
has 10-formyl THF synthetase activity (Tibbetts and Appling 2010). Despite the 
commonality between the MTHFD1 and MTHFD1L enzymes, it is the latter that has 
been associated with cancer proliferation and mortality (Sugiura et al. 2004, Jain et 
al. 2012). This fact leads to the hypothesis that It may be the “strategic positioning” 
of the MTHFD1L enzyme within the mitochondria that makes it so relevant in cancer 
and not necessarily its redundant functionality.  
 
Both Sugiura et al (2004) and Jain et al (2012) have previously associated MTHFD1L 
expression with increased cell proliferation. These findings were correlated in this 
research thesis whereby over expression of the MTHFD1L gene resulted in 
increased cell growth in HEK 293 cells. Although the increase in cell growth was 
somewhat modest in comparison to the high proliferation associated with its 
expression as described by Jain et al (2012) .It was similar to what was described by 
Sugiura et al (2004) who found that over expression of the MTHFD1L gene resulted 
in “increased colony formation” in HEK 293 cells. This research thesis has shown 
that MTHFD1L over expression and knock down at a genetic level resulted in a 
detectable alteration in the metabolite of MTHD1L, formate. Formate has also been 
shown to act a reliable biomarker for stage and progression of oesophageal cancer, 
as demonstrated by Wang and colleagues (2013).  Farshidfar et al (2012) also found 
that metabolomic analysis of serum samples from patients with adenocarcinoma 
identified that formate levels were significantly increased in patients with liver 
metastasis (p=0.0005) (Farshidfar et a.l 2012). 
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 Although Wang et al (2013) and Farshidfar et al (2012) successfully demonstrated 
formate as a biomarker, they failed to address or tentatively explore the underlying 
cause of this observation. The work presented in this research thesis provides 
evidence of the role of both MTHFD1L and its metabolite formate. This research 
thesis has sought to take a comprehensive view of the role of both the MTHFD1L 
enzyme and its metabolite formate.  Cause and effect was demonstrated with 
alterations in MTHFD1L at a genetic level resulting in alterations at a metabolite 
level. In concordance with the work of Farshidfar et al (2012) alterations in formate 
level were detected in the extracellular environment of HEK 293 cells with 
modulated MTHFD1L expression. All the evidence from both the literature and this 
research thesis is pointing towards MTHFD1L and formate being reliable biomarkers 
for not only cancer growth but also for staging and detection of metastasis (Jain et 
al. 2012, Farshidfar et al. 2012, Wang et al. 2013, Sugiura et al. 2004).  
 
Coming back to “strategic positioning” within the mitochondria, both the DHFRL1 
and MTHFD1L enzymes play critical roles within mitochondrial one carbon 
metabolism, with DHFRL1 playing a role in initiating the mitochondrial pathway in 
the provision of THF and in thymidylate synthesis and MTHFD1L responsible for the 
critical last step of the mitochondrial pathway (Anderson et al. 2011, Tibbetts and 
Appling 2010). The novel nature of the DHFRL1 enzyme means that much 
investigation is needed in order to begin to understand its functional relevance. It is 
thought that DHFRL1 and the de novo mitochondrial thymidylate synthesis pathway 
is necessary to maintain mitochondrial DNA (mtDNA) by preventing uracil 
incorporation (Anderson et al. 2011). Although, DHFRL1 has been shown to be a 
functional active enzyme, it has also been demonstrated that it has considerably 
less activity in comparison to DHFR (McEntee et al. 2011). McEntee et al (2011) 
have shown that the affinity of DHFRL1 for dihydrofolate (DHF) is ten times less 
than the affinity of DHFR for DHF. It is likely that the source of DHFRL1’s reduced 
activity comes from one or a number of the amino acid differences between itself 
and DHFR. As demonstrated in Chapter 4, the tryptophan at position 24 of the 
human DHFR enzyme is highly conserved across many species from chimpanzee to 
rat, indicating that it has functional significance. McEntee et al (2011) had also 
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previously identified the switch from a tryptophan to an arginine in the DHFRL1 
enzyme as significant, citing it may be a source of DHFRL1’s reduced activity. 
Production and expression of recombinant DHFR, DHFRL1, DHFR W24R and DHFRL1 
R24W in an E.coli expression system was successfully achieved. However, in the 
purification of the wild type enzymes DHFR and DHFRL1 it became apparent that 
insolubility of the DHFRL1 enzyme was an issue. Molecular dynamic simulations by 
Gao et al (2013) found that the structure of DHFRL1 was closer to the structure of 
E.coli DHFR than human DHFR. Molecular dynamic simulations also revealed that 
mutating the arginine at position 24 to a tryptophan in the DHFRL1 enzyme would 
cause the DHFRL1 enzyme to have a structure more similar to human DHFR (Gao et 
al. 2012). However, results from this research thesis indicate that the DHFRL1 R24W 
protein behaved no more like the wild type DHFR enzyme in terms of solubility and 
structure indicating that more amino acids may be involved in DHFRL1’s apparent 
structural changes. The fact that changing the DHFR tryptophan at position 24 to an 
arginine caused it to become insoluble highlights the important role that the 
tryptophan at 24 may have on the enzyme’s structure.   As mentioned in Chapter 4 
the solubility of the wild type and mutant DHFR and DHFRL1 enzymes was used as 
measure of structure as it has previously been shown that the structure of a protein 
in an E.coli system can depend on its structure (Idicula-Thomas and Balaji 2005). 
The predictive protein modelling results also mirrored the solubility results in terms 
of the effect that the amino acid 24 had. For example mutating the arginine in 
DHFRL1 to a tryptophan had no effect relative to the wild type DHFRL1 enzyme as 
assessed by Swiss-Model and protein solubility. The results from Chapter 4 indicate 
that the arginine at position 24 of the DHFRL1 enzyme results in DHFRL1 having an 
altered structure than DHFR.  
 
 
 The altered structure of the DHFRL1 enzyme may be in part why it has such a 
reduced affinity for DHF, as the residues required for its binding may not be 
properly exposed. Predictive modelling by Gao et al (2013) indicates that the pterin 
ring of DHF forms a hydrogen bond with arginine at position 24 and that this 
residue also forms two hydrogen bonds with NADPH. Arginine is quite a long 
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positively charged amino acid and is thought to extend deeply into the binding 
pocket of the DHFRL1 enzyme (Gao et al. 2013). So DHFRL1 may sequester DHF in a 
less efficient manner than DHFR resulting in a reduced affinity, as observed by 
McEntee et al (2011). The reduced affinity of DHFRL1 for DHF also suggests that the 
enzyme may have a reduced affinity for anti-folate chemotherapy drugs (McEntee 
et al. 2011). In Chapter 4 DHFRL1 was found to be up-regulated in the SW620 
metastatic cell line relative to the primary SW480 cells. This indicates that DHFRL1 
may also be part of the mitochondrial driven role in cancer cell development and 
metastasis. Further investigation would be needed in order to assess if DHFRL1 is a 
viable chemotherapeutic target, however it is likely that alternative drugs than 
those used to target DHFR would be needed to achieve efficient blocking of the 
enzyme. Predictive modelling by Gao et al (2013) indicated that DHFRL1 has a 
conformation closer to bacterial DHFR than to human DHFR. Perhaps alternative 
anti-folates that are known to have a much reduced affinity for human DHFR, such 
as anti-protozoals and anti-bacterials could be explored in the targeting of DHFRL1 
(Zimmerman et al. 1987). 
 
 The one carbon metabolism pathway flows primarily in a clockwise direction. As 
one would expect there are a number of essential enzymes which perform the 
intermediate steps between the actions undertaken by the DHFRL1 and MTHFD1L 
enzymes, which should not be overlooked (Tibbetts and Appling 2010).  A 
comprehensive view of the mitochondrial pathway is required in order to fully 
appreciate the molecular mechanisms underlying its association with cancer. The 
SW480 and SW620 cell lines provided an excellent cell line model for detecting 
changes at a genetic level between a primary tumour and a metastatic tumour 
(Leibovitz et al. 1976). The up regulation of the mitochondrial enzymes, in particular 
MTHFD1L, MTHFD2 and SHMT2 within the SW620 metastatic cell line was in 
concordance with the work of Jain et al (2012) who found that these enzymes were 
correlated with rapidly proliferating cell lines, but not their cytosolic counterparts. 
In addition, the up-regulation of the MTHFD1L gene in the metastatic SW620 cell 
line also supports the role of formate in cancer cell proliferation and supports the 
work by Wang et al (2013) and Fashfindar et al (2012) who found that the 
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metabolite of MTHFD1L, formate, was correlated with staging and the detection of 
metastasis in cancer.  These results taken collectively provide a very strong case for 
the mitochondrial one carbon metabolism pathway playing a central role in cancer 
development. 
 
It is not easy to decipher an exact sequence of events which results in the up-
regulation of the mitochondrial pathway; one thing that is obvious however, is that 
its up-regulation is extremely advantageous to a proliferating cancer cell. One of the 
first steps in mitochondrial one carbon metabolism is the cleavage of serine to 
glycine by the SHMT2 enzyme (Tedeschi et al. 2013). Serine is derived from the 
glycolysis pathway; up-regulation of the glycolytic pathway is concomitant with 
many cancers (Warburg et al. 1927, Tedeschi et al. 2013). Serine is produced by 
oxidation of the glycolytic intermediate 3-phophoglycerate by the enzymes 
Phosphoglycerate Dehydrogenase (PHGDH) and Phosphohydroxythreonine 
Aminotransferase (PSAT1) and Phosphoserine Phosphatase (PSPH) (Amelio et al. 
2014). Up-regulation of the PHGDH enzyme has found to be associated with triple 
negative breast cancer. Inhibition of the enzyme by shRNA was found cause a 
strong reduction in proliferating cancer cells that were shown to have an up-
regulation of the enzyme, but cells whose PHGDH was at normal levels were 
unaffected (Possemato et al. 2011). Interestingly, it was found that intracellular 
serine levels were unaffected but a drop in α-ketoglutarate, an intermediate of the 
TCA cycle was observed (Possemato et al. 2011). Possemato et al (2011) also found 
that even when the cells with shRNA suppression of PHGDH were cultured in serine, 
rescue of the suppressed proliferation did not occur. Up-regulation of the PHGDH 
enzyme was found to cause rapid proliferation and a predisposition to malignant 
transformation in the MCF710A cell line (Amelio et al. 2014). In their review in Cell, 
Amelio et al (2014) suggest that up-regulation of the PHGDH enzyme and increased 
serine levels is sufficient for malignant transformation and that it is the serine 
biosynthesis pathway that promotes cancer cell development and proliferation by 
the provision of serine and other outputs which help to fuel the TCA cycle. In 
addition, the synthesis of serine in turn provides glycine and methyl donor groups 
for mitochondrial one carbon metabolism resulting in increased formate for 
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cytoplasmic one carbon metabolism, providing cancer cells with the necessary fuel 
for cell division and proliferation; see Figure 6.1. As explored in Chapter 5, it may be 
the switch in a cells metabolism towards aerobic glycolysis resulting in increased 
serine and 1 carbon molecules that in turn causes an up-regulation of enzymes such 
as SHMT2, MTHFD2, MTHFD1L and DHFRL1 as observed in this research thesis in 
the SW620 cells and in the literature (Jain et al. 2012, Nilsson et al. 2013). 
 
 In contrast to the hypothesis that glycolysis causes up regulation of one carbon 
metabolism enzymes, Zang et al (2012) identified that over expression of the 
enzyme glycine decarboxylase (GLDC) causes an up regulation of glycolytic enzymes. 
Zhang et al (2012) identified that over expression of the mitochondrial enzyme 
GLDC may be sufficient to initiate tumourigenesis in non-small cell lung cancer. 
These authors also found that over expression of the mitochondrial enzyme GLDC 
actually causes an up regulation of glycolytic enzymes and propose that over 
expression of GLDC actually promotes glycolysis and up regulation of glycine related 
enzymes SHMT1/2 in non-small cell lung cancer (Zhang et al. 2012). Whether up 
regulation of the glycine pathway and its related enzymes are the answer as to why 
cancer cells switch their metabolism to glycolysis, or are up regulated as 
consequence of the switch in energy production, remains to be further investigated. 
 
The elucidation of any molecular mechanism in cancer generally has two main aims, 
1. the identification of biomarkers for increased cancer detection, 2. the 
identification of therapeutic targets. The data generated in this thesis add to the 
body of information currently in the literature for both the utilisation of 
mitochondrial genes and their products as both biomarkers for cancer and as 
possible therapeutic targets. Vasquez et al (2013) found a correlation between 
leukaemia patients with high expression of MTHFD2 and SHMT2 and increased 
sensitivity to methotrexate. One finding which was of note was the fact that DHFR 
expression was not found to correlate with methotrexate sensitivity. The authors 
also found that around 25% of cancers over express one carbon metabolism 
enzymes. This finding may also aid in the treatment of cancers by stratifying and 
identifying patients based on their molecular profile and selecting appropriate 
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treatments.  Jing et al (2015) found that shRNA knockdown of the serine producing 
enzyme PHGDH induced increased sensitivity of cisplatin treatment in cervical 
cancer cells, providing further evidence of the necessity of serine and its 
mitochondrial derivatives in cancer cells. There are currently a number of 
chemotherapy drugs both licensed and in clinical trials for targeting the one carbon 
metabolism and the serine/glycine biosynthetic pathways (Amelio et al. 2014). 
Perhaps the use of approved drugs such methotrexate and 5-fluorouracil against 
the enzymes DHFR and TYMS could be expanded or specifically used in cancers with 
up-regulation of folate enzymes in much the same strategy suggested by Vasquez 
and colleagues (Vasquez et al.  2013).  In addition, there are a number of drugs in 
pre-clinical and clinical trials which are aimed and specifically targeting serine and 
glycine biosynthesis (Amelio et al. 2014). 
 
 To conclude, the results presented in this research thesis provide further evidence 
to the growing body of results from the literature on the significance of the 
mitochondrial folate pathway in cancer development proliferation; see Figure 6.1.  
Data presented in this research thesis provide further information on the role and 
activity of the newly identified DHFRL1 enzyme and its possible use as a 
chemotherapeutic target. Evidence was provided for the use of the metabolite of 
MTHFD1L, formate, as a biomarker for cancer cell proliferation. The expression of 
mitochondrial folate enzymes was found to be associated with a metastatic cancer 
cell line. The mechanisms underlying the overexpression and association of the 
mitochondrial folate pathway with cancer are not easy to distinguish; however, the 
identification of this molecular signature provides ample opportunity in the 
treatment and identification of the disease by the provision of biomarkers and 
chemotherapy targets.   
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Figure 6.1. Overview of Enzymes Involved in One Carbon Metabolism and their Relationship with Cancer. Up-
regulation of glycolysis is a common feature of many cancers. Glycolysis provides serine which it is then utilised in 
the mitochondria (Tedeschi 2013). DHFRL1 reduces DHF to its active form THF for thymidylate synthesis and as a 
source of one carbon units for other mitochondrial reactions (Anderson et al 2011). DHFRL1 was found to be 3 
fold up-regulated in the metastatic SW620 cell line. DHFRL1 may be a potential anti-folate chemotherapeutic 
target; it is thought that different anti-folates than are currently used to target DHFR might be more effective. 
SHMT2, MTHFD2 and MTHFD1L are involved in the metabolism of THF and the one carbon derivatives from 
serine; all three enzymes have been found to be up-regulated in highly proliferative cancers (Jain et al 2012). 
MTHFD1L is crucial to the cell with it providing up to 75% of the one carbon donor molecules for cytoplasmic one 
carbon metabolism in the form of formate (Pike et al 2010). Formate has shown promise as a biomarker for 
cancer cell growth and metastasis. Image edited from Fox and Stover (2008). 
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Appendix B1 Thermo Scientific PAGE Ruler Pre-stained Protein 
Ladder (Product No. 26619). 
  
CLUSTAL O(1.2.1) MULTIPLE SEQUENCE ALIGNMENT 
 
 
R24W        ATGTTTCTTTTGCTAAACTGCATCGTCGCTGTGTCCCAAAACATGGGCATCGGCAAGAAC 
DHFRL1      ATGTTTCTTTTGCTAAACTGCATCGTCGCTGTGTCCCAAAACATGGGCATCGGCAAGAAC 
            ************************************************************ 
 
R24W        GGGGACCTGCCCTGGCCGCCGCTCAGGAATGAATTCAGGTATTTCCAGAGAATGACCACA 
DHFRL1      GGGGACCTGCCCAGGCCGCCGCTCAGGAATGAATTCAGGTATTTCCAGAGAATGACCACA 
            ************: *********************************************** 
 
R24W        ACTTCTTCAGTAGAGGGTAAACAGAATCTGGTGATTATGGGTAGGAAGACCTGGTTCTCC 
DHFRL1      ACTTCTTCAGTAGAGGGTAAACAGAATCTGGTGATTATGGGTAGGAAGACCTGGTTCTCC 
            ************************************************************ 
 
R24W        ATTCCTGAGAAGAATCGACCTTTAAAGGATAGAATTAATTTAGTTCTCAGCAGAGAACTC 
DHFRL1      ATTCCTGAGAAGAATCGACCTTTAAAGGATAGAATTAATTTAGTTCTCAGCAGAGAACTC 
            ************************************************************ 
 
R24W        AAGGAACCTCCACAAGGAGCTCATTTTCTTGCCAGAAGTTTGGATGATGCCTTAAAACTT 
DHFRL1      AAGGAACCTCCACAAGGAGCTCATTTTCTTGCCAGAAGTTTGGATGATGCCTTAAAACTT 
            ************************************************************ 
 
  R24W       ACTGAACGACCAGAATTAGCAAATAAAGTAGACATGATTTGGATAGTTGGTGGCAGTTCT 
DHFRL1      ACTGAACGACCAGAATTAGCAAATAAAGTAGACATGATTTGGATAGTTGGTGGCAGTTCT 
            ************************************************************ 
 
R24W        GTTTATAAGGAAGCCATGAATCACCTAGGCCATCTTAAACTATTTGTGACAAGGATCATG 
DHFRL1      GTTTATAAGGAAGCCATGAATCACCTAGGCCATCTTAAACTATTTGTGACAAGGATCATG 
            ************************************************************ 
 
R24W        CAGGACTTTGAAAGTGACACGTTTTTTTCAGAAATTGACTTGGAGAAATATAAACTTCTG 
DHFRL1      CAGGACTTTGAAAGTGACACGTTTTTTTCAGAAATTGACTTGGAGAAATATAAACTTCTG 
            ************************************************************ 
 
R24W        CCTGAATACCCAGGTGTTCTCTCTGATGTCCAGGAGGGGAAACACATCAAGTACAAATTT 
DHFRL1      CCTGAATACCCAGGTGTTCTCTCTGATGTCCAGGAGGGGAAACACATCAAGTACAAATTT 
            ************************************************************ 
 
R24W        GAAGTATGTGAGAAGGATGATTAA 
DHFRL1      GAAGTATGTGAGAAGGATGATTAA 
            ************************ 
 
 
 
 
 
 
 
 
 
Appendix C1 Clustal Omega Alignment of the DNA sequence of the DHFRL1 gene and 
R24W mutant sequencing results. The sequencing results for the DHFRL1 R24W 
mutation indicate that the nucleotide base change was successfully introduced, as 
denoted in red above. 
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CLUSTAL O (1.2.1) multiple sequence alignment 
 
 
R24W        MFLLLNCIVAVSQNMGIGKNGDLPWPPLRNEFRYFQRMTTTSSVEGKQNLVIMGRKTWFS 
DHFRL1      MFLLLNCIVAVSQNMGIGKNGDLPRPPLRNEFRYFQRMTTTSSVEGKQNLVIMGRKTWFS 
            ************************:*********************************** 
 
R24W        IPEKNRPLKDRINLVLSRELKEPPQGAHFLARSLDDALKLTERPELANKVDMIWIVGGSS 
DHFRL1      IPEKNRPLKDRINLVLSRELKEPPQGAHFLARSLDDALKLTERPELANKVDMIWIVGGSS 
            ************************************************************ 
 
R24W        VYKEAMNHLGHLKLFVTRIMQDFESDTFFSEIDLEKYKLLPEYPGVLSDVQEGKHIKYKF 
DHFRL1      VYKEAMNHLGHLKLFVTRIMQDFESDTFFSEIDLEKYKLLPEYPGVLSDVQEGKHIKYKF 
            ************************************************************ 
 
R24W        EVCEKDD 
DHFRL1      EVCEKDD 
            ******* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix C2 Clustal Omega amino acid alignment of the DHFRL1 enzyme and the 
R24W mutant. Translation of the DNA sequencing results for the R24W mutation to the 
amino acid sequence confirms that the single DNA base change made in the DHFRL1 
gene is non-synonymous and results in the conversion of the amino acid from arginine 
(R) to a tryptophan (W). 
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CLUSTAL O(1.2.1) multiple sequence alignment 
 
 
W24R      ATGGTTGGTTCGCTAAACTGCATCGTCGCTGTGTCCCAGAACATGGGCATCGGCAAGAAC 
DHFR      ATGGTTGGTTCGCTAAACTGCATCGTCGCTGTGTCCCAGAACATGGGCATCGGCAAGAAC 
          ************************************************************ 
 
W24R      GGGGACCTGCCCAGGCCACCGCTCAGGAATGAATTCAGATATTTCCAGAGAATGACCACA 
DHFR      GGGGACCTGCCCTGGCCACCGCTCAGGAATGAATTCAGATATTTCCAGAGAATGACCACA 
          ************:*********************************************** 
 
W24R      ACCTCTTCAGTAGAAGGTAAACAGAATCTGGTGATTATGGGTAAGAAGACCTGGTTCTCC 
DHFR      ACCTCTTCAGTAGAAGGTAAACAGAATCTGGTGATTATGGGTAAGAAGACCTGGTTCTCC 
          ************************************************************ 
 
W24R      ATTCCTGAGAAGAATCGACCTTTAAAGGGTAGAATTAATTTAGTTCTCAGCAGAGAACTC 
DHFR      ATTCCTGAGAAGAATCGACCTTTAAAGGGTAGAATTAATTTAGTTCTCAGCAGAGAACTC 
          ************************************************************ 
 
W24R      AAGGAACCTCCACAAGGAGCTCATTTTCTTTCCAGAAGTCTAGATGATGCCTTAAAACTT 
DHFR      AAGGAACCTCCACAAGGAGCTCATTTTCTTTCCAGAAGTCTAGATGATGCCTTAAAACTT 
          ************************************************************ 
 
W24R      ACTGAACAACCAGAATTAGCAAATAAAGTAGACATGGTCTGGATAGTTGGTGGCAGTTCT 
DHFR      ACTGAACAACCAGAATTAGCAAATAAAGTAGACATGGTCTGGATAGTTGGTGGCAGTTCT 
          ************************************************************ 
 
W24R      GTTTATAAGGAAGCCATGAATCACCCAGGCCATCTTAAACTATTTGTGACAAGGATCATG 
DHFR      GTTTATAAGGAAGCCATGAATCACCCAGGCCATCTTAAACTATTTGTGACAAGGATCATG 
          ************************************************************ 
 
W24R      CAAGACTTTGAAAGTGACACGTTTTTTCCAGAAATTGATTTGGAGAAATATAAACTTCTG 
DHFR      CAAGACTTTGAAAGTGACACGTTTTTTCCAGAAATTGATTTGGAGAAATATAAACTTCTG 
          ************************************************************ 
 
W24R      CCAGAATACCCAGGTGTTCTCTCTGATGTCCAGGAGGAGAAAGGCATTAAGTACAAATTT 
DHFR      CCAGAATACCCAGGTGTTCTCTCTGATGTCCAGGAGGAGAAAGGCATTAAGTACAAATTT 
          ************************************************************ 
 
W24R      GAAGTATATGAGAAGAATGATTAG 
DHFR      GAAGTATATGAGAAGAATGATTAG 
          ************************                        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix D1 Clustal Omega Alignment of the DNA sequence of the DHFR 
gene and the W24R mutant sequencing results. The sequencing results for the 
DHFRL W24R mutation indicate that the nucleotide base change was 
successfully introduced, as denoted in green above. 
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CLUSTAL O(1.2.1) multiple sequence alignment 
 
 
W24R      MVGSLNCIVAVSQNMGIGKNGDLPRPPLRNEFRYFQRMTTTSSVEGKQNLVIMGKKTWFS 
DHFR      MVGSLNCIVAVSQNMGIGKNGDLPWPPLRNEFRYFQRMTTTSSVEGKQNLVIMGKKTWFS 
          ************************ *********************************** 
 
W24R      IPEKNRPLKGRINLVLSRELKEPPQGAHFLSRSLDDALKLTEQPELANKVDMVWIVGGSS 
DHFR      IPEKNRPLKGRINLVLSRELKEPPQGAHFLSRSLDDALKLTEQPELANKVDMVWIVGGSS 
          ************************************************************ 
 
W24R      VYKEAMNHPGHLKLFVTRIMQDFESDTFFPEIDLEKYKLLPEYPGVLSDVQEEKGIKYKF 
DHFR      VYKEAMNHPGHLKLFVTRIMQDFESDTFFPEIDLEKYKLLPEYPGVLSDVQEEKGIKYKF 
          ************************************************************ 
 
W24R      EVYEKND 
DHFR      EVYEKND 
          ******* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix D2 Clustal Omega amino acid alignment of the DHFR enzyme and the W24R 
mutant. Translation of the DNA sequencing results for the W24R mutation to the amino 
acid sequence confirms that the single DNA base change made in the DHFR gene is non-
synonymous and results in the conversion of the amino acid from a tryptophan (W) to 
an arginine(R). 
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